Document:

EX-10.1

 Exhibit 10.1 

EQUITY JOINT VENTURE CONTRACT 

among 
 ANHUI RYZUR MEDICAL
EQUIPMENT MANUFACTURING CO., LTD. 

(安徽瑞德医疗设备制造有限公司) 

and 
 MYOMO, INC.

 and 
 BEIJING
RYZUR MEDICAL INVESTMENT CO., LTD. 

(北京瑞德医疗投资股份有限公司) 

with respect to 
 JIANGXI
MYOMO MEDICAL ASSISTIVE APPLIANCE CO., LTD. 

(江西迈欧缪医疗辅助器具有限公司) 

As of January 21, 2021 

 TABLE OF CONTENTS 

 

							
	 CHAPTER ONE DEFINITIONS
	  	 	1	 
			
	 1.1
	 	DEFINITIONS	  	 	1	 
	 1.2
	 	INTERPRETATION	  	 	1	 
		
	 CHAPTER TWO PARTIES
	  	 	2	 
			
	 2.1
	 	PARTIES	  	 	2	 
	 2.2
	 	REPRESENTATIONS AND WARRANTIES	  	 	2	 
	 2.3
	 	CHANGE OF REPRESENTATIVE	  	 	2	 
		
	 CHAPTER THREE ESTABLISHMENT AND CONTINUED EXISTENCE OF THE COMPANY
	  	 	3	 
			
	 3.1
	 	NAME OF THE COMPANY	  	 	3	 
	 3.2
	 	FILING WITH MOFCOM	  	 	3	 
	 3.3
	 	PRC LEGAL PERSON	  	 	3	 
	 3.4
	 	LIMITED LIABILITY	  	 	3	 
		
	 CHAPTER FOUR PURPOSE, SCOPE AND SCALE OF BUSINESS
	  	 	3	 
			
	 4.1
	 	PURPOSE	  	 	3	 
	 4.2
	 	SCOPE OF BUSINESS	  	 	4	 
		
	 CHAPTER FIVE TOTAL INVESTMENT AMOUNT AND REGISTERED CAPITAL
	  	 	4	 
			
	 5.1
	 	REGISTERED CAPITAL	  	 	4	 
	 5.2
	 	REGISTERED CAPITAL CONTRIBUTION	  	 	4	 
	 5.3
	 	CAPITAL RESERVE	  	 	4	 
	 5.4
	 	CONDITIONS PRECEDENT OF CAPITAL CONTRIBUTION	  	 	5	 
	 5.5
	 	ADDITIONAL FINANCING	  	 	5	 
	 5.6
	 	RESTRICTIONS ON TRANSFERS	  	 	5	 
	 5.7
	 	RIGHT OF FIRST REFUSAL	  	 	6	 
	 5.8
	 	RIGHT OF CO-SALE	  	 	7	 
	 5.9
	 	NEW SHAREHOLDER	  	 	8	 
	 5.10
	 	PUT OPTION	  	 	8	 
	 5.11
	 	IPO OF BEIJING RYZUR	  	 	9	 
		
	 CHAPTER SIX RESPONSIBILITIES OF THE PARTIES
	  	 	9	 
			
	 6.1
	 	ANHUI RYZUR’S RESPONSIBILITIES	  	 	9	 
	 6.2
	 	MYOMO’S RESPONSIBILITIES	  	 	9	 
		
	 CHAPTER SEVEN SHAREHOLDERS’ MEETING
	  	 	10	 
			
	 7.1
	 	SHAREHOLDERS’ MEETING	  	 	10	 
	 7.2
	 	CONVENING OF THE SHAREHOLDERS’ MEETING	  	 	10	 
	 7.3
	 	NOTICE OF SHAREHOLDERS’ MEETING	  	 	11	 
	 7.4
	 	LOCATION AND TIME OF SHAREHOLDERS’ MEETINGS	  	 	11	 
	 7.5
	 	APPROVAL OF THE SHAREHOLDERS’ MEETING	  	 	11	 
	 7.6
	 	WRITTEN CONSENT	  	 	13	 
		
	 CHAPTER EIGHT BOARD OF DIRECTORS
	  	 	13	 
			
	 8.1
	 	SIZE; APPOINTMENTS	  	 	13	 
	 8.2
	 	DUTIES OF CHAIRMAN	  	 	13	 
	 8.3
	 	QUORUM	  	 	13	 
	 8.4
	 	BOARD MEETINGS	  	 	14	 
	 8.5
	 	PROXIES	  	 	14	 
	 8.6
	 	MAJORITY VOTE STANDARD	  	 	14	 
	 8.7
	 	DUTY OF THE DIRECTORS	  	 	14	 
	 8.8
	 	ACTIONS REQUIRING UNANIMOUS CONSENT	  	 	15	 
	 8.9
	 	WRITTEN CONSENT	  	 	16	 
	 8.10
	 	CONFERENCE CALLS	  	 	16	 
	 8.11
	 	REMUNERATION	  	 	16	 

							
	 CHAPTER NINE SUPERVISOR
	  	 	16	 
			
	 9.1
	 	SUPERVISOR	  	 	16	 
	 9.2
	 	DUTY OF SUPERVISOR	  	 	16	 
	 9.3
	 	REMUNERATION	  	 	16	 
		
	 CHAPTER TEN BUSINESS MANAGEMENT
	  	 	17	 
			
	 10.1
	 	GENERAL MANAGER	  	 	17	 
	 10.2
	 	RESPONSIBILITIES OF GENERAL MANAGER	  	 	17	 
	 10.3
	 	OTHER MANAGEMENT PERSONNEL	  	 	17	 
	 10.4
	 	SUBSIDIARIES	  	 	17	 
		
	 CHAPTER ELEVEN LABOR MANAGEMENT
	  	 	17	 
			
	 11.1
	 	EMPLOYEES	  	 	17	 
	 11.2
	 	EMPLOYMENT PLAN	  	 	17	 
	 11.3
	 	LABOR CONTRACT	  	 	17	 
	 11.4
	 	EXPERT SUPPORT	  	 	18	 
		
	 CHAPTER TWELVE TAXATION, FINANCE, INSURANCE AND INSPECTION
	  	 	18	 
			
	 12.1
	 	TAXATION	  	 	18	 
	 12.2
	 	US TAX ELECTION	  	 	18	 
	 12.3
	 	ACCOUNTING	  	 	18	 
	 12.4
	 	AUDITING	  	 	18	 
	 12.5
	 	BANK ACCOUNTS	  	 	19	 
	 12.6
	 	INSURANCE	  	 	19	 
	 12.7
	 	INSPECTION	  	 	19	 
	 12.8
	 	INFORMATION	  	 	19	 
		
	 CHAPTER THIRTEEN PROFIT DISTRIBUTION
	  	 	20	 
			
	 13.1
	 	THREE FUNDS	  	 	20	 
	 13.2
	 	ACCUMULATED LOSSES AND PROFITS	  	 	20	 
	 13.3
	 	PROFIT DISTRIBUTION	  	 	20	 
		
	 CHAPTER FOURTEEN PURCHASE OF MYOPRO CONTROL SYSTEM
	  	 	20	 
			
	 14.1
	 	PURCHASE OF MYOPRO CONTROL SYSTEM	  	 	20	 
	 14.2
	 	GUARANTEED ANNUAL MINIMUM PAYMENT AMOUNT; ADJUSTMENT TO GUARANTEED MINIMUM
PAYMENT	  	 	20	 
	 14.3
	 	PURCHASE PRICE PER UNIT	  	 	21	 
	 14.4
	 	EXPORT TO MYOMO	  	 	21	 
		
	 CHAPTER FIFTEEN EFFECTIVENESS; TERM
	  	 	21	 
			
	 15.1
	 	EFFECTIVENESS OF THE CONTRACT	  	 	21	 
	 15.2
	 	TERM.	  	 	21	 
	 15.3
	 	EXTENSION	  	 	22	 
		
	 CHAPTER SIXTEEN TERMINATION AND LIQUIDATION
	  	 	22	 
			
	 16.1
	 	TERMINATION UPON EXPIRATION OF TERM	  	 	22	 
	 16.2
	 	TERMINATION BY MUTUAL AGREEMENT	  	 	22	 
	 16.3
	 	EARLY TERMINATION	  	 	22	 
	 16.4
	 	LIQUIDATION	  	 	23	 
	 16.5
	 	EFFECT OF TERMINATION	  	 	24	 
		
	 CHAPTER SEVENTEEN CONFIDENTIALITY AND
NON-COMPETITION
	  	 	24	 
			
	 17.1
	 	CONFIDENTIALITY	  	 	24	 
	 17.2
	 	NON-COMPETITION	  	 	25	 
		
	 CHAPTER EIGHTEEN COMPLIANCE WITH LAW
	  	 	26	 
			
	 18.1
	 	GENERAL COMPLIANCE	  	 	26	 
	 18.2
	 	U.S.TRADE LAWS	  	 	26	 
		
	 CHAPTER NINETEEN GOVERNING LAW; DISPUTE RESOLUTION
	  	 	26	 

							
	 19.1
	 	GOVERNING LAW	  	 	26	 
	 19.2
	 	DISPUTE RESOLUTION	  	 	27	 
	 19.3
	 	OTHER MATTERS UNAFFECTED	  	 	27	 
		
	 CHAPTER TWENTY LIABILITIES FOR BREACH OF CONTRACT
	  	 	27	 
			
	 20.1
	 	BREACH OF CONTRACT	  	 	27	 
	 20.2
	 	DAMAGES	  	 	27	 
		
	 CHAPTER TWENTY-ONE
MISCELLANEOUS
	  	 	28	 
			
	 21.1
	 	NOTICES	  	 	28	 
	 21.2
	 	FURTHER ASSURANCES	  	 	28	 
	 21.3
	 	ENTIRE AGREEMENT	  	 	28	 
	 21.4
	 	NO IMPLIED WAIVERS	  	 	28	 
	 21.5
	 	SEVERANCE	  	 	29	 
	 21.6
	 	AMENDMENTS	  	 	29	 
	 21.7
	 	NO ASSIGNMENT	  	 	29	 
	 21.8
	 	GUARANTEE BY BEIJING RYZUR	  	 	29	 
	 21.9
	 	FUTURE COOPERATION	  	 	29	 
	 21.10
	 	LANGUAGE	  	 	30	 
	 21.11
	 	COUNTERPARTS	  	 	30	 

  

			
	Schedule I	  	Definitions
	Schedule II	  	List of Company Competitors

 EQUITY JOINT VENTURE CONTRACT 

In accordance with the Foreign Investment Law of the People’s Republic of China, Company Law of the People’s Republic of
China, and in conformity with other relevant Laws of the PRC, and adhering to the principles of equality and mutual benefit and through friendly consultations: 
  

	(i)	 Anhui Ryzur Medical Equipment Manufacturing, Co., Ltd., (in Chinese
“安徽瑞德医疗设备制造有限公司”) (“Anhui Ryzur”), a limited liability company incorporated in and under the Laws of the
PRC and having its registered office at #4 and #5 factory, Ryzur Medical Industrial Park, Economic and Technological Development Zone, Hefei, Anhui Province, PRC
(安徽省合肥市经济技术开发区宿松路以西观海路以南瑞德医疗产业园4#、5#厂房);
 

  

	(ii)	 Myomo, Inc. (“Myomo”), a listed company incorporated under the Laws of
the State of Delaware, USA; and 

  

	(iii)	 Beijing Ryzur Medical Investment Co., Ltd., (in Chinese
“北京瑞德医疗投资股份有限公司”) (“Beijing Ryzur”), a company limited by shares incorporated in and under the Laws of the
PRC and having its registered office at Room 2218, #26 Yard, West Juyuan Road, Mapo Country, Shunyi District, Beijing, PRC
(北京市顺义区马坡镇聚源西路26号院2218室). 

hereby enter into this Equity Joint Venture Contract (this “Contract”) with respect to Jiangxi Myomo Medical Assistive Appliance Co., Ltd.
(江西迈欧缪医疗辅助器具有限公司) (the “Company”) as of January 21, 2021 (“Execution Date”). In this Contract, Myomo and
Anhui Ryzur are collectively referred to as “Parties”; and a “Party” means each or any of the Parties, as the context may require. 

Recitals 
 WHEREAS,
the Parties desire to jointly establish a Sino-foreign equity joint venture on and subject to the terms set forth in this Contract. 
 NOW,
THEREFORE, the Parties hereby agree as follows: 
 Chapter One 

Definitions and Interpretations 
  

	1.1	 Definitions. Unless the context otherwise requires, capitalized terms used in this Contract shall have
the meanings as defined in Schedule I attached hereto. 

  

	1.2	 Interpretation. For all purposes of this Contract, except as otherwise expressly provided, (a) the
defined terms shall have the meanings assigned to them in their respective definitions and include the plural as well as the singular, and pronouns of either gender or neuter shall include, as appropriate, the other pronoun forms; (b) all
references in this Contract to designated “Chapters”, “Sections” and other subdivisions are to the designated Chapters, Sections and other subdivisions of the body of this Contract unless explicitly stated otherwise, and all
references in this Contract to designated schedules and exhibits are to the schedules and exhibits attached to this 

  
 1 

	 	
Contract unless explicitly stated otherwise, (c) the words “herein”, “hereof”, and “hereunder” and other words of similar import refer to this Contract as a
whole and not to any particular Chapter, Section or other subdivision, (d) the titles of the Sections and Subsections of this Contract are for convenience of reference only and are not to be considered in construing this Contract, (e) any
reference in this Contract to any “Party” or any other Person shall be construed so as to include its successors in title, permitted assigns and permitted transferees, (f) any reference in this Contract to any agreement or instrument
is a reference to that agreement or instrument as amended or novated, and (g) this Contract is jointly prepared by the Parties and should not be interpreted against any Party by reason of authorship. 

Chapter Two 
 Parties

  

	2.1	 Parties. Parties to the Company are as follows: 

 

					
	(a)	  	Anhui Ryzur:	  	 Anhui Ryzur Medical Equipment Manufacturing, Co., Ltd., (in
Chinese“安徽瑞德医疗设备制造有限公司”)

		  	Registered Address:	  	#4 and #5 factory, Ryzur Medical Industrial Park, Economic and Technological Development Zone, Hefei, Anhui Province, PRC
(安徽省合肥市经济技术开发区宿松路以西观海路以南瑞德医疗产业园4#、5#厂房)

		  	Legal representative:	  	Ren Song
		  	 Position:
	  	Legal Representative
		  	 Nationality:
	  	PRC

  

					
	(b)	  	Myomo:	  	Myomo, Inc.
		  	Registered Address:	  	One Broadway, 14th Floor, Cambridge,
		  		  	MA 02142, USA
		  	Authorized representative:        	  	Paul Gudonis
		  	 Position:
	  	Chief Executive Officer
		  	 Nationality:
	  	USA

  

	2.2	 Representations and Warranties. Each Party represents and warrants to the other Party that: (i) it
is a duly organized and validly existing independent legal person in its jurisdiction of incorporation and has the full power and legal right to conduct its business in accordance with its charter documents; (ii) it possesses full power and
authority to enter into this Contract and to perform its obligations hereunder; (iii) its representative whose signature is affixed hereto has been fully authorized to sign this Contract and to bind itself as a Party thereby; (iv) its
execution, delivery and performance of this Contract do not and will not contravene or conflict with or constitute a violation of its corporate organizational documents or any board resolutions, or any provision of any Law applicable to that Party;
and (v) upon the effective date of this Contract, the provisions of this Contract shall constitute its legal, valid and binding obligations. 

  

	2.3	 Change of Representative. Each Party shall have the right to change its legal representative or
authorized representative but shall promptly notify the other Party in writing of such change and the name, position and nationality of its new legal representative or authorized representative. 

  
 2 

 Chapter Three 

Establishment of the Company 
  

	3.1	 Name of the Company. The name of the Company in Chinese is
“江西迈欧缪医疗辅助器具有限公司” or the name approved by the Registration Authority. 

The name of the Company in English is “Jiangxi Myomo Medical Assistive Appliance Co., Ltd.”. 

The registered address of the Company is: “1st Floor, Building No. 6, 544
Jiamaowu Road, inner Comprehensive Bonded Area, Xinjian District, Nanchang, Jiangxi Province
(江西省南昌市新建区综合保税区内嘉茂五路544号6栋1层)” 

 

	3.2	 Approvals and Filings. Immediately after the effective date of this Contract, the Parties shall:

  

	(a)	 register the establishment of the Company with the State Administration for Market Regulation or its competent
local counterpart (the “Registration Authority”) and to obtain the Company’s business license (the “Business License”) from the Registration Authority. The date of the issuance of the Business License shall be
referred to as the “Establishment Date;” Upon the Establishment Date, the Parties contemplate entering into the IP License Agreements, which will allow the Company to manufacture and sell products in the Territory incorporating
Myomo’s technology; 

  

	(b)	 complete all necessary procedures for the record-filing of the incorporation of Sino-Foreign equity joint
venture with the Ministry of Commerce of the PRC or its competent local counterpart (“MOFCOM”); and 

  

	(c)	 complete all necessary foreign exchange registration procedures in accordance with the PRC Law, and open RMB
deposit accounts and Foreign Exchange deposit accounts with authorized banks in the PRC. 

  

	3.3	 PRC Legal Person. The Company shall exist as a PRC legal person in the form of a Sino-foreign
equity joint venture. 

  

	3.4	 Limited Liability. The Company shall be a limited liability company. The Company shall be liable for all
its debts and obligations to the extent of its own assets. Each Party shall only be liable to the Company up to its committed capital contribution to the registered capital and capital reserve of the Company. Creditors of the Company (including
taxation and other authorities) shall have no recourse whatsoever against any Party for any Liability of the Company. 

Chapter Four 

Purpose, Scope and Scale of Business 
  

	4.1	 Purpose. The Company will, by itself or through its Subsidiaries, engage in the development,
manufacture, commercialization and distribution of Myomo Products (the “Business”) in the PRC, Hong Kong, Macau and Taiwan (the “Territory”). 

  
 3 

	4.2	 Scope of Business. The business scope of the Company is “development & research,
production, assembling and sale of the articles, tools, rehabilitation assistance appliance and daily electrical equipment for disabled; production and sale of Class I medical device; production and sale of Class II medical device
(研发、生产、装配、销售假肢、矫形器、轮椅、拐杖等残疾人用品、用具、其它康复辅助器具和生活电器。一类医疗器械、销售、制造,二类医疗器械制造、销售)”,
 which shall be subject to the Registration Authority’s approval. 

 Chapter Five 

Total Investment Amount and Registered Capital 
  

	5.1	 Registered Capital. The registered capital of the Company shall be US$600,000, which shall be
contributed by the Parties in accordance with Section 5.2 below. 

  

	5.2	 Registered Capital Contribution. Immediately after the Establishment Date but subject to the
conditions set out in Section 5.4: 

  

	(i)	 Anhui Ryzur shall, as promptly as practicable and in any event within fifteen (15) Business Days after the
Establishment Date, contribute the RMB equivalent of US$401,000 to the registered capital of the Company in the form of cash, which RMB equivalent shall be calculated based on the median US$-RMB exchange rate published by the People’s Bank of China on the date of contribution, representing a 66.83% equity interest in the Company on a fully-diluted
basis; 

  

	(ii)	 Myomo shall, within fifteen (15) Business Days after its receipt of the full amount of the License Fee
paid by the Company pursuant to the Technology License Agreement, contribute US$199,000 to the registered capital of the Company in the form of cash, representing a
33.17% equity interest in the Company on a fully-diluted basis. Anhui Ryzur shall ensure the Company has sufficient funds to pay Myomo the License Fee as agreed and provided in the Technology License
Agreement. 

 Upon the request of Myomo, the Company shall appoint an accounting firm or other qualified institution to
evaluate and verify each Party’s capital contribution. 
  

	5.3	 Capital Reserve. In addition to the registered capital contribution as provided in above
Section 5.2 but subject to the conditions set out in Section 5.4: 

  

	(i)	 Anhui Ryzur, together with any new investors of the Company introduced by Anhui Ryzur, will contribute such
additional capital of a minimum of US$8,000,000 and up to US$20,000,000 to the capital reserve of the Company during the first five (5) years after the Establishment Date: US$5,000,000 of which
shall be made as soon as practicable but no later than thirty (30) days after the Parties have agreed on the business plan, annual budget and financial model (the “Business Plan”) for the Company, which shall be agreed within
sixty (60) days following the Establishment Date, and the remainder of the capital contribution will be made pursuant to the Business Plan. For the avoidance of doubt, the Business Plan may not be amended or modified without the prior approval
of the Board (including the prior written consent of the Director appointed by Myomo); and 

  

	(ii)	 Any contribution to the capital reserve of the Company made by Anhui Ryzur or any new investors of the Company
shall not dilute Myomo’s shareholding percentage in the Company, being 33.17% of the equity interest of the Company before the Capital Increase or 19.9% of the equity interest of the Company after
the Capital Increase. 

  
 4 

	5.4	 Conditions Precedent of Capital Contribution. The Parties agree that neither of the Parties shall be
required to make any capital contribution to the Company in accordance with above Sections 5.2 or 5.3 until the following conditions are satisfied or waived by the Parties: 

 

	(a)	 the Company shall have been duly established under PRC Laws; and 

 

	(b)	 each of the Transaction Documents shall have been duly executed by the parties thereto. 

 

	5.5	 Additional Financing. 

 

	(a)	 The Parties agree that after the Establishment Date, the Master Fund will, through one of its affiliated
companies or SPV, subscribe for the RMB equivalent of US$400,000 newly issued registered capital of the Company (the “Capital Increase”) and after completion of the Capital Increase,
Anhui Ryzur will hold 40.1% equity interest in the Company on a fully-diluted basis, the Master Fund will hold 40% equity interest in the Company on a
fully-diluted basis and Myomo will hold 19.9% equity interest in the Company on a fully-diluted basis. The Parties, the Company and the Master Fund shall enter into necessary capital increase agreement
and the amended and restated Joint Venture Contract and amended and restated Articles of Association for the purpose of the Capital Increase. 

  

	(b)	 Any future capital raise (including increase of registered capital, issuance of equity, convertible securities
or equity-linked instruments) for the Group shall be subject to the written consent of the Parties and the unanimous approval of the Board. 

  

	(c)	 In the event that the Company or any member of the Group increases its registered capital or issues equity,
convertible securities or equity-linked instruments, the Parties will be entitled to participate on a pro rata basis as subscribers, through contribution of cash or other assets and on terms to be agreed to by the Parties. 

 

	5.6	 Restrictions on Transfers. 

 

	(a)	 Unless specifically permitted herein, no Party may, directly or indirectly, sell, assign, mortgage, pledge, or
otherwise dispose of (each a “Transfer”) all or any part of its equity interests in the Company to any third party, or otherwise create any third party rights or Encumbrance upon all or any part of its equity interests in the
Company, without the prior written consent of the other Party. 

  

	(b)	 Notwithstanding anything to the contrary under Section 5.6(a) above: 

 

	 	(i)	 any Party may Transfer all or any part of its equity interest in the Company either to its Affiliate(s) thereof
or otherwise in connection with its internal restructuring; and the other Party is hereby deemed to have given its consent to such Transfer and waived its statutory right of first refusal in connection with such Transfer; and 

 

	 	(ii)	 Anhui Ryzur shall be entitled to Transfer any part of its equity interests in the Company to any third party;
provided that (A) Anhui Ryzur shall notify Myomo in writing of each such Transfer prior to making such Transfer, and (B) after completion of such Transfer, (y) Anhui Ryzur shall own no less than 30% equity interests of the Company on a fully-diluted basis, and (z) Anhui Ryzur and any new investors of the Company introduced by Anhui Ryzur shall collectively own no less than 51% equity interests of the Company on a fully-diluted basis, 

  
 5 

 provided, in each of (i) and (ii) above, that none of the transferees of
such Transfer shall be a Company Competitor. 
  

	(c)	 As a condition to any permitted Transfer as set out in above Section 5.6(b), the transferee shall agree in
writing to be bound by the terms of this Contract and the Articles of Association to the same extent as the transferor was so bound. 

  

	(d)	 Any reference to the Transfer hereunder shall include any change in the direct and indirect beneficial interest
in a Party. For the avoidance of doubt, each Party shall not circumvent or otherwise avoid the Transfer restrictions set forth in this Contract, whether by holding the equity interests of the Company indirectly through another Person or by causing
or effecting, directly or indirectly, the Transfer or issuance of any equity interests by such Party or any such Person, or otherwise. 

  

	(e)	 Any purported Transfer or issuance of any equity interests of any shareholder of the Company or any such Person
in contravention of this Contract shall be void and ineffective for any and all purposes and shall not confer on any transferee or purported transferee any rights whatsoever, and no Party shall recognize any such Transfer or issuance.

  

	(f)	 If any Party should breach any restrictions under this Section, then without limiting any other non-breaching Party’s other right or remedy available to it under the Law or hereunder against the breaching Party, any such non-breaching Party shall be entitled to
apply to any competent administrative or judicial authorities for an injunction, to the extent such remedy is available under the applicable Law, to enjoin the breaching Party from any breaching Transfer. 

 

	5.7	 Right of First Refusal. 

 

	(a)	 When a Party (the “Transferring Party”) wishes to Transfer all or any part of its equity
interest in the Company to a third party, it shall give a written notice (the “Transfer Notice”) to the other Party (the “Non-Transferring Party”), setting forth the
equity interest it wishes to Transfer (the “Transfer Shares”), the price of such Transfer, the identity of the proposed transferee and any other relevant terms and conditions of the proposed transaction. The Non-Transferring Party shall have a right of first refusal to purchase all, but not less than all of the Transfer Shares on the same terms and conditions as the offer price that triggered this first right of
refusal. If the Non-Transferring Party wishes to exercise its right of first refusal, it shall deliver a notice (the “Exercise Notice”) of exercise of its right of first refusal to the
Transferring Party within thirty (30) days (the “Thirty Day Period”) after receipt of the Transfer Notice. The Exercise Notice shall be final and binding on such Non-Transferring
Party. If the Non-Transferring Party fails to deliver the Exercise Notice within the Thirty Day Period, the Transferring Party shall be free to sell such portion of the Transfer Shares to the proposed third
party transferee provided that the final purchase price and other material terms and conditions offered to such proposed transferee shall not be different than those offered to such
Non-Transferring Party. 

  
 6 

	(b)	 Upon the receipt of Exercise Notice by the Transferring Party, the Parties shall enter into an equity interest
purchase agreement within one (1) month in all material respects on the terms and conditions provided in the Transfer Notice, which equity interest purchase agreement shall provide, among other things, that (i) the payment for the Transfer
Shares to be purchased shall be made by wire transfer in immediately available funds of the appropriate currency, against delivery of such Transfer Shares to be purchased, at a place and time agreed by the Transferring Party and the Non-Transferring Party that have elected to purchase a majority of the Transfer Shares to be purchased by the Non-Transferring Party, and (ii) the scheduled time for
closing shall not be later than sixty (60) days following the expiration of Thirty Day Period or the last period during which any Non-Transferring Party may elect to purchase any Transfer Shares.

  

	5.8	 Right of Co-sale. 

 

	(a)	 In the equity transfer in accordance with above Section 5.7, in the event that Anhui Ryzur is the
Transferring Party (the “Lead Sale Party”), if Myomo does not exercise its right of first refusal under Section 5.7, Myomo shall also have the right (but not the obligation) (the
“Co-Sale Right”), to Transfer part or all of its equity interest in the Company (the “Co-Sale Shares”) to the proposed transferee, in
proportion to the Lead Sale Party’s right to transfer any of its equity interest, on the same terms and conditions with respect to the proposed Transfer by the Lead Sale Party of its Transfer Shares as set out in the Transfer Notice in
accordance with the procedure set forth in Section 5.8(b) below. If the proposed transferee declines to purchase all of the Transfer Shares proposed to be sold by the Lead Sale Party and the Co-Sale
Shares, the amount of the equity interest that the proposed transferee agrees to purchase shall be allocated between the Lead Sale Party and Myomo on a pro rata basis based on their respective shareholdings in the Company. 

 

	(b)	 Within thirty (30) Business Days after expiration of the Thirty Day Period (the “Co-Sale Period”), if Myomo does not exercise its right of first refusal with respect to the proposed Transfer of any Transfer Shares by the Lead Sale Party under Section 5.7 above in relation to the
Transfer Shares, Myomo shall have the right, exercisable upon delivery of a written notice (the “Co-Sale Notice”) to the Transferor and the Company, to participate in such sale of the Transfer
Shares. If Myomo delivers to the Transferring Party and the Company a Co-Sale Notice pursuant to the foregoing sentence, it shall have a right to participate in any sale by the Transferring Party of the Co-Sale Shares on the same terms and conditions as specified in the relevant Transfer Notice; provided that Myomo shall (i) only be required to provide representations and warranties
relating to title and ownership of the equity interest to be transferred by it and shall not be required to provide representations and warranties on the business or assets of the Company or any of its Subsidiaries and (ii) not be obliged to
pay any amount with respect to any Liabilities arising from the representations and warranties made by it in excess of its share of the total consideration paid by the proposed transferee. The Co-Sale Notice
shall indicate the amount of equity interest of the Company Myomo wishes to sell under its right to participate. 

  

	(c)	 To the extent that the Non-Transferring Party has not exercised its
rights to purchase all of the Transfer Shares within the Thirty Day Period specified in Section 5.7 above, and, to the extent a Lead Sale Party proposes to Transfer its equity interest in the Company to a proposed transferee, the Non-Transferring Party has not exercised its 

  
 7 

	 	
rights to participate in the sale of the Co-sale Shares within the Co-Sale Period specified in Section 5.8(b)
above, the Transferring Party shall have a time period of ninety (90) days from date of the expiration of the foregoing rights to sell the relevant Transfer Shares to any proposed transferee identified in the relevant Transfer Notice so long as
the terms and conditions (including the purchase price) of such sale are no more favorable to such proposed transferee than those specified in the relevant Transfer Notice. Within fifteen (15) Business Days of entering into any definitive
agreement to sell the Transfer Shares to a proposed transferee under this subsection, the Transferring Party shall furnish each Non-Transferring Party with a copy of all definitive agreements relating to such
sale. 

  

	5.9	 New Shareholder. Any new shareholder of the Company who is not already a party to this Contract shall,
not later than the time that it becomes a shareholder of the Company, enter into the amended and restated equity joint venture contract with respect to the Company or amendment to this Contract (as applicable) with all of the other then-existing
shareholders of the Company, provided that such amended and restated joint venture contract or amendment (as applicable) shall not substantively change the terms and conditions hereof or affect the purposes hereunder,
including without limitation the then-existing shareholders’ rights and obligations contemplated hereunder, in each case without the written consent of each then-existing shareholder of the Company (which consent may be withheld in the sole
discretion of each such then-existing shareholder). 

  

	5.10	 Put Option. 

 

	(a)	 Upon the expiration of the Joint Venture Term, Myomo may deliver a written notice (the “Redemption
Notice”) to Anhui Ryzur requesting that Anhui Ryzur to purchase all (and not less than all) of its then equity interest in the Company in exchange for the Redemption Price, payable in immediately available funds of the appropriate currency
in USD at the closing of such purchase. For purposes of this Contract, “Redemption Price” shall mean an aggregate price equal to the then fair market value of all of the equity interests in the Company then held by Myomo at the time
of Myomo’s delivery of the Redemption Notice, which shall be determined by an independent third-party appraiser as mutually selected by Anhui Ryzur and Myomo (the “Valuer”). The determination of such fair market value by the
Valuer shall, in the absence of manifest error, be final and binding for all parties concerned. The costs for appointing the Valuer for determination of such fair market value shall be borne by Anhui Ryzur and Myomo in proportion to their respective
ownership percentage in the registered capital of the Company. The Valuer shall act as expert and not as an arbitrator. 

  

	(b)	 In the event that Anhui Ryzur fails to pay the Redemption Price in full to Myomo within sixty (60) days
following Myomo’s delivery of the Redemption Notice, Myomo and its Affiliates shall be entitled to elect a majority of the Company’s Directors and shall have consent rights on all of the Company’s cash capital expenditures, in each
case until the Redemption Price is paid in full to Myomo. The Company shall, and Anhui Ryzur shall cause the Company to, do all things and take all actions necessary or desirable to enable Myomo to exercise the foregoing rights in accordance with
the Articles of Association and applicable Laws. Without limiting the foregoing, the Company shall procure that the profits of each Subsidiary of the Company for the time being available for distribution shall be paid to the Company for purposes of
making the redemption of equity interest held by Myomo and/or its Affiliates required to be made pursuant to this Section 5.10. 

  
 8 

	(c)	 If each of the Parties agrees in writing to renew the Joint Venture Term, then Myomo’s above put option
shall be only exercisable upon the expiration of such extended Joint Venture Term. 

  

	5.11	 IPO of Beijing Ryzur. If Beijing Ryzur or any of its Subsidiaries completes an initial public
offering and becomes listed on an internationally-recognized stock exchange, Beijing Ryzur and Myomo shall discuss in good faith for the purposes of agreeing on a way for Myomo to exchange its equity interests in the Company for equity interests in
Beijing Ryzur or such listed Subsidiary of an equal fair market value in a way satisfactory to both Beijing Ryzur and Myomo and compliant with the PRC Laws. Beijing Ryzur shall, or if applicable, shall cause such Subsidiary to, cooperate with Myomo
in effecting and implementing such exchange of equity interests. For purposes of implementing the exchange of equity interests as set forth in this Section 5.11, the fair market value of Myomo’s equity interests in the Company shall be
determined in the same manner as set forth in Section 5.10(a) above. 

 Chapter Six 

Responsibilities of the Parties 
  

	6.1	 Anhui Ryzur’s Responsibilities. In addition to its obligations stated in other
provisions of this Contract, Anhui Ryzur shall be responsible for the following matters: 

  

	(a)	 assisting the Company in obtaining proper premise at market rates for registering the Company;

  

	(b)	 assisting the Company in applying for and obtaining all possible Tax reductions and exemptions and all other
relevant investment incentives, privileges and preferences available to the Company under the Laws of the PRC; 

  

	(c)	 assisting the Company in applying for and being granted all necessary approvals, permits, certificates and
licenses required for the Business from the relevant Government Authorities; 

  

	(d)	 assisting the Company in its relations with Government Authorities and PRC domestic companies;

  

	(e)	 assuming its own costs incurred for the establishment of the Company; 

 

	(f)	 assisting the Company to maintain Myomo quality standards for products and related service;

  

	(g)	 providing the Company with a complete and comprehensive sales plan upon further discussion with Myomo and the
Company; and 

  

	(h)	 assisting in such other matters as are entrusted to it by the Board. 

 

	6.2	 Myomo’s Responsibilities. In addition to its obligations stated in other
provisions of this Contract, Myomo shall be responsible for the following matters: 

  

	(a)	 assisting the Company in recruiting management and technical personnel; 

 

	(b)	 licensing the Myomo IP to the Company in accordance with the IP License Agreements; 

  
 9 

	(c)	 assisting the Company in formulating its business strategy; 

 

	(d)	 assisting the Company in formulating standards for recruiting, evaluating and promoting staff and workers;

  

	(e)	 assuming its own costs incurred for the establishment of the Company, provided that, notwithstanding anything
to the contrary, if the Establishment Date has not occurred within six (6) months following the Execution Date, Anhui Ryzur and Beijing Ryzur, jointly and not severally, shall promptly reimburse Myomo for up to US$50,000 of Myomo’s
reasonable and documented expenses incurred for the establishment of the Company; and 

  

	(f)	 handling such other matters as are entrusted to it by the unanimous consents of the Board.

 Chapter Seven 

Shareholders’ Meeting 
  

	7.1	 Shareholders’ Meeting. 

 

	(a)	 The shareholders’ meeting (the “Shareholders’ Meeting”) is the highest authority of
the Company. 

  

	(b)	 The shareholders shall have such voting rights in proportion to their equity interests in the Company.

  

	(c)	 The first shareholdings’ meeting shall be convened and presided by Anhui Ryzur within thirty
(30) days after the issuance date of the first business license of the Company. 

  

	(d)	 The Shareholders’ Meetings include regular meetings and interim meetings. Regular meetings shall be
convened at least once every year. Shareholder(s) holding one-tenth or more of the voting rights of the Company, or one-third or more of the Directors, or any Supervisor
may propose to convene an interim meeting. 

  

	(e)	 No matter shall be approved by any Shareholders’ Meeting unless a quorum of shareholders is present at the
time when the meeting proceeds. A quorum shall consist of at least one shareholder representing Anhui Ryzur and one shareholder representing Myomo, either in person or proxy. 

 

	7.2	 Convening of the Shareholders’ Meeting. 

 

	(a)	 The Shareholders’ Meetings shall be convened by the Board and presided by the Chairman; if the Chairman is
unable or fails to preside over a Shareholders’ Meeting, the Vice Chairman shall preside over the Shareholders’ Meeting; if the Vice Chairman is unable or fails to preside over a Shareholder’s Meeting, a Director appointed by more
than half of all Directors shall preside over the Shareholders’ Meeting. 

  

	(b)	 If the Board is unable or fails to convene a Shareholders’ Meeting, any Supervisor shall convene and
preside over the meeting; if no Supervisor is able to convene and preside over a Shareholders’ Meeting, Shareholder(s) holding one-tenth or more of the voting rights of the Company may convene and preside
over the Shareholders’ Meeting. 

  
 10 

	7.3	 Notice of Shareholders’ Meetings. 

 

	(a)	 Written notice specifying the date, time, location and agenda of each regular Shareholders’ Meeting shall
be served to each Shareholder by the Chairman at least thirty (30) days prior to such meeting. Any Shareholder may add additional items to the agenda of a regular Shareholders’ Meeting by delivering a notice of such additional items to the
other Shareholder at least ten (10) days prior to the meeting. 

  

	(b)	 Written notice specifying the date, time, location and agenda of each interim Shareholder’s Meeting shall
be served to each Shareholder at least ten (10) days prior to the meeting. The Chairman shall issue notice to convene a Shareholders’ Meeting within seven (7) Business Days after receipt of the notice given by the Shareholder(s), the
Directors or Supervisor(s) in accordance with Section 7.2. 

  

	(c)	 No matters shall be decided at a Shareholders’ Meeting other than the matters specified in the notice
served in accordance with Section 7.3(a) and 7.3(b). 

  

	(d)	 The notice period referred to in this Section 7.3 may be abridged by the written consent of the
shareholders. 

  

	(e)	 All notices given under this Section 7.3 shall be given in both Chinese and English, unless waived in
writing by the relevant recipients. 

  

	7.4	 Location and Time of Shareholders’ Meetings. 

 

	(a)	 Shareholders’ meetings shall be held at the principal place of business of the Company or such other venue
as may be agreed by the shareholders at normal business hours. 

  

	(b)	 The shareholders may participate by telephone or video-conferencing, provided that each participating
shareholder’s representative can hear and be heard and are present from the commencement to the close of the meeting. 

  

	(c)	 The Shareholder’s representatives participating the Shareholders’ Meetings shall present and deliver
to the Secretary the power of authority issued by relevant shareholder before each meeting. 

  

	7.5	 Approval of the Shareholders’ Meeting. 

 

	(A)	 The following matters require the unanimous approval of shareholders: 

 

	(a)	 any amendment to, or any modification or alteration of, this Contract, the Articles of Association of the
Company, and the IP License Agreement; 

  

	(b)	 increase, reduction, repurchase, or alteration of the Company’s registered capital, or issuance of debt,
equity or equity-linked securities by the Company; 

  

	(c)	 creation or issuance of any equity securities of the Company that rank senior than, or pari passu with, the
equity interests held by Myomo in the Company; 

  

	(d)	 any decision on making an initial public offering or listing of the Company; 

 

	(e)	 election and appointment and replacement of the Director of the Board and Supervisors; 

  
 11 

	(f)	 approval of the Company’s operational guidelines and investment plans formulated by the Board, including
any material changes thereto and material deviation therefrom; 

  

	(g)	 deliberation and approval of reports of the Board formulated by the Board; 

 

	(h)	 deliberation and approval of reports of the Supervisors formulated by Supervisors; 

 

	(i)	 deliberation and approval of business plan, annual budgets and final accounts of the Company formulated by the
Board, including any material changes thereto and material deviation therefrom; 

  

	(j)	 deliberation and approval of the Company’s profit distribution plans and loss recovery plans, each
formulated by the Boards; 

  

	(k)	 increase or decrease of number of Directors, the composition of the Board or the roles, authority or
responsibilities thereof; 

  

	(l)	 any sale, transfer, license or other disposal of all or substantially all of assets of the Company or the
Group; 

  

	(m)	 liquidation, termination, dissolution or winding up of the Company; 

 

	(n)	 any proposed merger, combination, consolidation, amalgamation, division,
spin-off or splitting up of the Company; 

  

	(o)	 any sale, transfer, license or other disposal of any assets, properties, intellectual property rights,
interests or businesses with proceeds resulting from such sale, transfer, license or other disposal having a value that exceeds USD 500,000, whether in a single transaction or in a series of transactions cumulatively in any given Fiscal Year;

  

	(p)	 any acquisition (by merger, consolidation, scheme of arrangement, acquisition of stock or assets or otherwise)
or disposal by the Company, directly or indirectly, any assets, equity securities, properties, intellectual property rights, interest or businesses of or in any other entity; 

 

	(q)	 entry by the Company into any joint venture or partnership; 

 

	(r)	 effecting any voluntary bankruptcy, liquidation, dissolution, assignment for the benefit of creditors, winding
up, cessation of business, restructuring or reorganization of the Company; and 

  

	(s)	 change of the business scope of the Group, cessation of any business line of the Group or expansion of the
business of the Group within or outside of the Territory. 

  

	(B)	 All the other matters, which are subject to the approval of the Shareholders’ Meeting in accordance with
the Contract, the Articles of the Association and relevant laws of the PRC, require the approval of the Shareholders holding at least a majority of total voting right through a duly convened Shareholders’ Meeting. 

  
 12 

	7.6	 Written Consent. A resolution circulated to all the Shareholders for the time being and signed by such
number of the Shareholders as required to approve such resolution under Section 7.6, shall be valid and effective as if it had been a resolution passed at a meeting of the Shareholders duly convened and held and may consist of several documents
in the like form, each signed by one or more persons. Executed minutes of Shareholders’ Meeting and executed resolutions adopted in lieu of the Shareholders’ Meeting shall be kept in the minute book of the Company at the Company’s
domicile. 

 Chapter Eight 

Board of Directors 
  

	8.1	 Size; Appointments. 

 

	(a)	 The Board of Directors shall decide on all matters concerning the Company unless the Shareholders’
Meetings otherwise by unanimous consent authorizes or delegates the relevant decision-making power to a member of the Company’s management team. As of the Establishment Date, the Board of Directors shall consist of five (5) Directors, whom
shall be appointed or removed by the Shareholders’ Meeting in accordance with the following rules. The number of Directors shall not be increased or decreased without the unanimous approval of Shareholders’ Meeting: 

 

	 	(i)	 Anhui Ryzur shall be entitled to appoint three (3) Directors at its own discretion and Myomo shall be
entitled to appoint one (1) Director at its own discretion; the fifth (5th) Director shall be jointly appointed by Anhui Ryzur and Myomo, who shall also serve as the General Manager of the
Company; 

  

	 	(i)	 Each Director shall serve a term of three (3) years, renewable upon reappointment; and

  

	 	(ii)	 Each Party shall have the power to remove, reappoint and/or designate any successors to any Director which it
is entitled to appoint to the Board hereunder by written notice to the Company and the other Party. 

  

	(b)	 Anhui Ryzur shall appoint the chairman of the Board (the “Chairman”) and Myomo shall appoint
the vice-chairman of the Board (the “Vice-Chairman”). 

  

	(c)	 All operational decision-making powers shall be delegated to the General Manager, subject to the Board’s
authority to revoke or otherwise revise such delegation. 

  

	(d)	 Upon any future capital raise (including increase of registered capital, issuance of equity, convertible
securities or equity-linked instruments) of the Company by any new investor(s), Anhui Ryzur shall allocate one of its Board seats to a representative of such new investor(s) (if applicable). 

 

	8.2	 Duties of Chairman. The Chairman shall be the legal representative of the Company and such legal
representative shall exercise his authority within the limits prescribed by the Board. Should the Board determine that the Chairman is unable to perform his responsibilities, the Vice-Chairman shall perform such duties. 

 

	8.3	 Quorum. Subject to Section 8.6 and 8.8, the quorum for all Board meetings shall be not less than
three (3) Directors present throughout the meeting, including at least one (1) Director appointed by Anhui Ryzur and one (1) Director appointed by Myomo. No resolutions by the Board may be approved at any Board meeting unless notice
of such meeting has been given to all Directors in accordance with the provisions of Section 

  
 13 

	 	
8.4 or such notice has been waived by each Director that is not present at such meeting (it being agreed and understood that a Director’s presence at a meeting shall be automatically deemed
a waiver of any such notice requirements by such Director unless such presence is for the sole purpose of objecting to the holding of the meeting and announced as such by such Director at the beginning of the meeting). If a quorum is not present at
any meeting of the Board, the Directors present thereat may adjourn the meeting, until a quorum shall be present, provided that, if notice of the Board meeting has been duly delivered to all Directors in accordance with
the provisions of Section 8.4, and the quorum is not present within one half hour from the time appointed for the meeting, the meeting shall be adjourned to the seventh (7th) following Business Day at the same time and place with notice
delivered to all Directors at least five (5) days prior to the adjourned meeting and, if at the adjourned meeting, the quorum is not present within one half hour from the time appointed for the meeting, then the quorum for such adjourned
meeting shall be not less than three (3) Directors present throughout the meeting. 

  

	8.4	 Board Meetings. Board meetings shall be called and presided over by the Chairman or a Director
authorized by the Chairman. Regular meetings of the Board shall be convened each calendar quarter of each year, alternating between PRC and such other locations as the Board shall determine. Special meetings of the Board shall be convened by the
Chairman or a Director authorized by the Chairman on reasonable notice on a motion of at least two (2) Directors in writing. Participation by Directors may be telephonic. Each Director (including the Chairman) shall have one (1) vote on
any matter coming before the Board. Not less than fourteen (14) days’ notice (or such shorter period of notice in respect of any particular meeting as may be agreed by all the Directors) of each meeting of the Board specifying the date,
place and time, of the meeting and the business to be transacted thereat shall be given to all Directors. All of the resolutions and written consents adopted by the Board shall be recorded in both Chinese and English. 

 

	8.5	 Proxies. If a Director is unable to attend a meeting of the Board, he may appoint a proxy in writing to
be present and vote on his behalf. A proxy may represent one or more Directors. A proxy shall have the same rights and powers as the Director who appointed him. A proxy’s presence at a Board meeting shall be deemed to be the presence at such
meeting of the Director who appointed him. 

  

	8.6	 Majority Vote Standard. Subject to Section 8.8 and the other provisions of this Contract,
resolutions of any Board meeting shall be passed with the approval of a simple majority of the Directors attending a duly-convened Board meeting, whether present in person or by proxy. 

 

	8.7	 Duty of the Directors. Subject to the decisions or resolutions of Shareholders’ Meeting and
Section 8.8 below, the Directors of the Company shall exercise the following functions and powers: 

  

	(a)	 to convene the Shareholders’ Meeting and to report on its work to the Shareholders’ Meeting;

  

	(b)	 to implement the decisions or resolutions adopted by the Shareholders’ Meeting; 

 

	(c)	 to formulate the annual financial budget plan and final accounts of the Company; 

  
 14 

	(d)	 to formulate the operational guidelines and investment plans of the Company; 

 

	(e)	 to draw up plans for the increase or reduction of the registered capital and the issuance of debt, equity or
equity-linked securities by the Company; 

  

	(f)	 to draw up plans for the merger, division, change of corporate form and dissolution of the Company;

  

	(g)	 to decide on the appointment and dismissal of the employees, officers, and the members of senior management of
the Company, and the approval of their respective remuneration packages, including their bonuses and increments; 

  

	(h)	 to formulate the basic management system and regulations of the Company; 

 

	(i)	 to exercise other functions and powers stipulated by the Article of Association. 

 

	8.8	 Actions Requiring Unanimous Consent. Notwithstanding anything to the contrary provided herein, unless
otherwise agreed by the Parties in writing, resolutions involving any of the following matters may only be adopted at a duly constituted and convened meeting of the Board by the unanimous approval of all five (5) Directors, whether in person or
by proxy: 

  

	(a)	 incurrence of any indebtedness or borrowings by the Company in excess of US$500,000, whether in a single
transaction or a series of transactions cumulatively in any given Fiscal Year; 

  

	(b)	 incurrence of any capital expenditure in excess of US$500,000 or any obligations or Liabilities thereof,
whether in a single transaction or a series of transactions cumulatively in any given Fiscal Year; 

  

	(c)	 entry into any transaction or series of related transactions (or the termination, extension, continuation after
expiry, renewal, amendment, variation or waiver of any term thereunder) involving the Company or any of its Subsidiaries, on the one hand, and the Company or any of its Subsidiaries’ Affiliates or its or their employees, officers, directors,
partners, members, shareholders or their respective Affiliates, on the other hand, excluding any transactions (i) contemplated under the Transaction Documents or (ii) involving payments (or the provision of
non-cash items) by the Company and/or its Subsidiaries not exceeding (or having a value not exceeding) US$500,000 (or the equivalent thereof in other currencies) over the term of such transaction or series of
transactions; 

  

	(d)	 appointment or removal of CEO, CFO and General Manager of the Company or approval of their respective
remuneration packages, including their bonuses and increments; 

  

	(e)	 initiation or settlement of any litigation, arbitration, regulatory or administrative proceeding involving any
Person resulting in monetary damages or claims in excess of US$1,000,000; and 

  

	(f)	 adoption or any change or update to the list of Company Competitors as set forth in Schedule II.

  
 15 

	8.9	 Written Consent. A resolution circulated to all the Directors for the time being and signed by such
number of the Directors as required to approve such resolution under Sections 8.6 and 8.8, shall be valid and effective as if it had been a resolution passed at a meeting of the Board duly convened and held and may consist of several documents in
the like form, each signed by one or more persons. 

  

	8.10	 Conference Calls. Any Director may participate at a meeting of the Board by conference call or by means
of similar communication equipment whereby all persons participating in the meeting are able to hear and be heard by one another, in which event such Director shall be deemed to be present at the meeting. A Director participating in a meeting in the
manner aforesaid shall also be taken into account in ascertaining the presence of a quorum at the meeting. 

  

	8.11	 Remuneration. Each Director shall serve in such capacity without any remuneration, but all reasonable
costs incurred by the Directors in the performance of their duties as members of the Board (such as transportation and accommodation costs) shall be borne or reimbursed by the Company. 

Chapter Nine 

Supervisors 
  

	9.1	 Supervisors. As of the Establishment Date, the Company shall have two (2) supervisors (the
“Supervisors”, and each a “Supervisor”) in lieu of a board of supervisors, of whom Anhui Ryzur shall appoint one (1) Supervisor and Myomo shall appoint one (1) Supervisor. Each Supervisor shall be
authorized to take any action set forth hereunder independently. None of the members of the Board, the General Manager or any other senior officer of the Company may concurrently serve as a Supervisor. The term of office of the Supervisor shall be
three (3) years, renewable upon reappointment. Each of Anhui Ryzur and Myomo shall have the power to remove, reappoint and/or designate any successors to any Supervisor which it is entitled to appoint hereunder by written notice to the Company
and the other Party. 

  

	9.2	 Duty of Supervisor. The Supervisors shall each exercise the following duties: 

 

	(a)	 to examine the financial matters of the Company; 

 

	(b)	 to supervise and monitor the activities of the Directors, the General Manager and other senior officer of the
Company when they perform their duties to the Company; to propose to the Board the dismissal of any Director, the General Manager or other senior officer who is in violation of Laws, administrative regulations or the Articles of Association;

  

	(c)	 to require the Directors, the General Manager and other senior officer of the Company to rectify any of his/her
acts that is harmful to the interests of the Company; and 

  

	(d)	 to bring lawsuits against the Directors, the General Manager or any other senior officer of the Company in
accordance with the relevant Law of the PRC. 

  

	9.3	 Remuneration. Each Supervisor shall serve in such capacity without any remuneration, but all reasonable
costs incurred by each Supervisor in the performance of his/her duties hereunder (such as transportation and accommodation costs) shall be borne or reimbursed by the Company. 

  
 16 

 Chapter Ten 

Business Management 
  

	10.1	 General Manager. The
day-to-day work of operations management of the Company shall be managed by a general manager (the “General Manager”), which is subject to the
supervision of the Board and the Supervisors. The General Manager shall be jointly recommended by Anhui Ryzur and Myomo, and appointed by the unanimous consent of the Board of Directors. Anhui Ryzur and Myomo shall further be entitled to jointly
propose, and the Board shall have the power to effect, the removal of the General Manager and to recommend any successor to fill any vacancy caused by the resignation, death or removal thereof. 

 

	10.2	 Responsibilities of General Manager. The responsibilities of the General Manager shall be to
implement the various resolutions of the Shareholders’ Meeting and the Board and to organize and lead the day-to-day operations management work of the Company. All
of the Company’s official chops and seals, as well as original copies of licenses, permits, approvals, and other original documents shall be under the custody of the General Manager, who may further entrust the custody of any such items to
other employees of the Company as necessary. The General Manager shall directly report to the Board. 

  

	10.3	 Other Management Personnel. Subject to Section 8.8, other management personnel, including the
management team of any member of the Group, shall be appointed by the Board or the General Manager as authorized by the Board. Management personnel shall be employed pursuant to such terms as shall be set out in an employment contract entered into
between each employee and the Company. The General Manager or the Board, as applicable, shall further be entitled to recommend and/or approve, as applicable, the removal of any of such management personnel and the appointment of any successor to
fill any vacancy caused by the resignation, death or removal thereof. 

  

	10.4	 Subsidiaries. The corporate governance structure and rules of the Subsidiaries of the Company shall be
determined by the Board. 

 Chapter Eleven 

Labor Management 
  

	11.1	 Employees. Employees of the Company (other than the General Manager) shall be employed through open
recruitment based on qualification, experience and competency. 

  

	11.2	 Employment Plan. The General Manager shall formulate plans regarding recruitment, qualifications,
testing, employment, dismissal, resignation, wages, labor insurance, welfare benefits, bonuses, labor disciplines, retirement insurance and other matters concerning the employees of the Company for review and approval by the Board.

  

	11.3	 Labor Contract. The Company shall sign an individual labor contract with each of its full-time employees
(including management personnel and workers). Provisions relating to the employment, dismissal, resignation, remuneration, labor insurance, welfare benefits, bonuses and labor discipline of the employee shall be specified in such individual labor
contract. 

  
 17 

	11.4	 Expert Support. The Company shall reimburse Myomo on a quarterly basis for the costs (payroll, travel,
etc.) that staff assigned to work with the Company have incurred in order to ensure a high-quality launch of the Company and the transfer of know-how, provided that Myomo shall designate the following
full-time or part-time staff to support the Company: Project Manager, Engineer, Manufacturing Specialist, Quality Specialist and Clinical Support staff. 

Chapter Twelve 

Taxation, Finance, Insurance and Inspection 
  

	12.1	 Taxation. The Company and the Parties shall pay Taxes and comply with all Tax filing and reporting
obligations in accordance with the Laws of the PRC and any other applicable jurisdictions. The Parties shall seek to confirm the benefits for the Company, the Parties and all of their personnel of all of the applicable Tax exemptions, reductions,
privileges and preferences which are now or in the future become obtainable under the Laws of the PRC and under any applicable treaties or international agreements to which the PRC may now be or may hereafter become a party. The applicable records,
including contemporaneous documentation of all intercompany transactions and Tax related computations, shall be prepared by the Company and maintained by the Company. 

 

	12.2	 US Tax Election. For US federal, state and local income tax purposes, all items of income, gain, loss,
deduction and credit of the Company will be allocated among the Parties in a manner consistent with the economic arrangement of the Parties as described herein as shall be determined by Myomo. Myomo shall have final decision-making authority with
respect to all US federal, state and local tax matters involving the Company and its Subsidiaries, including (i) the election pursuant to United States Treasury Regulation 301.7701-3 to treat the Company
and any Subsidiary thereof as a pass-through entity for US federal income tax purposes and (ii) all other elections and decisions relevant to the US federal, state and local tax returns of the Company and its Subsidiaries.

  

	12.3	 Accounting. The Company shall adopt the calendar year as its Fiscal Year, which shall run from
January 1 to December 31 of the same year. All accounting records, vouchers, books and statements of the Company must be made and kept in Chinese with proper English translation. In addition, the Company shall provide to Myomo on quarterly
basis unaudited financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles and maintain effective internal control over financial reporting. 

The General Manager shall arrange the formulation of balance sheet, statement of profits and losses, statement of financial changes and profit
distribution scheme for the previous Fiscal Year and submit to the Board within the first thirty (30) days of each Fiscal Year. 
  

	12.4	 Auditing. The Company shall engage an internationally recognized accounting firm registered in PRC to
audit its accounts and prepare its annual financial statements and reports. The Company’s auditor shall be jointly selected by the Parties and appointed and approved by the Board. 

  
 18 

	12.5	 Bank Accounts. The Company may open RMB bank accounts and foreign currency bank accounts in the PRC. The
Company may also open foreign currency bank accounts outside of the PRC in accordance with relevant PRC foreign exchange Laws and may authorize such non-PRC bank to issue trade letters of credit for purposes
of its purchase of products from Myomo in accordance with this Contract. 

  

	12.6	 Insurance. Subject to approval of the Board and without prejudice to the Parties’ obligations under
Section 8.1(c), the Company shall, at its own expense, purchase and maintain from reputable insurance companies within the PRC full and adequate insurance of the Company against other risks as may be decided by the Board or are customarily
insured against. 

  

	12.7	 Inspection. The Company shall ensure that each Party and its authorized personnel (including, but not
limited to, its internal auditors) shall be permitted, at such Party’s expense, to examine any property or facility owned or used by the Company, the books of account and records of the Company and discuss the business, finances and accounts of
the Company with the Directors, senior officers, employees, the Company’s auditor and legal counsel thereof, all at such reasonable times as such Party may request. 

 

	12.8	 Information. The Company shall prepare and deliver to each Party: 

 

	(a)	 as soon as possible, but in any event within forty-five (45) days after the end of each Fiscal Year of the
Company, annual consolidated financial statements of the Company for such Fiscal Year, which statements shall include the balance sheet, profit and loss statements and cash flow statements and shall have been audited under US GAAP and certified
by the Company’s auditor, at the Company’s cost; 

  

	(b)	 as soon as possible, but in any event within twenty (20) days after each fiscal quarter, quarterly
consolidated unaudited financial statements of the Company for such fiscal quarter; 

  

	(c)	 as soon as possible, but in any event within ten (10) Business Days after each fiscal quarter, the
capitalization table of the Company as of the end of such fiscal quarter; and within five (5) Business Days after any change to the capital structure of the Company, the latest updated capitalization table of the Company reflecting such change;

  

	(d)	 as soon as possible, but in any event not later than thirty (30) days prior to the end of each Fiscal
Year, the proposed Business Plan of the Company for the succeeding Fiscal Year to be approved by the Board, which shall include (i) the annual projected budgets of the Company; (ii) any annual dividend or distribution to be declared or
paid by the Company; (iii) the projected incurrence, assumption or refinancing of indebtedness of the Company; and (iv) all other material matters relating to the operation, development and business of the Company; and

  

	(e)	 as soon as practicable, but in any event within ten (10) Business Days after the Company first becomes
aware of any such action, written notice of any actual or prospective material change in the businesses, operations, assets, Liabilities, conditions (financial or otherwise) or prospects of the Group, which written notice shall include full details
of such actual or prospective change; and 

  

	(f)	 as soon as practicable, any other information reasonably requested by any Party as required to meet its
internal requirements for purpose of compliance with applicable Laws. 

  
 19 

 The Company shall verify and confirm that any information delivered to each Party is true, correct, complete
and not misleading. The financial statements of the Company, including the balance sheet, income statement and cash flow statement, shall consolidate the Company and all its Subsidiaries. The financial statements of the Company shall be prepared in
accordance with PRC GAAP and US GAAP and audited by a qualified accounting firm approved by the unanimous consent of the Board of Directors. 

Chapter Thirteen 

Profit Distribution 
  

	13.1	 Three Funds. The Company shall make allocations of after Tax profits to a reserve fund, an enterprise
expansion fund and a bonus and welfare fund for employees of the Company (collectively, the “Three Funds”), as determined by the Board in accordance with the business circumstances of the Company and pursuant to applicable PRC Law.
Any amounts to be contributed to such Three Funds shall be set aside prior to distribution of after-tax profits. 

  

	13.2	 Accumulated Losses and Profits. The Company may not distribute profits until the losses of the previous
Fiscal Years have been made up. Undistributed profits from previous Fiscal Years may be distributed together with the profits of the current Fiscal Year as determined by the Board. 

 

	13.3	 Profit Distribution. 

 

	(a)	 The Board shall decide any matters relating to profit distribution from the Company and any Subsidiary of the
Company, including for purposes of Section 16.4(g). The Company shall distribute dividends to the Parties in proportion to their respective ownership percentage in the registered capital of the Company. 

 

	(b)	 Periodic dividends shall be mandated once certain profit or other operating targets mutually agreed by the
Parties are achieved. All dividends shall be distributed in accordance with this Section 13.3. 

 Chapter Fourteen

 Purchase of MyoPro Control System 
  

	14.1	 Purchase of MyoPro Control System. Myomo shall sell to the Company, and the Company shall purchase
exclusively from Myomo, the MyoPro Control System units, for each Myomo Product that is manufactured by the Company to be distributed in the Territory, in accordance with the terms and conditions provided in this Chapter Fourteen.

  

	14.2	 Guaranteed Annual Minimum Payment Amount; Adjustment to Guaranteed Minimum Payment. Upon
its receipt of the requisite consents, permits and approvals by the NMPA and comparable regulatory authorities in the applicable jurisdictions to market and distribute the Myomo Products in the Territory (the “NMPA
Approvals”), the Company shall purchase a guaranteed minimum quantity of the MyoPro Control System units per year so that the aggregate annual payment made by the Company to Myomo for purchase of the MyoPro Control System units will be no
less than the amounts set forth in the table below. 

  
 20 

					
	 	 	 Year(s) after Receipt of NMPA Approvals
	  	 Guaranteed Annual Minimum Payment

Amount (paid in equal quarterly installments)

			
		 	1 – 3	  	US$750,000
			
	          	 	4 – 7	  	US$1,000,000
			
		 	8 – 10	  	US$1,500,000

 After the tenth (10th) anniversary following the
Company’s receipt of the NMPA Approvals, the Parties shall negotiate in good faith in order to agree upon the annual minimum payment amount payable by the Company to Myomo for purchase of the MyoPro Control System units in subsequent years, it
being agreed that such amount shall not be less than the annual minimum payment amount for the eighth (8th) to the tenth (10th) year following
the Company’s receipt of the NMPA Approvals as set forth in the table above. 
 If any of Myomo’s patent applications set forth in
the Technology License Agreement is denied, or if such patent is issued and is subsequently invalidated, in each case in a final ruling in the Territory by the PRC Governmental Authorities, then the Company’s obligation to make the foregoing
guaranteed minimum payments for the MyoPro Control System units shall be reduced by 25% commencing with the subsequent year. Should
the aforementioned patents be issued or deemed not invalid at a later date, then the guaranteed minimum payments shall revert to the full original amount in the year following such issuance or validation. 

 

	14.3	 Purchase Price Per Unit. The purchase price for each MyoPro Control System unit payable by the Company
to Myomo under the purchase set forth in Section 14.2 above shall be the product of (a) RMB 11,000 minus (b) the cost of goods sold for such MyoPro Control System unit,
provided that in no event shall the amount in this clause (b) be less than the RMB equivalent of US$200 per unit, which RMB equivalent shall be calculated based on the
median US$-RMB exchange rate published by the People’s Bank of China on the date of such purchase. 

  

	14.4	 Export to Myomo. The Company may sell to Myomo and Myomo may purchase from the Company, the parts and
semi-finished product in accordance with Myomo’s purchase orders. 

 Chapter Fifteen 

Effectiveness; Term 
  

	15.1	 Effectiveness of the Contract. This Contract shall become effective from the date hereof upon the
Parties’ execution of this Contract. 

  

	15.2	 Term. The term of the Company shall be twenty (20) years commencing from the Establishment Date
(the “Joint Venture Term”), unless terminated by the Parties pursuant to Chapter Fifteen or extended by the Parties pursuant to Section 15.3 below. 

  
 21 

	15.3	 Extension. Subject to PRC Laws, the Parties may agree to extend the Joint Venture Term specified in
Section 15.2 above as well as any extended term thereof. 

 Chapter Sixteen 

Termination and Liquidation 
  

	16.1	 Termination upon Expiration of Term. This Contract shall automatically terminate upon expiration of the
Joint Venture Term specified under Section 15.2 or, as applicable, the expiration of the extended Joint Venture Term made in accordance with Section 15.3. 

 

	16.2	 Termination by Mutual Agreement. The Parties may mutually agree in writing to terminate this
Contract at any time. 

  

	16.3	 Early Termination. Any Party (except as otherwise provided below in this Section) shall have the right
(but not obligation) to terminate this Contract by sending a termination notice to the other Party upon the occurrence of any of the following events: 

  

	(a)	 any Party materially breaches any provision of, or is in material default under, this Contract, the Articles of
Association, or any other Transaction Document to which it is a party, and such breach or default is not curable or, if capable of being cured, is not cured within sixty (60) days after the date of written notification of such breach, in which
event any non-breaching Party has the right to terminate; 

  

	(b)	 the Company ceases to carry on its business or is unable to repay its debts or obligations when due, in which
event any Party has the right to terminate; provided that if the foregoing is caused by or results from a Party’s material breach of or material default under this Contract, the Articles of Association, or any
other Transaction Document to which it is a party, then only any non-breaching Party has the right to terminate; 

  

	(c)	 all or substantially all of assets of the Company are nationalized or expropriated by any Government
Authorities, in which event any Party has the right to terminate; provided that if the foregoing is caused by or results from a Party’s material breach of or material default under this Contract, the Articles
of Association, or any other Transaction Document to which it is a party, then only any non-breaching Party has the right to terminate; 

 

	(d)	 a Change of Law occurs causing any Party to suffer a material adverse effect in respect of its interests or
rights in relation to the Company as a result of such Change of Law, in which event only such affected Party has the right to terminate; 

  

	(e)	 the Company is not established by March 31, 2021, in which event any Party has the right to terminate;
provided that if the foregoing is caused by or results from a Party’s material breach of or material default under this Contract, the Articles of Association, or any other Transaction Document to which it is a
party, then only any non-breaching Party has the right to terminate; or 

  

	(f)	 any other specific termination event as agreed to by the Parties in writing. 

  
 22 

 16.4 Liquidation. 
  

	(a)	 (i) At the expiration of the Joint Venture Term (or any extension thereof) in accordance with above
Section 16.1 without renewal or without Myomo’s exercise of its put option set out in above Section 5.10, or (ii) after the termination of the Contract in accordance with above Section 16.2 or Section 16.3, unless
otherwise agreed by the Parties, then the Board shall, as soon as practicably possible, appoint a liquidation group (the “Liquidation Group”) which shall have the power to represent the Company in all legal matters. The Liquidation
Group shall value and liquidate the Company’s assets in accordance with the applicable Laws of the PRC and the principles set out herein. 

  

	(b)	 The Liquidation Group shall consist of four (4) members: Anhui Ryzur shall be entitled to appoint two
(2) members, Myomo shall be entitled to appoint one (1) member, and the fourth (4th) member shall be jointly appointed by the Parties. Decisions of the Liquidation Group shall be made by
a simple majority vote, which majority vote shall always include the affirmative vote or consent of the member appointed by Myomo. Members of the Liquidation Group may, but need not be, Directors or senior employees of the Company. Any Party may
appoint professional advisors to be members of the Liquidation Group and the Liquidation Group may also, at the Company’s cost, appoint non-member professional advisors to assist it.

  

	(c)	 The Liquidation Group shall conduct a thorough examination of the Company’s assets and Liabilities, on the
basis of which it shall, in accordance with the relevant provisions of this Contract, develop a liquidation plan which, if approved by the Board, shall be executed under the Liquidation Group’s supervision. The liquidation plan shall provide
that the Parties will have a priority right, assuming equal price and other terms, over third parties to purchase any of the Company’s machinery, equipment and other facilities and assets. 

 

	(d)	 In developing and executing the liquidation plan, the Liquidation Group shall use every effort to obtain the
highest possible price for the Company’s assets. 

  

	(e)	 Proprietary information which may be authorized or licensed by any Party or its Affiliates to the Company
(including, without limitation, the Myomo IP), shall not be deemed an asset of the Company for purposes of liquidation proceedings, and may not be transferred except with the prior written consent of such Party (which may be withheld in such
Party’s sole and absolute discretion). 

  

	(f)	 The liquidation expenses, including remuneration of members and advisors to the Liquidation Group, shall be
paid out of the Company’s assets in priority to the claims of other creditors. 

  

	(g)	 After the liquidation of the Company’s assets and the settlement of all of its outstanding debts, the
remaining assets of the Company shall be paid to the Parties in proportion to their respective ownership interests in the registered capital in the Company, which payment shall be offset by any Liabilities or indebtedness owed by the applicable
Party to the Company (including, without limitation, any unpaid capital contribution payable by such Party to the Company). 

  

	(h)	 On completion of all liquidation procedures, the Liquidation Group shall submit to competent Government
Authority a final report approved by the Board and an internationally recognized independent accounting firm registered in the PRC, surrender the Business License to the Registration Authority and complete the deregistration of the Company and all
other formalities for nullifying the Company’s accounting books and other documents at its own expenses and the Parties shall provide reasonable assistance in relation thereto, but the originals thereof shall be left in the care of Anhui Ryzur,
and Myomo shall be entitled to retain copies thereof. 

  
 23 

	(i)	 The other members in the Group (if any) shall also be liquidated if the Company is liquidated.

  

	16.5	 Effect of Termination. 

 

	(a)	 The termination of this Contract for any reason shall not release a Party from its Liabilities to pay any sums
of money accrued, due and payable to the other Party, or to discharge its then-accrued and unfulfilled obligations, including any obligation to the Company or to the other Party in respect of breach of this Contract or any obligation otherwise
stipulated in this Contract. Notwithstanding anything to the contrary contained herein, the provisions contained in Section 3.4, this Chapter Sixteen, Chapter Seventeen, Chapter Nineteen, Chapter Twenty and Chapter Twenty-one hereof shall survive the expiration or earlier termination of this Contract. 

Chapter Seventeen 

Confidentiality and Non-Competition 

 

	17.1	 Confidentiality. 

 

	(a)	 All IP, technology, know-how, techniques, trade secrets, trade practices, methods, specifications, designs and
other proprietary information disclosed by any Party to each other or to the Company under the terms of this Contract or otherwise, or developed by the Company, as well as the terms of this Contract and other confidential business and technical
information of any Party or the Company (collectively, “Confidential Information”) shall be used by the Parties, the Company and their respective personnel solely for the Company’s account and purposes provided
that the ownership of any Confidential Information disclosed by any Party shall remain the property of the relevant Party. Each Party and the Company shall maintain the secrecy of all Confidential Information that may be disclosed or
furnished to it by the Company or the other Party, and it shall not disclose or reveal any such Confidential Information to any third party absent explicit written authorization from the Board (with respect to Confidential Information disclosed or
furnished by the Company) or the relevant Party (with respect to Confidential Information disclosed or furnished by such relevant Party), as the case may be. Confidential Information shall exclude information the receiving Party can demonstrate by
competent evidence: (a) was independently developed by the receiving Party without any use of or access to the disclosing Party’s Confidential Information; (b) became lawfully known to the receiving Party, without restriction, from a
source (having a right to disclose such information) other than the disclosing Party without breach of this Contract or any other Transaction Document to which it is a party; (c) was generally available in the public domain at the time it was
disclosed or enters the public domain through no act or omission of the receiving Party; (d) was lawfully known by the receiving Party, without restriction, at the time of disclosure; or (e) was approved for disclosure by the disclosing
Party beforehand and in writing. 

  
 24 

	(b)	 Confidential Information received by a Party may be disclosed by that Party to its directors, officers,
employees and advisors only insofar as their duties require such disclosure for the implementation of this Contract. In the event of such disclosure, the receiving Party shall take all reasonable precautions, including the entry into confidentiality
contracts with each such directors, officers, employees or advisors, to prevent such persons from using Confidential Information for their personal benefit and to prevent any unauthorized disclosure of such Confidential Information to any third
party. 

  

	(c)	 The Parties shall also ensure that the Company shall take all reasonable precautions, including the entry into
confidentiality agreements with its directors, officers and employees, to prevent the Company’s directors, officers and employees from using Confidential Information for their personal benefit and to prevent any unauthorized disclosure of such
Confidential Information to any third party. 

  

	(d)	 Notwithstanding the foregoing, the Parties and the Company may without prior written approval of the Party who
disclosed the Confidential Information reveal Confidential Information to government personnel only to the extent necessary to obtain any required governmental approval, and to outside lawyers, accountants and consultants to the extent necessary for
them to provide their professional assistance, and to regulatory authorities to which the Parties or their respective holding companies are subject, provided that Confidential Information so revealed in written
form is marked confidential and that such government personnel, outside individuals and, to the extent possible, the regulatory authorities, shall be requested to undertake to respect the confidentiality provisions of this Contract.

  

	17.2	 Non-Competition. 

 

	(a)	 The Company shall be the exclusive vehicle through which each Party, directly or indirectly, will conduct any
Business in the Territory. 

  

	(b)	 Each of Anhui Ryzur and Myomo (each, together with its respective Affiliates, a “Non-Compete Party”) covenants, severally and not jointly, that it shall not, and shall cause its Affiliates not to, during the period that such Non-Compete Party
remains a shareholder of the Company and for a period of two (2) years following (i) the termination, liquidation, dissolution or winding up of the Company or (ii) such Non-Compete Party ceasing
to be a shareholder of the Company, whichever occurs earlier, without the prior written consent of the other Party, directly or indirectly (A) conduct or engage in any Competing Business in the Territory, (B) invest, or hold any equity
interests, directly or indirectly, in any Company Competitor, or (C) solicit or entice away or attempt to solicit or entice away to any Company Competitor, any employee, consultant, supplier, customer, client, representative or agent of any
Group Company. 

  

	(c)	 Notwithstanding the foregoing, nothing in this Section 17.2 shall prevent Anhui Ryzur, Myomo or any of
their respective Affiliates from (i) making passive investments in any Company Competitor, provided that Anhui Ryzur or Myomo, together with its respective Affiliates, does not directly or indirectly (x) own
more than one percent (1%) of the equity interests (in the aggregate) of such Company Competitor (or in the case of the general partner of the Master Fund, own more than nine percent (9%) of the equity interests (in the aggregate) of such Company
Competitor), or (y) have a seat of the board of directors or any similar governing body or any management rights in such Company Competitor; or (ii) keeping existing investments made prior to the Establishment Date. 

  
 25 

	(d)	 Notwithstanding anything to the contrary in this Contract, (i) the restrictions set forth in this
Section 17.2 shall not apply to Anhui Ryzur, or any of its Affiliates if the Company is terminated, liquidated, dissolved or wound up due to the material breach of any terms of this Contract by Myomo; and (ii) the restrictions set forth in
this Section 17.2 shall not apply to Myomo or any of its Affiliates if the Company is terminated, liquidated, dissolved or wound up due to the material breach of any terms of this Contract by Anhui Ryzur. 

Chapter Eighteen 

Compliance with PRC Law 
  

	18.1	 General Compliance. The Parties shall at all times, and shall procure that at all times the Company and
all of the directors, officers, employees and agents of the Company, comply with all Laws (including without limitation PRC Laws) applicable thereto including but not limited to those with respect to inspections, audits and record-keeping
requirements, anti-bribery, anti-corruption, anti-money laundering and export control. 

  

	18.2	 U.S. Trade Laws. The Parties acknowledge and understand that Myomo is subject to U.S. export control and
sanctions laws and regulations, including those administered and enforced by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”), the U.S. Department of State, the U.S. Department of Commerce and
other applicable export control or sanctions authorities (collectively, the “Trade Laws”), and that the technology contributed by Myomo to the Company is also subject to the Trade Laws. In its performance of activities with
respect to the Company, each Party agrees to comply with the Trade Laws. Each Party represents and warrants to each other Party that (i) neither it nor any of its Subsidiaries or Affiliates is the target of any economic or trade sanctions
administered and enforced by OFAC or any other applicable U.S. sanctions authority (collectively, “Sanctions”), nor is it or any of their respective Subsidiaries or Affiliates listed on any Sanctions-related list, including the
Specially Designated Nationals and Blocked Persons List maintained by OFAC, (ii) no action by or before any Government Authority involving such Party or its Subsidiaries or Affiliates with respect to the Trade Laws is pending or, to the
knowledge of such Party, threatened, nor, to the knowledge of such Party, is any investigation by or before any Government Authority involving such Party or its Subsidiaries or Affiliates with respect to the Trade Laws pending or
threatened. Furthermore, each Party agrees that it nor any of its Subsidiaries or Affiliates shall take any action, or cause any action to be taken, directly or indirectly (through any of their respective directors, officers, employees or
agents) with respect to the Company in violation of the Trade Laws or that would cause Myomo to be in violation of the Trade Laws, nor shall such Party or its Subsidiaries or Affiliates use any proceeds of the Company to fund any operations, finance
any investments or activities, or make any payments, in each case in violation of the Trade Laws. 

 Chapter Nineteen

 Governing Law; Dispute Resolution 
  

	19.1	 Governing Law. The formation, validity, interpretation, execution, amendment and termination of and
settlement of Disputes under this Contract shall all be governed by the Laws of the PRC. 

  
 26 

	19.2	 Dispute Resolution. Any dispute, controversy, difference or claim (a “Dispute”) arising
out of or in connection with this Contract, including the existence, validity, invalidity, breach or termination thereof, or any dispute regarding non-contractual obligations arising out of or in relation to
it shall be referred to and finally resolved by arbitration administered by the Hong Kong International Arbitration Centre in accordance with the Hong Kong International Arbitration Centre Administered Arbitration Rules as at present in force and as
may be amended by the rest of this paragraph. The seat of the arbitration shall be Hong Kong. The arbitration tribunal shall consist of three (3) arbitrators. The claimant and the respondent to such Dispute shall each select one arbitrator
within thirty (30) days after giving or receiving the demand for arbitration. The chairman of the Hong Kong International Arbitration Center shall select the third arbitrator, who shall be qualified to practice law in the PRC. The language of
the arbitration shall be English (with Chinese translation, if requested by a Party at such Party’s cost). The arbitral award shall be final and binding upon the Parties. 

 

	19.3	 Other Matters Unaffected. When any Dispute occurs and when any Dispute is under arbitration, except for
the matters in Dispute, the Parties shall continue to fulfill their respective obligations and shall be entitled to exercise their rights under this Contract. 

Chapter Twenty 

Liabilities for Breach of Contract 
  

	20.1	 Breach of Contract. A Party shall be in breach of this Contract if it fails to fully perform, or
unlawfully suspends its performance of, its obligations under this Contract or any of the Transaction Documents to which it is a party. 

  

	20.2	 Damages. 

  

	(a)	 If the Company incurs or suffers any cost, Liability or loss directly or indirectly as a result of (i) any
breach of or inaccuracy in any representation or warranty made by any Party in this Contract, any IP License Agreement or the Articles of Association or (ii) any breach or default in performance by any Party of such Party’s covenant,
responsibility, agreement or obligation under this Contract, any IP License Agreement or the Articles of Association, such Party in breach or default shall indemnify and hold the Company harmless in respect of any such cost, Liability or loss,
including, but not limited to, interest paid or lost as a result thereof and reasonable attorney’s fees and expenses; provided that, if the Party in breach or default is Anhui Ryzur, Anhui Ryzur shall indemnify and
hold harmless the Company in respect of any such cost, Liability or loss incurred by the Company in accordance with this Section 20.2(a). 

  

	(b)	 If a non-breaching Party incurs or suffers any cost, Liability or loss directly or indirectly as a result of
(i) any breach of or inaccuracy in any representation or warranty made by any Party in this Contract, any IP License Agreement or the Articles of Association or (ii) any breach or default in performance by any Party of such Party’s
covenant, responsibility, agreement or obligation under this Contract, any IP License Agreement or the Articles of Association, such Party in breach or default shall indemnify and hold such non-breaching Party harmless in respect of any such cost,
Liability or loss incurred by such non-breaching Party, including, but not limited to, interest paid or lost as a result thereof and reasonable attorney’s fees and expenses; provided that, if the Party in breach or
default is Anhui Ryzur, Anhui Ryzur shall indemnify and hold harmless Myomo in respect of any such cost, Liability or loss incurred by Myomo in accordance with this Section 20.2(b). 

  
 27 

 Chapter Twenty-one 

Miscellaneous 
  

	21.1	 Notices. Any notices or communications required or permitted to be given by this Contract must be
(i) given in writing in English (with Chinese translation, if requested by a Party at such Party’s cost) and (ii) personally delivered or mailed, by prepaid, certified mail or overnight courier, or transmitted by facsimile or
electronic mail transmission (including PDF), to the Party to whom such notice or communication is directed, to the mailing address or regularly-monitored electronic mail address of such Party as follows: 

Anhui Ryzur and Beijing Ryzur: 

Attention: REN Song 
 Address:
801 Zitan Building, No. 27 Jianguo Road, 
 Chaoyang District, Beijing, PRC 

Email: david.ren@ryzur.com.cn 

Telephone: +86 10 58198900 
  

			
	 Myomo:
	  	Attention: Paul R. Gudonis
		  	Address: One Broadway, 14th Floor, Cambridge,
		  	MA 02142, USA
		  	Email: paul@myomo.com

 with a copy (which shall necessarily include a copy by email to the following and alone shall not constitute
notice) to: 
 Goodwin Procter LLP:             Attention: James Xu 

Address: 100 Northern Avenue, Boston, MA 02210, USA 

Email: jxu@goodwinlaw.com 
  

	21.2	 Further Assurances. Each Party shall do and perform, or cause to be done and performed, all such further
acts and things and shall execute and deliver all such other agreements, certificates, instruments and documents as the other Party may reasonably request to give effect to the terms and intent of this Contract. 

 

	21.3	 Entire Agreement. This Contract, the Transaction Documents and their appendices, schedules and exhibits,
if any, constitute the complete and only agreement between the Parties on the subject matter thereof and replace all previous oral or written agreements, contracts, understandings and communications of the Parties in respect of the subject matter of
thereof. In the event of any inconsistency between the terms and provisions of this Contract and the terms and provisions of the Articles of Association, the terms and provisions of this Contract shall prevail between the Parties.

  

	21.4	 No Implied Waivers. A Party that in a particular situation waives its rights in respect of a breach of
contract by any of the other Party shall not be deemed to have waived its rights against such other Party for a similar breach of contract in other situations. 

  
 28 

	21.5	 Severance. If any provision of this Contract or part thereof is rendered void, illegal or unenforceable
in any respect under any Law, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

  

	21.6	 Amendments. Amendments to this Contract must be made by a written agreement signed by each of the
Parties in both Chinese and English, each of which shall have equal validity and legal effect. 

  

	21.7	 No Assignment. This Contract shall be binding upon and shall be enforceable by each Party hereto and its
respective successors and assigns. Subject to Sections 5.6, 5.7 and 5.8, no Party may assign any of its rights or obligations hereunder to any Person or party without the prior written approval of the other Party. 

 

	21.8	 Guarantee by Beijing Ryzur. Notwithstanding anything to the contrary in this Contract, Beijing
Ryzur hereby unconditionally and irrevocably (y) guarantees to Myomo and the Company the punctual performance by Anhui Ryzur of all of its obligations under this Contract and (z) undertakes to Myomo and the Company that:

  

	(a)	 whenever Anhui Ryzur does not pay or cause to be paid any amount when due under this Contract, Beijing Ryzur
shall immediately on first demand pay such amount as if it was the principal obligor; 

  

	(b)	 whenever Anhui Ryzur fails to perform or cause to be performed its other obligations under this Contract,
Beijing Ryzur shall immediately on demand perform (or procure performance of) and satisfy (or procure the satisfaction of) that obligation, so that the same benefits are conferred on Myomo and/or the Company (as applicable) as they would have
received if such obligation had been performed and satisfied by Anhui Ryzur; and 

  

	(c)	 whenever the Company fails to pay any of the License Fee to Myomo in accordance with the Technology License
Agreement, Beijing Ryzur shall immediately make such payment to Myomo upon Myomo’s demand. 

 The guarantee under this
Section 21.8 is a continuing guarantee and will extend to the ultimate balance of sums payable by Anhui Ryzur under this Contract or the Company under the Technology License Agreement, regardless of any intermediate payment or discharge.
Beijing Ryzur unconditionally and irrevocably waives any right which it may have to first require Myomo to proceed against Anhui Ryzur or the Company (as the case may be) before claiming from Beijing Ryzur under this Section 21.8. 

 

	21.9	 Future Cooperation. To ensure the operation and implementation of the Business in the Territory, both
Parties agrees to take the following actions: 

  

	(a)	 The Parties agrees to use commercially best efforts to reach an agreement with respect to the integration of
supply chain and product manufacturing of the Company; 

  

	(b)	 The Parties agrees to formulate an operational plan of the Company (including plans to staff), train sufficient
sales representatives and clinical support staff to achieve the annual volume goals of the Company, and to provide after-sales clinical and technical support for the Company. 

  
 29 

	(c)	 The Parties are seeking to build a long-term partnership whereas Anhui
Ryzur may support Myomo in making acquisitions in the rehabilitation industry in the US and other countries. 

  

	21.10	 Language. This Contract and its schedules are written in both Chinese and English in four
(4) originals. Each Party shall retain one original. Any remaining originals shall be retained by the Company for use as necessary. The two language versions shall have equal validity and legal effect. 

 

	21.11	 Counterparts. This Contract and any amendment hereto or any other agreement (or document) delivered
pursuant hereto may be executed on one or more signature pages, and shall become binding (unless otherwise therein provided) when the executed signature pages are exchanged by the Parties either in person or remotely via fax or emails.

 [The remainder of this page is intentionally left blank.] 

 

  
 30 

 IN WITNESS HEREOF, the Parties hereby cause this Contract to be executed by their duly
authorized representatives as of the date first above written. 
 Anhui Ryzur Medical Equipment Manufacturing, Co., Ltd.
(安徽瑞德医疗设备制造有限公司) (company chop) 
  

			
	By:	 	          

		 	Name:
		 	Title:

 JVC Signature Page 

 IN WITNESS HEREOF, the Parties hereby cause this Contract to be executed by their duly
authorized representatives as of the date first above written. 
  

			
	Myomo, Inc.
		
	By:	 	              

		 	Name:
		 	Title:

 JVC Signature Page 

 IN WITNESS HEREOF, the Parties hereby cause this Contract to be executed by their duly
authorized representatives as of the date first above written. 
 With respect to Section 5.11 and Section 21.8
only: 
 Beijing Ryzur Medical Investment Co., Ltd.
(北京瑞德医疗投资股份有限公司) 
 (company chop) 

 

			
	By:	 	              

		 	Name:
		 	Title:

 JVC Signature Page 
  

 Schedule I: 

Definitions 

“Affiliate” means, with regard to a given Person, a Person that Controls, is Controlled by, or is under common Control with,
the given Person; provided that for purposes of this Contract, none of Anhui Ryzur or its Affiliates shall be deemed an Affiliates of any Group Company. The term “Affiliated” has meanings correlative to
the foregoing. 
 “Anhui Ryzur” has the meaning ascribed thereto in the Preamble. 

“Articles of Association” means the Articles of Association of the Company executed by the Parties on the date hereof, as
amended, modified or supplemented from time to time. 
 “Beijing Ryzur” has the meaning ascribed thereto in the Preamble.

 “Board” or “Board of Directors” means the board of directors of the Company. 

“Business” has the meaning ascribed thereto in Section 4.1. 

“Business Day” means a day other than a Saturday, Sunday or public holiday on which banks in the PRC, Hong Kong and the US
are open for general business. 
 “Business License” has the meaning ascribed thereto in Section 3.2(a). 

“Business Plan” has the meaning ascribed thereto in Section 5.3(i). 

“Capital Increase” has the meaning ascribed thereto in Section 5.5(a). 

“Chairman” has the meaning ascribed thereto in Section 8.1(b). 

“Change of Law” means any event or circumstance, occurring after the Establishment Date, in which the PRC national or local
government or any other national or local public body or authority in the PRC that has the power to make decisions or rules binding upon the Company, undertakes any of the following: (i) adopts any new Laws, (ii) amends or repeals any
provision of any existing Laws, or (iii) adopts any different interpretation or method of implementation of any Law, which, in each case, has a material adverse effect on either of the Parties or the Company. 

“Co-Sale Right” has the meaning ascribed thereto in Section 5.8(a). 

“Co-Sale Shares” has the meaning ascribed thereto in Section 5.8(a). 

“Company” has the meaning ascribed thereto in the Preamble. 

  
 I-1 

 “Company Competitor” means any Person operating, conducting or engaging in,
directly or indirectly, any of the Competing Business in the Territory, including without limitation the Persons listed in Schedule II, which list shall be updated once every six (6) months by the Board (including the prior written
consent of the Director appointed by Myomo) in accordance with Section 8.8(f). 
 “Competing Business” means any
business or activity in competition with or similar to the Business or any business involving the Core Technology, in each case, regardless of whether such business or activity is then conducted by the Company or any of its Subsidiaries. 

“Confidential Information” has the meaning ascribed thereto in Section 17.1(a). 

“Contract” has the meaning ascribed thereto in the Preamble hereto. 

“Control” with respect to a Person, means (i) ownership of more than fifty percent (50%) of the equity interest or
voting stock of such Person, (ii) the power to appoint or elect a majority of the directors of such Person, or (iii) the power to direct or cause the direction of the business, management and policies of that Person, directly or
indirectly, whether through the ownership of voting securities, by contract or otherwise. The terms “Controlled” and “Controlling” have meanings correlative to the foregoing. 

“Core Technology” means the technology being used to develop, research and produce the myoelectric controlled orthosis
products (以表面肌电监测为基础的辅助器具). 

“Director” means a member of the Board of the Company. 

“Dispute” has the meaning ascribed thereto in Section 19.2. 

“Encumbrance” means any mortgage, pledge, lien, charge, hypothecation, deed of trust, lease, option, right of first refusal,
easement, servitude, security interest or other encumbrance, security agreement or arrangement of any kind, purchase or option agreement or arrangement, and contracts or other agreements to create or effect any of the foregoing. 

“Establishment Date” has the meaning ascribed thereto in Section 3.2(a). 

“Execution Date” has the meaning ascribed thereto in the Preamble hereto. 

“Exercise Notice” has the meaning ascribed thereto in Section 5.7(a). 

“Fiscal Year” means a period beginning on January 1 and ending December 31 of each year. 

“General Manager” has the meaning ascribed thereto in Section 10.1. 

“Government Authority” means any governmental authority or judicial, regulatory, or administrative body of any country or
political subdivision thereof. 

  
 I-2 

 “Group” means the Company and all of its direct or indirect Subsidiaries,
taken as a whole, and a “Group Company” means any of the foregoing. 
 “Intellectual Property” or
“IP” means all the following whether arising under the laws of the USA, PRC or of any other jurisdiction: (i) patents, patent applications (including patents issued thereon) and statutory invention registrations, including
reissues, divisions, continuations, continuations in part, extensions and reexaminations thereof, and all rights therein provided by international treaties or conventions; (ii) copyrights, moral rights, mask work rights, database rights and
design rights, whether or not registered, and registrations and applications for registration thereof, and all rights therein provided by international treaties or conventions; (iii) trade secrets; (iv) trademarks; and
(v) intellectual property rights arising from or in respect of domain names. 
 “IP License Agreements” means
collectively the Technology License Agreement and Trademark License Agreement, and an “IP License Agreement” means any of the foregoing. 

“Joint Venture Term” has the meaning ascribed thereto in Section 15.2. 

“Law” means any published laws, regulations, rules, provisions, circulars, permits, authorizations, interpretations,
government orders or decisions of any Government Authorities or legislative authorities and, in relation to any common law jurisdictions, judgments, awards, decisions or interpretations of any judicial authorities. 

“Lead Sale Party” has the meaning ascribed thereto in Section 5.8(a). 

“Liabilities” means any and all debts, losses, damages, adverse claims, liabilities and obligations of any kind, character or
description, whether accrued or fixed, known or unknown, absolute or contingent, matured or unmatured or determined or determinable, direct or indirect, asserted or unasserted, liquidated or unliquidated, due or to become due, whether in contract,
tort, strict liability or otherwise and including all costs and expenses relating thereto, including, without limitation, those arising under any applicable Law, action or government order and those arising under any contract. 

“License Fee” means the license fee agreed and provided in the Technology License Agreement. 

“Liquidation Group” has the meaning ascribed thereto in Section 16.4(a). 

“Master Fund” means the PRC fund entity co-invested by Shanghai Electric and
Chinaleaf Capital. 
 “MOFCOM” has the meaning ascribed thereto in Section 3.2. 

“Myomo” has the meaning ascribed thereto in the Preamble. 

“Myomo IP” means the IPs to be licensed from Myomo to the Company as agreed in the IP License Agreements. 

  
 I-3 

 “Myomo Products” means the line of medical devices defined as a powered
orthosis (brace) designed by Myomo to help restore function to joints that have been paralyzed or weakened by injury or disease and marketed under the name MyoPro and other future medical device trademarked names. 

“MyoPro Control System” means the microprocessor and embedded software programmed into the said microprocessor that allows
the fully assembled MyoPro product to perform its intended function. The microprocessor and embedded software are intended to be used with a specific MyoPro electro-mechanical design created by Myomo. 

“NMPA” means the National Medical Products Administration of the PRC or its competent local counterpart. 

“NMPA Approvals” has the meaning ascribed thereto in Section 14.2. 

“Non-Compete Party” has the meaning ascribed thereto in Section 17.2(b). 

“Non-Transferring Party” has the meaning ascribed thereto in Section 5.7(a).

 “Party” or “Parties” has the meaning ascribed thereto in the Preamble. 

“Person” means any natural person, company, corporation, association, partnership, organization, business, firm, joint
venture, trust, unincorporated organization or any other entity or organization. 
 “PRC” means the People’s Republic
of China (solely for the purpose of this Contract, excluding the province of Taiwan, Hong Kong and the Macau Special Administrative Region). 

“Registration Authority” has the meaning ascribed thereto in Section 3.2(a). 

“Subsidiary” or “Subsidiaries” of any Person means any corporation, partnership, limited liability company,
joint venture or other legal entity of which such Person (either alone or through or together with any other Subsidiary) directly or indirectly, (i) owns more than 50% of the outstanding share capital, voting securities or other equity
interests or (ii) is generally entitled to appoint a majority of the board of directors or comparable governing body of such corporation, partnership, limited liability company, joint venture or other legal entity; provided
that neither the Company nor its Subsidiaries, if any, shall be deemed to be a Subsidiary of any Party or their respective Affiliates. 

“Supervisor” has the meaning ascribed thereto in Section 9.1. 

  
 I-4 

 “Tax” or “Taxes” means (A) any domestic or foreign
national, provincial, municipal or local taxes, charges, fees, levies or other assessments, including, without limitation, all net income (including enterprise income tax, individual income tax and withholding tax), sales, use, transfer, turnover
(including value-added tax, business tax and consumption tax), resource (including urban and township land use tax), special purpose (including land value-added tax, urban maintenance and construction tax, and additional education fees), property
tax (real or personal), documentation (including stamp duty and deed tax), filing, recording, social insurance (including pension, medical, disability, unemployment, housing or any other social insurance withholding), tariffs (including import
duty), estimated taxes, charges, fees, levies alternative minimum, add-on minimum, registration, excise, natural resources, severance, occupation, premium, windfall profit, environmental, customs, duties,
capital stock, payroll, license, employee or other withholding, whether computed on a separate or consolidated, unitary or combined basis or other assessments of any kind whatsoever and any interest, penalties or additions in connection therewith
and (B) Liability of the Company for the payment of any amounts of the type described in clause (A) as a result of any obligation to indemnify or otherwise assume or succeed to the Liability of any other Person. 

“Technology License Agreement” means a technology license agreement, substantially in the form attached hereto as Exhibit A,
to be entered into by and between the Company and Myomo with respect to Myomo’s license of certain of Myomo’s IP (other than Myomo’s trademarks and trademark-related rights) as set forth in such agreement to the Company. 

“Territory” has the meaning ascribed thereto in Section 4.1. 

“Thirty Day Period” has the meaning ascribed thereto in Section 5.7(a). 

“Three Funds” has the meaning ascribed thereto in Section 13.1. 

“Trademark License Agreement” means a trademark license agreement, substantially in the form attached hereto as Exhibit B, to
be entered into by and between the Company and Myomo with respect to Myomo’s license of certain of Myomo’s trademarks as set forth in such agreement to the Company. 

“Transaction Documents” means this Contract, the Articles of Association and the IP License Agreements. 

“Transfer” has the meaning ascribed thereto in Section 5.6(a). 

“Transfer Notice” has the meaning ascribed thereto in Section 5.7(a). 

“Transferring Party” has the meaning ascribed thereto in Section 5.7(a). 

“Valuer” has the meaning ascribed thereto in Section 5.10(a). 

“Vice-Chairman” has the meaning ascribed thereto in Section 8.1(b). 

  
 I-5 

 Schedule II: 

List of Company Competitors 
 Ottobock 

Ossur 
 Hanger Inc. 

Ekso Bionics 
 ReWalk 

Bionik Labs 
 Rex Bionics 

Cyberdyne (Japan) 
 Parker-Hannifin Corp. 

DIH International (Hong Kong) and Hocoma subsidiary 
 Deltason
(Hong Kong) 
 Abilitech 

  
 II-1 

 Exhibit A 

Technology License Agreement 
  

 EXHIBIT A 

TECHNOLOGY LICENSE AGREEMENT 
 This
TECHNOLOGY LICENSE AGREEMENT (this “License Agreement”) dated as of ______________, 2021 (the “Signing Date”), is entered into by and between Myomo, Inc., a Delaware corporation (“Licensor”) having
its principal office at One Broadway, 14th Floor, Cambridge, MA 02142, USA and Jiangxi Myomo Medical Assistive Appliance Co., Ltd.
(江西迈欧缪医疗辅助器具有限公司) a company incorporated under the laws of the PRC (“Licensee” or the “JV”) having its principal
office at 1st Floor, Building No. 6, 544 Jiamaowu Road, inner Comprehensive Bonded Area, Xinjian District, Nanchang, Jiangxi Province
(江西省南昌市新建区综合保税区内嘉茂五路544号6栋1层). 

WHEREAS, pursuant to an Equity Joint Venture Contract, dated as of [•] by and between Myomo, Inc., Anhui Ryzur Medical Equipment
Manufacturing, Co., Ltd. and Beijing Ryzur Medical Investment Co., Ltd. (the “JV Contract”), Licensor agrees to (a) contribute capital equal to USD$199,000 to the JV, and (b) supply the Licensee with certain hardware and
software components of Licensor’s MyoPro Control System; and 
 WHEREAS, subject to the terms and conditions of this License Agreement,
Licensee desires and is willing to secure from Licensor, and Licensor desires and is willing to grant to Licensee an exclusive license in the Field and in the Territory in and to certain Licensed IP (as defined below); and 

WHEREAS, the JV Contract contemplates the entry into this License Agreement in connection with the execution of the JV Contract. 

NOW, THEREFORE, in consideration of these premises and the mutual covenants, agreements, representations and warranties herein contained, the
Parties hereby agree as follows: 
 1. Certain Defined Terms. Capitalized terms used but not otherwise defined herein shall have
the meanings set forth in the JV Contract. The following terms shall have the meanings set forth below: 
 1.1 “Action” shall have
the meaning set forth in Section 11.3 
 1.2 “Affiliate” shall have the meaning set forth in the JV Contract. 

1.3 “Authority of Commerce” means the Ministry of Commerce of the PRC or its competent local branches; 

1.4 “Challenge” shall have the meaning set forth in Section 2.6. 

1.5 “Claim” shall have the meaning set forth in Section 11.1 

1.6 “Control”, “Controls” or “Controlled by” means, with respect to any item of or right
under the Licensed IP or the subject matter of the Licensed IP, the possession of (whether by ownership or license, other than pursuant to this License Agreement), or the ability of Licensor to grant access to, or a license or sublicense of such
item or right as provided for herein without violating the terms of, or requiring the payment of any royalty or any other fee under, any agreement or other arrangement with any Third Party existing at the time Licensor would be required hereunder to
grant Licensee such access, right or (sub)license. 

 1.7 “Copyrights” means copyrights and related rights under copyright and
similar Laws in original published and unpublished works of authorship fixed in a tangible medium of expression and related registrations and applications for registration in the United States Copyright Office or in any similar office or agency
anywhere in the world. 
 1.8 “Effective Date” shall mean the date on which the all of the following have occurred:
(i) parties have executed definitive documents for the JV Contract; (ii) the parties have agreed on a business plan for the JV as defined in Section 5.3(i) of the JV Contract, and (iii) registered capital contributions described
in Section 5.2(i) and capital reserve of US$5,000,000 described in Section 5.3(i) of the JV Contract have been completed by
Ryzur (as defined in the JV Contract). 
 1.9 “Field” means the field of powered orthosis designed to help restore
function to arms and hands paralyzed or weakened by CVA stroke, brachial plexus injury, cerebral palsy or other neurological or neuromuscular disease or injury. 

1.10 “Improvement” or “Improvements” means any modification, derivative work or improvement of any
intellectual property, whether patented or not and whether patentable or not. 
 1.11 “Initial Patents” shall have the
meaning set forth in Section 1.21. 
 1.12 “Joint Improvement” means any Improvement of any Licensed IP that is
created, developed or conceived by or on behalf of (a) Licensee or its Subsidiaries, without any contribution to creation, development or conception by Licensor or its Affiliates, or (b) Licensee or its Subsidiaries, and, Licensor or its
Affiliates, with some contribution to creation, development or conception from each Party. 
 1.13 “JV Contract” shall have
the meaning set forth in the Recitals hereto. 
 1.14 “Know-How” means all
confidential, technical and/or proprietary information and knowledge, whether or not patentable and whether or not in written form, including, without limitation, information, inventions, know-how and
knowledge regarding inventions, discoveries, techniques, research in progress, trade secrets, systems, methods, processes, algorithms, technical data, formulae, drawings, designs, schematics, specifications, blueprints, flow charts, models,
prototypes, techniques, practices, manufacturing and design information, and financial, business, marketing and client information. 
 1.15
“Laws” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or
foreign. 
 1.16 “License Agreement” shall have the meaning set forth in the Preamble hereto, and includes without
limitation all schedules and attachments. 

  
 2 

 1.17 “Licensed Copyrights” means any and all Copyrights in any and all
documents and other works of authorship as identified on Schedule B. 
 1.18 “License Fee” shall have the meaning set forth
in Section 6.1. 
 1.19 “Licensed IP” means, collectively, any and all of the Licensed Copyrights, Licensed Know-How, and Licensed Patents. 
 1.20 “Licensed
Know-How” means any and all rights Controlled by Licensor under applicable trade secret Laws during the Term in and to any and all Know-How embodied in the
Licensed Copyrights. 
 1.21 “Licensed Patents” means any and all Patents listed on Schedule A hereto (the
“Initial Patents”) and any Patents Controlled by Licensor during the Term which include claims which cover any updates to any of the inventions claimed in the Initial Patents which updates are created by Licensor during the Term.

 1.22 “Licensed Product” means any and all products identified in Schedule D as such Schedule may be updated to
include additional products which are marketed and sold by Licensor during the Term. 
 1.23 “Licensed Software” means, any
and all software listed on Schedule C. 
 1.24 “Licensed Software Documentation” means any and all end user
documentation and technical documentation (e.g., Source Code documentation and other technical documentation) Controlled by Licensor during the Term that is associated with the Licensed Software. 

1.25 “Licensee” shall have the meaning set forth in the Introductory Paragraph. 

1.26 “Licensee Indemnitees” shall have the meaning set forth in Section 11.2. 

1.27 “Licensor” shall have the meaning set forth in the Introductory Paragraph. 

1.28 “Licensor Improvement” means any Improvement of any Licensed IP that is created, developed or conceived by or on behalf
of Licensor or its Affiliates, without any contribution to creation, development or conception by Licensee or its Subsidiaries. 
 1.29
“Licensor Indemnitees” shall have the meaning set forth in Section 11.1. 
 1.30 “Loss” shall have the
meaning set forth in Section 11.1. 
 1.31 “MyoPro Control System” shall have the meaning set forth in the JV Contract.

 1.32 “Object Code” means computer software programs, assembled or compiled substantially or entirely in binary form,
which are readable and usable by computer equipment, but not generally readable by humans without reverse assembly, reverse compiling or reverse engineering. 

  
 3 

 1.33 “Party” means Licensee or Licensor, individually, and
“Parties” means Licensee and Licensor, collectively. 
 1.34 “Patents” means all of the following under
patent and similar Laws: (a) patents and patent applications (which for the purposes of this License Agreement shall be deemed to include certificates of invention and applications for certificates of invention), (b) all divisionals,
continuations, request for continued examination applications and continuation-in-part applications of any patents or applications described in the foregoing clause 1.34
or this clause 1.34, (c) all patents issuing on any of the foregoing, (d) all registrations, grants, reissues, reexaminations, renewals, and supplemental protection certificates, including any term adjustments, restorations or extensions of any
of the foregoing, (e) all other patents and patent applications of any type issued or filed anywhere in the world claiming priority in whole or in part to or from any of the foregoing, and (f) all international patents, utility models,
invention registrations of any kind, and any other patent applications of any kind corresponding to any of the foregoing. 
 1.35
“Person” shall have the meaning set forth in the JV Contract. 
 1.36 “PRC” means the People’s
Republic of China. 
 1.37 “Signing Date” shall have the meaning set forth in the Introductory Paragraph. 

1.38 “Source Code” means the human readable representation of a computer program or designs written in any
computer-programming language (e.g., VHDL, Verilog, Matlab, SPICE, C, C++, TCL, Perl, assembly code, etc.). 
 1.39 “Term”
shall have the meaning set forth in Section 9.1. 
 1.40 “Territory” means the PRC, Hong Kong S.A.R., Macau S.A.R., and
Taiwan. 
 1.41 “Title 11” shall have the meaning set forth in Section 13. 

1.42 “Third Party” means any Person other than Licensee, Licensor and their respective Affiliates. 

2. License Grants. 
 2.1 Patents
and Know-How. Subject to the terms and conditions set forth in this License Agreement, Licensor hereby grants to Licensee, and Licensee hereby accepts, a limited, revocable, exclusive (in the Territory and
Field), non-transferable (except as expressly permitted by Section 14.7), and non-sublicenseable right and license under the Licensed Patents and Licensed Know-How
in the Field and Territory only, to make, have made, use, sell, have sold, offer for sale, have offered for sale, import, and have imported the Licensed Products, and the right to practice the methods claimed in such Licensed Patents or Licensed Know-How in direct connection with such Licensed Products. 

  
 4 

 2.2 Copyrights. In addition to the rights grant in Section 2.1 above and subject
to the terms and conditions set forth in this License Agreement, Licensor hereby grants to Licensee, and Licensee hereby accepts, a limited, revocable, exclusive (in the Territory and Field), non-transferable
(except as expressly permitted by Section 14.7), and non-sublicenseable right and license under the Licensed Copyrights in the Field and Territory only, to reproduce, display, distribute, modify, and create derivative works and/or perform the
works of authorship that are the subject matter of the Licensed Copyrights in each case for the purpose of developing and commercializing the Licensed Products. 

2.3 Software. 
 (a)
Source Code License Grant. Subject to the terms and conditions set forth in this License Agreement, Licensor hereby grants to Licensee, and Licensee hereby accepts, a limited, revocable, exclusive (in the Territory and Field), non-transferable (except as expressly permitted by Section 14.7), and non-sublicenseable right and license under the Licensed Copyrights, in the Field and Territory only, to use, reproduce, modify, and create
derivative works of all or any portion or portions of the Source Code of the Licensed Software in direct connection with the research, development or commercialization of the Licensed Products. 

(b) Object Code License Grant. Subject to the terms and conditions set forth in this License Agreement, Licensor hereby grants to
Licensee, and Licensee hereby accepts, a limited, exclusive (in the Territory and Field), perpetual, irrevocable, non-transferable (except as expressly permitted by Section 14.7), and non-sublicenseable
right and license, in the Field and Territory only, to use, reproduce, modify, and create derivative works of all or any portion or portions of the Object Code of the Licensed Software and to perform, display and distribute such Object Code only for
use in direct connection with the research, development or commercialization of the Licensed Products. 
 (c) Documentation License
Grant. Subject to the terms and conditions set forth in this License Agreement, Licensor hereby grants to Licensee, and Licensee hereby accepts, a limited, exclusive (in the Territory and Field), perpetual, irrevocable, non-transferable (except as expressly permitted by Section 14.7), and non-sublicenseable right and license, in the Field and Territory only, to use, reproduce, display, distribute, modify, and create derivative
works of all or any portion or portions of the Licensed Software Documentation for purposes of creating new versions of the Licensed Software Documentation and to distribute such Documentation only for use in direct connection with the research,
development or commercialization of the Licensed Products. 
 2.4 Reservations; Restrictions. 

(a) Except as expressly set forth herein, Licensor reserves all right, title and interest in the Licensed IP. Licensee shall not sell, transfer
or otherwise provide, directly or indirectly, the Licensed Products for use or sale outside of the Territory or outside of the Field. 
 (b)
To the extent that Licensee enters into a written agreement relating to any Licensed Product with a Third Party after the Signing Date, Licensee shall restrict such Third Party and require similar restrictions throughout the supply chain, from
shipping or selling Licensed Products outside of the Field. Licensee shall exercise its reasonable commercial efforts to enforce such restrictions, including without limitation by (i) promptly suspending shipments of the

  
 5 

 
Licensed Products to a Third Party if the Licensed Products are being sold or used by such Third Party outside the Field, (ii) notifying such Third Party in writing of such alleged
violation, (iii) conducting an investigation of such violation as reasonably appropriate under the circumstances, (iv) following completion of such investigation, terminating any such Third Party the investigation of which revealed that
such Third Party failed to comply with such restrictions, and (v) pursuing a damage claim (or authorizing Licensor to pursue such damage claim on its behalf) against any such Third Party that failed to comply with its restriction. In any
written agreement with a Third Party, Licensee shall require that such Third Party agrees that Licensor shall be treated as an intended third party beneficiary for purposes of enforcing under such agreement the restrictions described in this
Section 2.4. 
 2.5 Licensee Covenant Not to Sue. Licensee covenants and agrees that Licensee shall not directly or indirectly
commence, authorize or assist in any suit or other proceeding (including asserting any claim or counterclaim against, or participate in or join or otherwise aid, other than as required by Law, in any claim or action against, Licensor) under the
Licensed IP or any other intellectual property rights sold or licensed by Licensor under the JV Contract (if any) to the extent based on a claim that, solely because of the sale of such assets under the JV Contract or the rights and licenses granted
by Licensor to Licensee under this License Agreement, Licensor or any Affiliate of Licensor does not have the rights reasonably necessary or useful to perform (a) its obligations under the JV Contract or (b) research, development,
regulatory and quality assurance activities to support developing, manufacturing, marketing or selling products outside of the Territory or the Field. The covenant not to sue in this Section 2.5 is not transferable by either Party, except that
it will transfer (x) as set forth in Section 14.7 and (y) with any sale, disposition or other grant or authorization of rights by Licensee of the applicable intellectual property right. 

2.6 Termination Upon Patent Challenge. In the event that Licensee or any of its Affiliates, licensees, sublicensees or
distributors, anywhere in the Territory, without the prior written consent of Licensor institutes, prosecutes or otherwise participates in (other than to defend any Licensed Patent), or in any way aids any Third Party in instituting, prosecuting or
participating in, before any indicial administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or
for an enjoinment, injunction or any other equitable remedy, including any interference, re-examination, opposition or any similar proceeding, alleging that any claim in a Licensed Patent is invalid,
unenforceable or otherwise not patentable (a “Challenge”), Licensor shall have the right to terminate this License Agreement, including the rights of any such licensees, sublicensees or distributors by written notice to the
Licensee; provided, however, that such termination shall not take effect if (a) the Challenge is brought by a licensee or sublicensee of Licensee (and not by Licensee or its Affiliates) or (b) Licensee unintentionally and
unknowingly provided aid to any such Third Party regarding the Challenge, and if, within ten (10) days of receipt of such notice of termination, Licensee with respect to such clause 2.6 terminates the sublicense it granted such licensee or
sublicensee, or with respect to such clause 2.6 causes such aid to cease, respectively, and notifies Licensor thereof. 
 2.7 Future
Product Lines. The Parties agree to negotiate in good faith the terms, including licensing terms and additional consideration, under which Licensee may develop and commercialize any future medical product developments or enhancements created by
Licensor during the Term. 

  
 6 

 3. Transfer of Copies of Licensed IP; Technical Assistance. 

3.1 Transfer of Copies of Licensed IP. Within fifteen (15) days after receipt of the entire License Fee paid in accordance with
Section 6.1 below, Licensor shall transfer or make available to Licensee sufficient copies of documents and materials Controlled by Licensor that document, describe or embody the Licensed IP or the subject matter of the Licensed IP. Until such
time as the entire License Fee is paid to Licensor, Licensee will purchase from Licensor, Licensed Products for use in any clinical studies required in China for NMPA approval. 

3.2 Technical Support. Licensor shall provide sufficient technical support, assistance and trainings to Licensee to ensure the transfer
of know how so that Licensee can produce Myomo Products in Licensee’s factory as detailed in Schedule E hereto. Licensor shall be compensated by the JV for direct costs incurred in the provision of such support assistance and trainings.

 4. Marking. To the extent commercially feasible and consistent with prevailing business practices, Licensee and/or its
Affiliates shall mark all Licensed Products in a manner to provide sufficient notice under applicable Law. In the event that a Licensed Product cannot be marked itself, the patent notice shall be placed on associated tags, labels, packaging, or
accompanying documentation, either electronic or paper, as appropriate to provide sufficient notice under applicable Law. 
 5. Ownership of Licensed
IP and Improvements. 
 5.1 Ownership of Licensed IP. Except for the licenses and rights expressly granted to Licensee in this
License Agreement, all right, title, and interest in and to the Licensed IP shall remain vested in Licensor. If Licensee acquires any right, title or interest in or to the Licensed IP, Licensee hereby assigns and will assign, for no additional
consideration, all right, title and interest in any of the foregoing to Licensor. 
 5.2 Ownership and Use of Improvements. 

(a) Notwithstanding the above, it is agreed that (i) Licensor and Licensee shall jointly own all right, title and interest in and to any
Joint Improvement, and (ii) Licensor shall solely and exclusively own all right, title and interest in and to any Licensor Improvement. 

(b) Licensee shall have the exclusive right to use any Joint Improvement in the Field and Territory, but shall not license or transfer its
interests in such Joint Improvement to any Third Party. Licensee shall have no right to use any Joint Improvement outside of the Field or outside of the Territory, except upon prior written consent of Licensor. Licensor shall have no restrictions on
its use, transferability or licensing of any Licensor Improvement outside of the Field (even if within the Territory) and/or outside of the Territory (even if within the Field). Upon creation of any Joint Improvement, Licensee shall promptly
(i) notify Licensor, (ii) describe such Joint Improvement in reasonable detail, and (iii) provide to Licensor any tangible embodiment of such Joint Improvement that Licensee creates for Licensor’s own research or development.

  
 7 

 6. Consideration. 

6.1 License Fee. As consideration under this License Agreement, Licensee shall pay to Licensor, a
non-refundable license fee equal to US$214,920 plus US$2,500,000 (the “License
Fee”), which shall be paid by Licensee to Licensor as follows: 
 (a) within thirty (30) business days after the
Effective Date, Licensee shall pay to Licensor the first installment equal to US$214,920 plus US$2,000,000; and 

(b) within thirty (30) business days after the NMPA Approvals (as defined in the JV Contract) have been obtained by Licensor with evidence
reasonably satisfactory to Licensee, Licensee shall pay to Licensor the remaining US$500,000. 
 6.2 Tax. Any withholding or other
taxes due by the JV or Myomo as a result of the payment of the License Fee shall be the responsibility of the JV. 
 7. Representations and
Warranties. 
 7.1 Licensor. Licensor hereby represents and warrants to Licensee that as of the date hereof and the Effective
Date: 
 (a) To the Licensor’s knowledge and belief, Licensor can lawfully license the Licensed IP, Licensed Software and Licensed
Products under the laws of the United States to Licensee in accordance with this Agreement. 
 (b) All corporate action on the part of
Licensor and on the part of each of its officers and directors necessary for the authorization, execution, and delivery of this License Agreement and the performance of its obligations hereunder has been taken. 

(c) This License Agreement is the legal, valid, and binding obligation of Licensor, enforceable against it in accordance with its terms. 

(d) Neither the execution and delivery of this License Agreement nor the performance of the obligations contemplated hereby will:
(i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or constitute a default under any provision of any contract or any other
obligation to which Licensor is a party or under which Licensor is subject or bound, (ii) violate any judgment, order, injunction, decree or award of any governmental authority against, or affecting or binding upon, Licensor or upon the assets,
property or business of Licensor, or (iii) constitute a violation by Licensor of any applicable Law of any jurisdiction as such Law relates to Licensor or to the property or business of Licensor. 

(e) To Licensor’s knowledge, no action, suit, proceeding, or investigation is pending or is threatened in writing, nor has any claim or
demand been made in writing, that challenges the legality, validity, enforceability, use or ownership by Licensor of any of the Licensed IP, Licensed Software and Licensed Products. 

  
 8 

 7.2 Licensee. Licensee hereby represents and warrants to Licensor that as of the date
hereof and the Effective Date: 
 (a) All corporate action on the part of Licensee and on the part of each of its officers and directors
necessary for the authorization, execution, and delivery of this License Agreement and the performance of its obligations hereunder has been taken. 

(b) This License Agreement is the legal, valid, and binding obligation of Licensee, enforceable against it in accordance with its terms. 

(c) Neither the execution and delivery of this License Agreement nor the performance of the obligations contemplated hereby will:
(i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or constitute a default under any provision of any contract or any other
obligation to which Licensee is a party or under which Licensee is subject or bound, (ii) violate any judgment, order, injunction, decree or award of any governmental authority against, or affecting or binding upon, Licensee or upon the assets,
property or business of Licensee, or (iii) constitute a violation by Licensee of any applicable Law of any jurisdiction as such Law relates to Licensee or to the property or business of Licensee. 

(d) Licensee or its Affiliates shall not challenge the validity, enforceability or ownership of any Licensed Patents, and Licensee instituting
such a challenge shall be considered a material breach of this License Agreement. 
 7.3 Disclaimers. 

(a) Notwithstanding anything to the contrary in this License Agreement, Licensor makes no representation or warranty regarding the sufficiency
of the Licensed IP to support the operation of Licensee’s business, or the making, using, selling, or importation of any product by Licensee. 

(b) THE LICENSED IP AND ANY LICENSES GRANTED BY LICENSOR TO LICENSEE ARE PROVIDED UNDER THIS LICENSE AGREEMENT “AS IS” AND MAY
CONTAIN DEFICIENCIES, AND, EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES INCLUDED IN THE JV CONTRACT, LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES REGARDING THE USE OR PERFORMANCE OF SUCH LICENSED IP OR LICENSED RIGHTS. EXCEPT FOR THE
REPRESENTATIONS AND WARRANTIES BY EACH PARTY AS SET FORTH IN SECTIONS 7.1 AND 7.2 ABOVE, EACH PARTY MAKES NO REPRESENTATIONS OR WARRANTIES UNDER THIS LICENSE AGREEMENT AND DISCLAIMS ALL IMPLIED REPRESENTATIONS AND WARRANTIES, INCLUDING ANY IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. NOTWITHSTANDING THE FOREGOING TO THE CONTRARY, THE LICENSED IP IS SUBJECT TO THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THE JV CONTRACT. 

  
 9 

 8. Confidentiality. 

8.1 Confidentially Obligation. During the Term and thereafter, except as expressly provided below, each of Licensee and Licensor shall
keep in strictest confidence, and shall cause its employees and agents, to keep in strictest confidence, the existence, source, content and substance of all Licensed Know-How and any unpublished patent
applications included in any Licensed Patents. Licensee shall not use any such Licensed Know-How or unpublished patent applications in any way, for its own account or the account of any Third Party, except to
the extent reasonably necessary to exercise its rights or perform its obligations under the JV Contract. Neither Party shall disclose any Licensed Know-How or such unpublished patent applications to any Person
(including employees and contractors) unless such Person is bound by written agreements or, in the case of professional advisers, such professional advisers are subject to ethical duties respecting such subject matter in accordance with the terms of
this Section 8, and such written agreements contain protections as least as restrictive as those contain in this License Agreement. 

8.2 Exceptions. Notwithstanding the foregoing, Section 8.1 above shall not apply to all or any part of the Licensed Know-How or unpublished patent applications included in the Licensed Patents that (a) is or becomes publicly known, from no act or failure to act on the part of the Party claiming the availability of the
exception of this clause 8.2, (b) is disclosed to the Party claiming the availability of the exception of this clause 8.2 by a Third Party as a matter of right and without restriction on disclosure, or (c) is developed independently by the
Party claiming the availability of the exception of this clause 8.2 without any reliance on or reference to the Licensed Know-How. 

8.3 Disclosures Required by Law. In the event the disclosure of the Licensed Know-How is
required by applicable Law, judicial or regulatory subpoena, the Party required to make such disclosure must provide the other Party with prompt written notice of any such requirement in order to afford such other Party time either to seek an
appropriate protective order (or other remedy) or a waiver of compliance therewith. If such order or other remedy is not obtained, the Party required to make such disclosure shall disclose only that portion of the subject Licensed Know-How that in the opinion of counsel to such Party is legally required to be disclosed and shall exercise all reasonable efforts to obtain assurances that confidential treatment will be accorded the Licensed Know-How. The Party to make the applicable disclosure shall cooperate reasonably with the other Party in all respects in seeking to obtain a protective order or other remedy or otherwise to diligently contest or
limit the required disclosure. 
 8.4 Terms of License Agreement. 

(a) Neither Party may disclose any of the terms of this License Agreement (including the existence of this License Agreement) or any non-public and/or proprietary information about the other Party to any Person without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose such terms (i) to its
accountants and advisors who have a “need-to-know” solely for the purpose of providing services to such Party, or (ii) to existing and potential
investors, lenders and acquirers and the accountants and advisors of any of the foregoing; provided, however, that in the case of this clause (a), any such recipient is bound by a written agreement (or in the case of attorneys or other
professional advisors, formal ethical duties) requiring such recipients not to disclose the terms of this License Agreement to any Third Party and to use such terms only for purposes of evaluating the applicable investment, loan or acquisition. 

  
 10 

 (b) In addition, this License Agreement and terms herein may be disclosed as otherwise
required pursuant to applicable law, regulation, stock market or stock exchange rule or rule of a self-regulatory organization (e.g., rules or regulations of the United States Securities and Exchange Commission or the NYSE); provided that a
Party proposing to make such a disclosure as required by law, rule or regulation shall inform the other Party a reasonable time prior to such required disclosure, shall provide the other Party with a copy of the text of such proposed disclosure
sufficiently in advance of the proposed disclosure to afford such other Party a reasonable opportunity to review and comment upon the proposed disclosure (including, if applicable, the redacted version of this Agreement) and shall reasonably
consider, consistent with applicable law, rule and regulation (including interpretations thereof), the requests of the other Party regarding confidential treatment for such disclosure. 

8.5 The obligations of each Party under this Section 8 shall survive and continue to be binding upon such Party after the termination or
expiration of this License Agreement. 
 9. Term. 

9.1 Term. This License Agreement shall remain in effect in accordance with its terms until the effective date of termination of the JV
Contract (which, for the avoidance of doubt, shall include any dissolution, liquidation, cessation of operations or winding up of Licensee) or the exercise of the put option by Licensor in accordance with Section 5.11 (Put Option) of the JV
Contract, whichever is earlier (the “Term”). 
 9.2 Renewal. This License Agreement may be renewed only upon mutual
written agreement between the Parties. 
 9.3 Termination. This License Agreement may be terminated prior to its expiration: 

(a) at any time by the mutual written agreement of Licensor and Licensee; or 

(b) by either Party, if the other Party breaches or defaults in any of its material obligations hereunder and such breach or default is
(i) not curable, or (ii) if curable, not cured within 30 (thirty) days or such longer period as may be mutually agreed to by the Parties after written notice of such breach or default is given by the
non-defaulting Party to the defaulting Party. 
 (c) If a U.S. government entity prohibits the
license agreement and transfer of IP. In this event, any License Fee paid to Myomo shall be refunded to the JV. 
 9.4 Effect of
Termination or Expiration. Upon the termination or expiration of the License Agreement: (a) all rights and licenses granted to Licensee shall immediately cease, (b) Licensee shall promptly return to Licensor or destroy, at
Licensor’s election in its sole discretion, all tangible embodiments of the Licensed IP, and (c) Licensee shall promptly cease all research, development, production and commercialization of the Licensed Products. 

  
 11 

 10. Limitations. THE PARTIES HERETO AGREE THAT, NOTWITHSTANDING ANY OTHER
PROVISION IN THIS LICENSE AGREEMENT, EXCEPT FOR (A) EITHER PARTY’S BREACH OF SECTION 8 (CONFIDENTIALITY), (B) LICENSEE’S BREACH OF SECTION 2 (LICENSE GRANTS) OR (C) LICENSEE’S INFRINGEMENT OF LICENSOR’S INTELLECTUAL
PROPERTY RIGHTS, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE TO THE OTHER OR ANY OTHER PERSON FOR CONSEQUENTIAL, INCIDENTAL OR SPECIAL DAMAGES, LOST PROFITS, LOST SAVINGS, LOSS OF GOODWILL OR OTHERWISE, OR FOR EXEMPLARY DAMAGES, EVEN IF
SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 11. Indemnification. 

11.1 Licensee Indemnification Obligations. Licensee shall defend, indemnify and hold Licensor, its Affiliates and their respective
officers, directors, employees and agents (the “Licensor Indemnitees”) harmless, and hereby forever releases and discharges the Licensor Indemnitees, from and against all losses, liabilities, damages and expenses (including
reasonable attorneys’ fees and costs and expenses of investigation and defense) (“Losses”) resulting from (a) all claims, demands, actions and other proceedings brought by any Third Party (“Claims”) to the extent
arising from or related to (a) the use, development, production or commercialization by Licensee of any Licensed IP, or (b) any inaccuracy in or breach, default or non-performance of any of the
representations, warranties, covenants or agreements made by Licensee herein. 
 11.2 Licensor Indemnification
Obligations. Licensor shall defend, indemnify and hold Licensee, its Affiliates and their respective officers, directors, employees and agents (the “Licensee Indemnitees”) harmless, and hereby forever releases and
discharges the Licensee Indemnitees, from and against all Losses resulting from all Claims to the extent arising from or related to (a) the use, development, production or commercialization by Licensor of any Licensed IP or Licensed Software or
Licensed Products, or (b) any inaccuracy in or breach, default or non-performance of any of the representations, warranties, covenants or agreements made by Licensor herein. Notwithstanding the foregoing
or anything else to the contrary in this License Agreement, Licensor’s indemnity obligations will not apply to Claims to the extent arising from (x) modification of the Licensed IP, Licensed Software or Licensed Products by any party other
than Licensor without Licensor’s express written consent, (y) the combination, operation, or use of the Licensed IP, Licensed Software or Licensed Products with other product(s), data or services where the Licensed IP, Licensed Software or
Licensed Products would not by itself be infringing, or (z) unauthorized or improper use of the Licensed IP, Licensed Software or Licensed Products. If the use of the Licensed IP, Licensed Software or Licensed Products by Licensee has become,
or in Licensor’s opinion is likely to become, the subject of any claim of infringement, Licensor may at its option and expense (A) procure for Licensee the right to continue using the Licensed IP, Licensed Software or Licensed Products as
set forth hereunder, (B) replace or modify the Licensed IP, Licensed Software or Licensed Products to make it non-infringing so long as the Licensed IP, Licensed Software or Licensed Products have at
least equivalent functionality, or (C) substitute an equivalent for the Licensed IP, Licensed Software or Licensed Products. If options (A)-(C) are not reasonably practicable, Licensor may terminate this License Agreement. This
Section 11.2 states Licensor’s entire obligation and Licensee’s sole remedies in connection with any claim regarding the intellectual property rights of any Third Party. 

  
 12 

 11.3 Procedure. If Licensor Indemnities or Licensee Indemnitees become aware of any
matter for which it believes it should be indemnified or defended under Section 11.1 or Section11.2, as applicable, involving any claim, action, suit, investigation, arbitration or other proceeding against such Party by any Third Party (each,
and “Action”), such Licensor Indemnitee or Licensee Indemnitee will give the other Party prompt written notice of such Action. Licensor Indemnitees or Licensee Indemnitees will cooperate, at the expense of the other Party, with the
other Party and its counsel in the defense and Licensor Indemnitees or Licensee Indemnitees, as applicable, will have the right to participate fully, at its own expense, in the defense of such Action with counsel of its own choosing. Any compromise
or settlement of an Action will require the prior written consent of both Parties hereunder, such consent not to be unreasonably withheld, conditioned or delayed. 

12. Injunctive Relief; Costs of Actions. Notwithstanding anything to the contrary contained in this License Agreement, each of the Parties
hereto acknowledges and agrees that a breach by it (or any of its Affiliates) of any of the provisions of this License Agreement would cause irreparable injury to the other Party which would not be adequately compensated by money damages.
Accordingly, in addition to any and all other rights and remedies existing, the other Party and/or its successors or assigns shall be entitled to obtain an injunction, specific performance or other appropriate equitable relief upon application to
any court of competent jurisdiction in order to enforce or prevent any breach or threatened breach of this License Agreement, in each case without the requirement of posting a bond or proving actual damages. The prevailing Party in any legal action
brought by one Party against the other arising out of this License Agreement, will be entitled, in addition to any other rights it may have, to reimbursement of its costs and expenses associated with such legal action, including court costs and
reasonable attorneys’ fees. 
 13. Bankruptcy. All rights and licenses granted by Licensor under or pursuant to this License
Agreement are, for all purposes of Section 365(n) of Title 11 of the United States Code (“Title 11”), licenses of rights to “intellectual property” as defined in Title 11. Licensor agrees that, in the event of the
commencement of bankruptcy proceedings by or against Licensor under Title 11, Licensee, as licensee of such rights under this License Agreement, shall retain and may fully exercise all of its rights under this License Agreement (including the
license granted hereunder) and all of its rights and elections under Title 11. Without limiting the generality of the foregoing, if this License Agreement is terminated under any applicable insolvency law, or Licensor or an administrator refuses to
further perform this License Agreement (or any of Licensor’s obligations hereunder) under any applicable insolvency law, then Licensee may elect to retain all of its license rights under this License Agreement (including without limitation the
rights described in Section 2 above) for the remainder of the Term. 
 14. Miscellaneous Provisions. 

14.1 Filing. The Licensee may register this License Agreement with the competent Authority of Commerce in accordance with the relevant
PRC Law. As soon as such registration is granted or completed (and in any case within three (3) Business Days following the granting or completion of such registration), the Licensee shall promptly inform the Licensor of the granting or
completion of such registration and provide the Licensor with a copy of the relevant Registration Certificate of Technology Import. 

  
 13 

 14.2 Notices. Any notice, request, demand other communication required or permitted
hereunder shall be (a) given in writing in English (with Chinese translation, if requested by a Party at such Party’s cost) and (b) personally delivered or mailed, by prepaid, certified mail or overnight courier, or transmitted by
facsimile or electronic mail transmission (including PDF), to the Party to whom such notice or communication is directed, to the mailing address or regularly-monitored electronic mail address of such Party as follows: 

 

			
	If to Licensor:	  	Attention: Paul R. Gudonis
		  	Address: One Broadway, 14th Floor, Cambridge,
		  	MA 02142, USA
		  	Email: paul@myomo.com

 with a copy (which shall necessarily include a copy by email to the following and alone shall not constitute
notice) to: 
 Goodwin Proctor LLP: Attention: James Xu 

Address: 100 Northern Ave., Boston, 

MA 02142, USA 

Email: jxu@goodwinlaw.com 
 If
to Licensee: 
 Attention: REN Song 

Address: 801 Zitan Building, No. 27 Jianguo Road, 

Chaoyang District, Beijing, PRC 

Email: david.ren@ryzur.com.cn 

Telephone: +86 10 58198900 
 Any
notice given hereunder may be given on behalf of any Party by its counsel or other authorized representative. 
 14.3 Third Party
Rights. Notwithstanding anything to the contrary in this License Agreement, the grant of rights by Licensor under this License Agreement shall be subject to and limited in all respects by the terms of the applicable Third Party agreements and
arrangements pursuant to which Licensor acquired any Licensed IP, and all rights or sublicenses granted under this License Agreement shall be limited to the extent that Licensor may grant such rights and sublicenses under the Licensed IP. 

14.4 Captions and Gender. The captions in this License Agreement are for convenience only and shall not affect the construction or
interpretation of any term or provision hereof. The use in this License Agreement of the masculine pronoun in reference to a Party hereto shall be deemed to include the feminine or neuter pronoun, as the context may require. 

14.5 Parties in Interest. Nothing in this License Agreement, express or implied, is intended to confer on any person other than the
Parties and their respective successors and assigns any rights or remedies under or by virtue of this License Agreement. 

  
 14 

 14.6 Governing Law; Consent to Jurisdiction. 

(a) All questions concerning the construction, validity and interpretation of this License Agreement shall be governed by and construed in
accordance with the laws of the State of New York applicable to contracts executed in and to be performed in the State of New York. 
 (b)
THE PARTIES AGREE THAT JURISDICTION AND VENUE IN ANY ACTION BROUGHT BY ANY PARTY PURSUANT TO THIS LICENSE AGREEMENT SHALL PROPERLY AND EXCLUSIVELY LIE IN ANY FEDERAL OR STATE COURT LOCATED IN THE STATE OF NEW YORK. BY EXECUTION AND DELIVERY OF THIS
LICENSE AGREEMENT, EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY WITH RESPECT TO SUCH ACTION. THE PARTIES IRREVOCABLY AGREE THAT VENUE WOULD BE PROPER IN SUCH COURT, AND HEREBY
WAIVE ANY OBJECTION THAT SUCH COURT IS AN IMPROPER OR INCONVENIENT FORUM FOR THE RESOLUTION OF SUCH ACTION. THE PARTIES FURTHER AGREE THAT THE MAILING BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, OF ANY PROCESS REQUIRED BY ANY SUCH
COURT SHALL CONSTITUTE VALID AND LAWFUL SERVICE OF PROCESS AGAINST THEM, WITHOUT NECESSITY FOR SERVICE BY ANY OTHER MEANS PROVIDED BY STATUTE OR RULE OF COURT. 

14.7 Assignment. 
 (a)
Licensee may not assign or transfer this License Agreement, including by operation of law or upon a change of control, without the consent of Licensor. In the case of any such permitted assignment, the assignee assumes all responsibilities under
this License Agreement. 
 (b) This License Agreement and the obligations of the Parties hereunder shall be binding upon and enforceable by,
and shall inure to the benefit of, the Parties and their respective successors, executors, administrators, estates, heirs and permitted assigns, and no others. 

14.8 Severability. If any term or other provision of this License Agreement is invalid, illegal or incapable of being enforced by any
rule of law or public policy, all other conditions and provisions of this License Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any
manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this License Agreement so as to effect
the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible. 

14.9 Relationship Between Parties. The relationship between the Parties created under this License Agreement is that of independent
contractors. With respect to the relationship created under this License Agreement, the Parties are not joint venturers, partners, principal and agent, master and servant, employer and employee, and have no relationship other than as independent
contracting Parties, and neither Party shall have the power to bind or obligate the other in any manner. 

  
 15 

 14.10 Entire Agreement. This License Agreement, including the Schedules hereto, and
the documents referred to herein contain the entire agreement between the Parties with respect to the subject matter hereof and supersede any prior understandings, agreements or representations by or between the Parties, written or oral, which may
have related to the subject matter hereof in any way. 
 14.11 Amendments and Waiver. This License Agreement may not be amended or
modified, nor may compliance with any condition or covenant set forth herein be waived, except by a writing duly and validly executed by each of the Parties hereto, or, in the case of a waiver, the Party waiving compliance. No delay on the part of
any Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any Party of any such right, power or privilege, or any single or partial exercise of any such right, power or
privilege, preclude any further exercise thereof or the exercise of any other such right, power or privilege. 
 14.12 Construction.
Each Party hereto agrees that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this License Agreement. As used in this License
Agreement, the words “include” and “including” and variations thereof, shall not be deemed to be terms of limitation. 

14.13 Languages and Counterparts. This License Agreement and its schedules are written in English language and Chinese language. In case
there is a conflict between the English version and the Chinese version, the English version shall control. This License Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same document. The delivery of a counterpart hereto by facsimile or other electronic transmission shall be deemed an original. 

[REMAINDER OF PAGE BLANK; SIGNATURE PAGE FOLLOWS] 

  
 16 

 In Witness Whereof, the Parties have caused this Technology License Agreement to be duly
executed in their respective names and on their behalf, as of the date first above written. 
  

			
	Myomo, Inc.
		
	By:	 	              

	Title:	 	  

	Date:	 	  

	
	Jiangxi Myomo Medical Assistive Appliance Co., Ltd. (江西迈欧缪医疗辅助器具有限公司)
		
	By:	 	              

	Title:	 	  

	Date:	 	  

  
 17 

 SCHEDULE A 

Licensed Patents 
  

	 	•	 	 Myomo Chinese patent portfolio necessary for Licensee to make, have made, use, sell, have sold, offer for sale,
have offered for sale, import, and have imported the Licensed Products. 

  
 18 

 SCHEDULE B 

Licensed Copyrights 
  

	 	•	 	 Assembly and testing instructions and procedures for manufacturing the MyoPro robotic kit elements;

  

	 	•	 	 Custom orthotic design and fabrication instructions to manufacture individual patient braces integrating the
MyoPro robotic kits; 

  

	 	•	 	 Quality system documents and procedures 

 

	 	•	 	 Device repair procedures and training program; 

 

	 	•	 	 Clinical research protocols and documentation; 

 

	 	•	 	 Training materials for prosthetist/orthoptist and occupational therapist support of the MyoPro patient
evaluation, fitting, and training process; 

  

	 	•	 	 User manuals for patients and clinicians; 

 

	 	•	 	 Regulatory filings to support NMPA approval for the MyoPro in China; 

 

	 	•	 	 Sales and marketing materials, including product brochures and marketing information; 

 

	 	•	 	 Website content available for translation into local language; and 

 

	 	•	 	 Updates to any of the foregoing created or developed by or on behalf of Licensor 

  
 19 

 SCHEDULE C 

Licensed Software 
  

	 	•	 	 Laptop/mobile software application “myConfig” for device setting configuration, to be translated into
local language by Licensee; and 

  

	 	•	 	 Updates to the foregoing created or developed by or on behalf of Licensor. 

  
 20 

 SCHEDULE D 

Licensed Products 
  

	 	•	 	 MyoPro Motion G 

  

	 	•	 	 MyoPro Motion W 

  

	 	•	 	 MyoPro Motion E 

  

	 	•	 	 Mobile Arm Rehabilitation System (MARK) 

  
 21 

 SCHEDULE E 

Licensor’s technical support plan (i.e., Upper Limb Orthosis Project Proposal) 

(see attached) 

 Exhibit B 

Trademark License Agreement 

 EXHIBIT B 

TRADEMARK LICENSE AGREEMENT 
 This
TRADEMARK LICENSE AGREEMENT (this “Trademark License Agreement”) dated as of ______________, 2021, is entered into by and between Myomo, Inc., a Delaware corporation (“Licensor”) having its principal office at One
Broadway, 14th Floor, Cambridge, MA 02142, USA and Jiangxi Myomo Medical Assistive Appliance Co., Ltd.
(江西迈欧缪医疗辅助器具有限公司) a company incorporated under the laws of the PRC (“Licensee” or the “JV”) having its principal
office at 1st Floor, Building No. 6, 544 Jiamaowu Road, inner Comprehensive Bonded Area, Xinjian District, Nanchang, Jiangxi Province
(江西省南昌市新建区综合保税区内嘉茂五路544号6栋1层). 

WHEREAS, pursuant to the Equity Joint Venture Contract, dated as of [•], by and between Myomo, Inc., Anhui Ryzur Medical Equipment
Manufacturing, Co., Ltd. and Beijing Ryzur Medical Investment Co., Ltd. (the “JV Contract”), Licensor agrees to (a) contribute capital equal to
USD$199,000 to the JV, and (b) supply the Licensee with certain hardware and software components of Licensor’s MyoPro
Control System; and 
 WHEREAS, pursuant to that certain Technology License Agreement, dated as of [•], by and between Myomo,
Inc. and the JV (the “Technology License Agreement”), Licensor agrees to grant a Licensee a license to certain intellectual property; and 

WHEREAS, subject to the terms and conditions of this Trademark License Agreement, Licensee desires and is willing to secure from Licensor, and
Licensor desires and is willing to grant to Licensee an exclusive license in the Field (as defined below) and in the Territory (as defined below) in and to certain Licensed Trademarks (as defined below); and 

WHEREAS, the JV Contract contemplates the entry into this License Agreement in connection with the execution of the JV Contract. 

NOW, THEREFORE, in consideration of these premises and the mutual covenants, agreements, representations and warranties herein contained, the
Parties hereby agree as follows: 
 1. Certain Defined Terms. Capitalized terms used but not otherwise defined herein shall have
the meanings set forth in the JV Contract. The following terms shall have the meanings set forth below: 
 1.1 “Affiliate”
shall have the meaning set forth in the JV Contract. 
 1.2 “Effective Date” shall have the meaning set forth in the
Technology License Agreement 
 1.3 “Field” shall have the meaning set forth in the Technology License Agreement. 

1.4 “JV Contract” shall have the meaning set forth in the Recitals hereto. 

 1.5 “Laws” means all laws, statutes, rules, regulations, ordinances and
other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.6 “Licensed Product” means any and all products identified in Schedule B as such Schedule may be updated from time to
time to include additional products that are marketed and sold by Licensor during the Term. 
 1.7 “Licensed Trademarks”
means the Trademarks listed on Schedule A hereto. 
 1.8 “Licensee” shall have the meaning set forth in the
Introductory Paragraph. 
 1.9 “Licensor” shall have the meaning set forth in the Introductory Paragraph. 

1.10 “Party” means Licensee or Licensor, individually, and “Parties” means Licensee and Licensor,
collectively. 
 1.11 “Person” shall have the meaning set forth in the JV Contract. 

1.12 “PRC” means the People’s Republic of China. 

1.13 “Term” shall have the meaning set forth in Section 6.1. 

1.14 “Territory” means the PRC, Hong Kong S.A.R., Macau S.A.R., and Taiwan. 

1.15 “Third Party” means any Person other than Licensee, Licensor and their respective Affiliates. 

1.16 “Trademarks” means trademarks, trade names, brand names, logos, symbols, service marks and designs under trademark and
similar Laws, the goodwill of the business symbolized thereby, and related registrations and applications for registration in the United States Patent and Trademark Office or in any similar office or agency anywhere in the world. 

1.17 “Trademark License Agreement” shall have the meaning set forth in the Introductory Paragraph hereto, and includes without
limitation all schedules and attachments. 
 2. License Grants. 

2.1 License. Subject to the terms and conditions set forth in this Trademark License Agreement, Licensor hereby grants to Licensee, and
Licensee hereby accepts, a limited, revocable, exclusive (in the Territory and Field), fully paid-up, non-transferable (except as expressly permitted by
Section 8.6), and non-sublicenseable right and license under the Licensed Trademarks, in the Field and Territory only, to use and display the Licensed Trademarks in advertising and other promotional materials (whether in traditional print or
electronic format) relating to the marketing, advertising, promotion, and/or selling of any Licensed Product. 

  
 2 

 2.2 Quality Standards. The Parties acknowledge that the Licensed Trademarks have
established goodwill, and acknowledge the importance of Licensor’s control over the quality of Licensee’s use thereof so as to preserve the continued validity of the Licensed Trademarks and to protect the goodwill associated therewith.
Licensee agrees that the quality of the products and services provided by Licensee under the Licensed Trademarks and the associated advertising and promotion (including without limitation advertising and promotion collateral and materials) shall
equal or exceed the standard of quality heretofore established and maintained by Licensor with respect to the same or similar products and services. If Licensor determines that Licensee is using or displaying any Licensed Trademark in a manner that
is or may be detrimental to Licensor’s interest, Licensor may issue reasonable instructions to Licensee concerning the manner, if any, in which Licensee may continue to use such Licensed Trademark. Licensee shall promptly comply with such
instructions or cease the use or display of such Licensed Trademark. 
 2.3 Ownership. This rights granted to and obtained by Licensee
as a result of or in connection with this Trademark License Agreement are license rights only, and nothing contained in this Trademark License Agreement constitutes or shall be construed to be an assignment of any or all of Licensor’s rights in
the Licensed Trademarks or to permit Licensee to acquire any ownership rights in the Licensed Trademarks. Except as expressly set forth herein, Licensor reserves all right, title and interest in the Licensed Trademark. To the extent that Licensee
does acquire any ownership rights in or to any of the Licensed Trademarks, Licensee shall and does hereby assign to Licensor all such rights. All goodwill resulting from Licensee’s use of the Licensed Trademarks shall inure to the benefit of
Licensor, and Licensee shall and does hereby assign to Licensor all such goodwill. 
 2.4 Restrictions. During the Term and
thereafter, Licensee shall not adopt, use, registered, or apply for registration any word, name, mark, symbol, other designation or trade style that in Licensor’s reasonable and sole opinion is likely to cause confusion or dilute any of the
Licensed Trademarks, and Licensee shall not make any unlicensed use of trademarks or service marks which, in Licensor’s sole opinion, is confusingly similar to or dilutive of any of the Licensed Trademarks. In addition, Licensee agrees that it
shall not use any of the Licensed Trademarks in combination with any word, name, mark, symbol, other designation or trade style so as to create a composite mark. 

2.5 Marking. When using any Licensed Trademark, Licensee shall comply with the marking requirements set forth on Schedule C. 

3. Consideration 
 3.1 License
Fee. The Parties agree that there shall be no monetary fee owed by Licensee to Licensor for the license of the Licensed Trademarks under this Trademark License Agreement. 

4. Representations and Warranties. 

4.1 Licensor. Licensor hereby represents and warrants to Licensee that as of the Effective Date: 

(a) All corporate action on the part of Licensor and on the part of each of its officers and directors necessary for the authorization,
execution, and delivery of this Trademark License Agreement and the performance of its obligations hereunder has been taken. 

  
 3 

 (b) This Trademark License Agreement is the legal, valid, and binding obligation of
Licensor, enforceable against it in accordance with its terms. 
 (c) Neither the execution and delivery of this Trademark License Agreement
nor the performance of the obligations contemplated hereby will: (i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or constitute a
default under any provision of any contract or any other obligation to which Licensor is a party or under which Licensor is subject or bound, (ii) violate any judgment, order, injunction, decree or award of any governmental authority against,
or affecting or binding upon, Licensor or upon the assets, property or business of Licensor, or (iii) constitute a violation by Licensor of any applicable Law of any jurisdiction as such Law relates to Licensor or to the property or business of
Licensor. 
 4.2 Licensee. Licensee hereby represents and warrants to Licensor that as of the Effective Date: 

(a) All corporate action on the part of Licensee and on the part of each of its officers and directors necessary for the authorization,
execution, and delivery of this Trademark License Agreement and the performance of its obligations hereunder has been taken. 
 (b) This
Trademark License Agreement is the legal, valid, and binding obligation of Licensee, enforceable against it in accordance with its terms. 

(c) Neither the execution and delivery of this Trademark License Agreement nor the performance of the obligations contemplated hereby will:
(i) conflict with or result in any violation of or constitute a breach of any of the terms or provisions of, or result in the acceleration of any obligation under, or constitute a default under any provision of any contract or any other
obligation to which Licensee is a party or under which Licensee is subject or bound, (ii) violate any judgment, order, injunction, decree or award of any governmental authority against, or affecting or binding upon, Licensee or upon the assets,
property or business of Licensee, or (iii) constitute a violation by Licensee of any applicable Law of any jurisdiction as such Law relates to Licensee or to the property or business of Licensee. 

5. Confidentiality. 
 5.1 Neither
Party may disclose any of the terms of this Trademark License Agreement to any Person without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose such terms (i) to its accountants and advisors
who have a “need-to-know” solely for the purpose of providing services to such Party, or (ii) to existing and potential investors, lenders and acquirers
and the accountants and advisors of any of the foregoing; provided, however, that any such recipient is bound by a written agreement (or in the case of attorneys or other professional advisors, formal ethical duties) requiring such
recipients not to disclose the terms of this Trademark License Agreement to any third party and to use such terms only for purposes of evaluating the applicable investment, loan or acquisition. 

  
 4 

 5.2 In addition, this Trademark License Agreement and terms hereof may be disclosed as
otherwise required pursuant to applicable law, regulation, stock market or stock exchange rule or rule of a self-regulatory organization (e.g., rules or regulations of the United States Securities and Exchange Commission, the Nasdaq or the
NYSE); provided that a Party proposing to make such a disclosure as required by law, rule or regulation shall promptly inform the other Party of such proposed disclosure, shall provide the other Party with a copy of the text of such proposed
disclosure sufficiently in advance of the proposed disclosure to afford such other Party a reasonable opportunity to review and comment upon the proposed disclosure (including, if applicable, the redacted version of this Trademark License
Agreement), and shall reasonably consider, consistent with applicable law, rule and regulation (including interpretations thereof), the requests of the other Party regarding confidential treatment for such disclosure. 

6. Term. 
 6.1 Term. This
Trademark License Agreement shall remain in effect in accordance with its terms until the effective date of termination of the JV Contract (which, for the avoidance of doubt, shall include any dissolution, liquidation, cessation of operations or
winding up of Licensee) or the exercise of the put option by Licensor in accordance with Section 5.10 (Put Option) of the JV Contract, whichever is earlier (the “Term”). 

6.2 Renewal. This Trademark License Agreement may be renewed only upon mutual written agreement between the Parties. 

6.3 Termination. This Trademark License Agreement may be terminated prior to its expiration: 

(a) at any time by the mutual written agreement of Licensor and Licensee; or 

(b) by either Party, if the other Party breaches or defaults in any of its material obligations hereunder and such breach or default is
(i) not curable, or (ii) if curable, not cured within 30 (thirty) days or such longer period as may be mutually agreed to by the Parties after written notice of such breach or default is given by the
non-defaulting Party to the defaulting Party. 
 6.4 Effect of Termination or Expiration. Upon
the termination or expiration of the Trademark License Agreement, (a) all rights and licenses granted to Licensee shall immediately cease, (b) Licensee shall immediately discontinue all use of the Licensed Trademarks, including removing
all instances of the Licensed Trademarks from circulation, display or other use, and (c) Licensee shall promptly return any materials supplied to Licensee by Licensor hereunder at Licensee’s expense. Upon termination or expiration of this
Trademark License Agreement, the following Sections shall survive: 1 (Definitions), 2.3 (Ownership), 2.4 (Restrictions), 5 (Confidentiality), 6.4 (Effect of Termination), and 8 (Miscellaneous). 

7. Injunctive Relief; Costs of Actions. Notwithstanding anything to the contrary contained in this Trademark License Agreement, each of
the Parties hereto acknowledges and agrees that a breach by it (or any of its Affiliates) of any of the provisions of this Trademark License Agreement would cause irreparable injury to the other Party which would not be adequately compensated by
money damages. Accordingly, in addition to any and all other rights and remedies existing, the other Party and/or its successors or assigns shall be entitled to obtain an injunction, specific performance or other appropriate equitable relief upon
application to any court of competent jurisdiction in order to enforce or prevent any breach or threatened breach of this Trademark License Agreement, in each case without the requirement of posting a bond or proving actual damages. The prevailing
Party in any legal action brought by one Party against the other arising out of this Trademark License Agreement, will be entitled, in addition to any other rights it may have, to reimbursement of its costs and expenses associated with such legal
action, including court costs and reasonable attorneys’ fees. 

  
 5 

 8. Miscellaneous Provisions. 

8.1 Notices. Any notice, request, demand other communication required or permitted hereunder shall be (a) given in writing in
English (with Chinese translation, if requested by a Party at such Party’s cost) and (b) personally delivered or mailed, by prepaid, certified mail or overnight courier, or transmitted by facsimile or electronic mail transmission
(including PDF), to the Party to whom such notice or communication is directed, to the mailing address or regularly-monitored electronic mail address of such Party as follows: 

 

			
	If to Licensor:	  	Attention: Paul R. Gudonis
		  	Address: One Broadway, 14th Floor, Cambridge,
		  	MA 02142, USA
		  	Email: paul@myomo.com

 with a copy (which shall necessarily include a copy by email to the following and alone shall not constitute
notice) to: 
 Goodwin Procter LLP: Attention: James Xu 

Address: 100 Northern Avenue, Boston, MA 02210, USA 

Email: jxu@goodwinlaw.com 
 If to Licensee: 

Attention: REN Song 
 Address:
801 Zitan Building, No. 27 Jianguo Road, 
 Chaoyang District, Beijing, PRC 

Email: david.ren@ryzur.com.cn 

Telephone: +86 10 58198900 
 Any notice given
hereunder may be given on behalf of any Party by its counsel or other authorized representative. 
 8.2 Third Party Rights.
Notwithstanding anything to the contrary in this Trademark License Agreement, the grant of rights by Licensor under this Trademark License Agreement shall be subject to and limited in all respects by the terms of the applicable Third Party
agreements and arrangements pursuant to which Licensor acquired any Licensed Trademark, and all rights or sublicenses granted under this Trademark License Agreement shall be limited to the extent that Licensor may grant such rights and sublicenses
under the Licensed Trademark. 
 8.3 Captions and Gender. The captions in this Trademark License Agreement are for convenience only
and shall not affect the construction or interpretation of any term or provision hereof. The use in this Trademark License Agreement of the masculine pronoun in reference to a Party hereto shall be deemed to include the feminine or neuter pronoun,
as the context may require. 

  
 6 

 8.4 Parties in Interest. Nothing in this Trademark License Agreement, express or
implied, is intended to confer on any person other than the Parties and their respective successors and assigns any rights or remedies under or by virtue of this Trademark License Agreement. 

8.5 Governing Law; Consent to Jurisdiction. 

(a) All questions concerning the construction, validity and interpretation of this Trademark License Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to contracts executed in and to be performed in the State of New York. 

(b) THE PARTIES AGREE THAT JURISDICTION AND VENUE IN ANY ACTION BROUGHT BY ANY PARTY PURSUANT TO THIS TRADEMARK LICENSE AGREEMENT SHALL
PROPERLY AND EXCLUSIVELY LIE IN ANY FEDERAL OR STATE COURT LOCATED IN THE STATE OF NEW YORK. BY EXECUTION AND DELIVERY OF THIS TRADEMARK LICENSE AGREEMENT, EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS FOR ITSELF AND IN
RESPECT OF ITS PROPERTY WITH RESPECT TO SUCH ACTION. THE PARTIES IRREVOCABLY AGREE THAT VENUE WOULD BE PROPER IN SUCH COURT, AND HEREBY WAIVE ANY OBJECTION THAT SUCH COURT IS AN IMPROPER OR INCONVENIENT FORUM FOR THE RESOLUTION OF SUCH ACTION. THE
PARTIES FURTHER AGREE THAT THE MAILING BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, OF ANY PROCESS REQUIRED BY ANY SUCH COURT SHALL CONSTITUTE VALID AND LAWFUL SERVICE OF PROCESS AGAINST THEM, WITHOUT NECESSITY FOR SERVICE BY ANY OTHER
MEANS PROVIDED BY STATUTE OR RULE OF COURT. 
 8.6 Assignment. 

(a) Licensee may not assign or transfer this Trademark License Agreement, including by operation of law or upon a change of control, without
the consent of Licensor. In the case of any such permitted assignment, the assignee assumes all responsibilities under this Trademark License Agreement. 

(b) This Trademark License Agreement and the obligations of the Parties hereunder shall be binding upon and enforceable by, and shall inure to
the benefit of, the Parties and their respective successors, executors, administrators, estates, heirs and permitted assigns, and no others. 

8.7 Severability. If any term or other provision of this Trademark License Agreement is invalid, illegal or incapable of being enforced
by any rule of law or public policy, all other conditions and provisions of this Trademark License Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not
affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Trademark License
Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible. 

  
 7 

 8.8 Relationship Between Parties. The relationship between the Parties created under
this Trademark License Agreement is that of independent contractors. With respect to the relationship created under this Trademark License Agreement, the Parties are not joint venturers, partners, principal and agent, master and servant, employer
and employee, and have no relationship other than as independent contracting Parties, and neither Party shall have the power to bind or obligate the other in any manner. 

8.9 Entire Agreement. This Trademark License Agreement, including the Schedules hereto, and the documents referred to herein contain the
entire agreement between the Parties with respect to the subject matter hereof and supersede any prior understandings, agreements or representations by or between the Parties, written or oral, which may have related to the subject matter hereof in
any way. 
 8.10 Amendments and Waiver. This Trademark License Agreement may not be amended or modified, nor may compliance with any
condition or covenant set forth herein be waived, except by a writing duly and validly executed by each of the Parties hereto, or, in the case of a waiver, the Party waiving compliance. No delay on the part of any Party in exercising any right,
power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any Party of any such right, power or privilege, or any single or partial exercise of any such right, power or privilege, preclude any further
exercise thereof or the exercise of any other such right, power or privilege. 
 8.11 Construction. Each Party hereto agrees that any
rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Trademark License Agreement. As used in this Trademark License Agreement, the words
“include” and “including” and variations thereof, shall not be deemed to be terms of limitation. 
 8.12 Languages and
Counterparts. This Trademark License Agreement and its schedules are written in English languages. This Trademark License Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same document. The delivery of a counterpart hereto by facsimile or other electronic transmission shall be deemed an original. 

8.13 Cooperation in Filing in the PRC. To the extent required under the PRC Trademark Law, after the Licensed Trademarks have been duly
registered in the PRC State Trademark Office, the Licensor and the Licensee shall reasonably cooperate with each other to enter into standard trademark license agreement in Chinese for the Licensee to file such trademark license with the PRC State
Trademark Office. 
 [REMAINDER OF PAGE BLANK; SIGNATURE PAGE FOLLOWS] 

  
 8 

 In Witness Whereof, the Parties have caused this Trademark License Agreement to be duly
executed in their respective names and on their behalf, as of the date first above written. 
  

			
	Myomo, Inc.

 
			
		
	By:	 	
                     

	Title:	 	  

	Date:	 	  

	
	Jiangxi Myomo Medical Assistive Appliance Co., Ltd.
(江西迈欧缪医疗辅助器具有限公司)

 
			
		
	By:	 	  

	Title:	 	  

	Date:	 	  

 [Signature Page to Trademark License Agreement] 

 SCHEDULE A 

Licensed Trademarks 
  

															
	 Mark
	  	Class	 	  	Country	 	  	App. Filing Date	 	  	 App. No.

	 MYOMO
	  	 	10	 	  	 	CN	 	  	 	3/7/2019	 	  	TBD. Please see Exhibit A for filing receipt.
	 MYOPRO
	  	 	10	 	  	 	CN	 	  	 	3/7/2019	 	  	TBD. Please see Exhibit A for filing receipt.

  
 SCH A-1

 EXHIBIT A TO SCHEDULE A 

Exhibit A 
 Filing
Receipt 
 (as attached) 

  
 SCH A-2

 SCHEDULE B 

Licensed Products 
  

	 	•	 	 [MyoPro product line] 

  
 SCH B-1

 SCHEDULE C 

Trademark Notice 
 A federally
registered trademark should carry both of the following forms of notice: 
  

	 	•	 	 The symbol ® placed on the “shoulder” or the
“heel” of the trademark, as in [MARK]®. Alternatively, an asterisk placed on the shoulder of the trademark with a footnote reading “Registered in the U.S. Patent and Trademark
Office” or “Reg. U.S. Pat. & Tm. Off.” 

  

	 	•	 	 A notation that the trademark is owned by Licensor, as in: “[MARK] is a registered trademark of
Licensor”. You may place this type of notation on the page where the trademark appears. When a brochure refers to several different products, an alternative is to place this sentence at the front or back of the brochure. “The following are
trademarks of Licensor:                (list of trademarks) “ . 

When the trademark has not been federally registered, give one or more of the following forms of notice: 

 

	 	•	 	 An asterisk placed on the shoulder of the trademark with a footnote reading “Trademark of Licensor”

  

	 	•	 	 The initials “SM” on the shoulder or heel of the mark, e.g. [MARK]SM. 

  

	 	•	 	 A notation or legend that Licensor claims trademark rights, as: “[MARK], and [MARK] plus the [MARK] design
are trademarks of Licensor” Place this legend in the same location as for registered trademarks. 

  
 SCH C-1EX-10.2

 Exhibit 10.2 

FABRICATION AND SERVICES AGREEMENT 
 This
Fabrication and Services Agreement (the “Agreement”) is made effective as of this 1st day of January, 2021 (the “(“Effective Date”) by and between Myomo, Inc. a Delaware corporation, whose principal executive offices are
located at One Broadway, 14th Floor, Cambridge, MA 02142 (the “Company”) and Geauga Rehabilitation Engineering, Inc. (“GRE”) an Ohio corporation, with a business address of
13376 Ravenna Road, Chardon, OH. 44024. Hereinafter, referred to as the “Parties”. 
 The Company and GRE, for valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, intending to be legally bound hereby, agree as follows: 
  

	 	1)	 SCOPE OF WORK: 

GRE shall provide central fabrication and services (the “Work”) for the Company, including, but not limited to: 

 

	 	•	 	 MyoPro® orthosis fabrication of each customer order from
a certified Myomo customer; 

  

	 	•	 	 MARK Units non-custom units with adjustable orthotic components;

  

	 	•	 	 MyoPal® orthosis fabrication of each customer order from
a certified Myomo customer; 

  

	 	•	 	 Orders from the Company for Demonstration (“Demo”) Units of MyoPro® or MyoPal® Orthosis; 

Company will ship its MyoPro Kits (“Kits”) to GRE. Company will ship kits based on customer orders or minimum stock quantities
subject to adjustment by the Parties on a periodic basis. Kit components may be shipped in packaging with single quantities of each item such as the motor unit, sensor assembly, battery and charger, while other items may be shipped in bulk, such as
documentation, so they can be drawn from to fulfill each order. Accessories such as laptops, tablets and other mobile devices, carrying bags and merchandising materials may also be included in orders based upon Company’s sales campaigns and
customer orders. 
 Custom MyoPro orthosis fabrication shall include all rigid frames, thermo-formed plastic, soft goods (padding, strapping,
and harnessing), and fasteners and assembly. 
 Kits shall include MyoPro motor units, sensor assembly, battery and case, charger and product
documentation, finger components, axel adapters, and product carry cases. 
 Each party shall source and stock components and supplies for
their respective portion of the product. 
  

	 	•	 	 Company shall provide GRE expected volume forecasts, in writing with management signoff every quarter with
updates to those forecasts completed monthly. 

	 	•	 	 GRE will inspect incoming Cogmedix motors and other parts that Company instructs GRE to perform inspections @ $75/hr. 

  

	 	•	 	 GRE to charge $2.10, per sq. ft per month for the storage of all
Company kits, Lunas, HCB, foam, bubble wrap and Hanke+ Protect bags. (Storage and Warehouse fee). 

  

	 	•	 	 GRE shall charge the Company a $25 administration fee when orders
are modified or otherwise incomplete, such as but not limited to coming off hold, put on hold, return to fabrication, require collection of missing elements such as color, measurements, or other invalid order intake. For clarity, the administrative
fee shall not be applied to the first occurrence of orders being placed on insurance hold. 

 During the COVID-19 pandemic, incoming casts are not opened and touched for 48 hours after being received. After the 48 hour quarantine, normal intake and time for fabrication procedures begin. The COVID-19 environment is dynamic and subject to change. Both parties agree work together to resolve any production delays caused by the COVID-19 pandemic. However,
notwithstanding anything to the contrary contained herein, neither party may terminate this Agreement prior to the expiration of the Term as defined in Section 25 with or without cause during a temporary shutdown or due to a COVID-19 outbreak. 
 CHANGES TO THE WORK: 

Company and GRE may, by mutual written consent, make changes to the scope of Work. 

 

	 	2}	 DEFINITIONS: 

  

	 	a)	 REVENUE UNITS: patient orders where the Company is billing their customer for a product. Includes DEMO
UNITS if being sold to a customer. 

  

	 	b)	 DEMO UNITS: products the Company supplies for the purposes of demonstrating the product where it may or
may not collect fees for the demo product. These units may or may not be uniquely sized for a specific individual. 

  

	 	c)	 MARK UNITS: products the Company supplies to its customers for
non-custom fabrication where it bills their customer for the product. 

  

	 	d)	 Labor: non-project related and consists of basic repairs or
unique fabrication not involving the time of senior fabrication specialists. Examples of labor include basic fabrication following existing instructions, and repairs to devices when a MyoPro is not in working order.,_ Other examples include sewing,
gluing, or assembling as basic labor, and not for the design of a new part. 

  

	 	e)	 Deviation charge: this is a charge required when Company instructs GRE to add or alter the normal
fabrication charge to accommodate an individual order that otherwise can’t be fabricated using the normal fabrication process. Often, additional materials are used to strengthen or reinforce a device, as occasionally done on very large arms.

  

	 	3)	 BILLING 

Pricing in this agreement shall be applied to devices put into production as of the Effective Date. The “Work” shall be direct billed
by GRE to the Company at the following rate schedule: 

 REVENUE AND DEMO UNITS 

Pricing from GRE to the Company is as follows (“Base Fee”): 
  

	 	•	 	 $1,126.80 on MyoPro model E 

 

	 	•	 	 $1,095.78 on MyoPro model W, including wrist parts

  

	 	•	 	 $1,238.40 on MyoPro model G, including grasp and wrist parts

 The Base Fee assumes the following amounts for a MyoPro G based on 400 units annual production: 

 

							
		  	 MotionE
	  	 Motion W
	  	 MotionG

	Total	  	$1,126.80	  	$1,095.78	  	$1,238.40

 Additional fees dependent on product and order: 

 

	 	•	 	 $75 for the MyoPro harness 

 

	 	•	 	 Deviation charge= a unique PO to be determined in good faith
based on the complexity, time, and materials used to fabricate the unique deviation. 

 MARK KITS 

Base Fee 
  

	 	•	 	 $1,425.41 for each MARK unit, left or right. A MARK unit kit
consists of 2 units, a left and right for a total of$2,850.82. Includes grasp and wrist parts. 

The Base Fee assumes the following amounts: 
  

			
	MARK	  	$1,425.41

 Additional fees dependent on product and order: 

 

	 	•	 	 $75 for the MyoPro harness 

PRODUCT DEVELOPMENT AND ENGINEERING SERVICES 
  

	 	•	 	 shall follow a separate fee schedule mutually agreed upon by both Parties as set forth in the scope of work
document. 

 LABOR/or repairs and service as defined above is $75/hour for general labor and $125/hour for senior technician time. 

 Other Fees 
  

	 	•	 	 Shipping charges: GRE will use the Company’s shipping account for all MyoPro orders being shipped to The
Company for validation or to the end customer. 

  

	 	•	 	 There shall be no other charges applied unless agreed upon via a purchase order (PO) in writing by both Parties.

  

	 	•	 	 Price changes will reflect cost changes as product design and volumes change. 

 

	 	•	 	 Design & Engineering Subcontracting-designing or engineering completed per the Company’s request to
GRE = $125/hr. Projects can also be quoted on a non-hourly cost-per-project basis agreed upon by both parties with a
separate project agreement outside the scope of this agreement, charged in $37.50 increments, 1⁄2 of the $75/hr labor fee, Technician labor time for checking in orders on hold will be billed in 1/4hr increments with most orders requiring 30 minute check-in.

  

	 	•	 	 Other fees not referred to above are included in Exhibit A. 

Invoices shall contain and shall reference on each page, as appropriate, the following: purchase order number, item number, unique invoice
number, invoice date, payment terms, remit to, sold to, and ship to. Invoices shall break out applicable component costs (price, freight, taxes, etc.). GRE understands that its failure to follow invoicing requirements may result in delayed payments
by Company. If Company encounters an invoice that appears to be in violation with the above noted requirements, Company will notify GRE in writing what is perceived to be in error and GRE shall have 30 days to correct the documentation. However,
such correction of documentation shall not excuse Company from paying invoiced fees pursuant to the applicable payment terms. 
 Volume
Guarantee 
 The Company guarantees GRE $495,000 of revenue for the twelve (12) month period from the Effective Date (the “Annual
Guarantee”). Should monthly billings for materials, fabrication and other services be less than $41,250 (the “Monthly Guarantee”), GRE shall be entitled to charge the Company for the difference (the “Guarantee True-Up”) between the Monthly Guarantee and actual billings to the Company for the month. Any Guarantee True-Up amounts billed shall be payable within 30 days and applied
to the Annual Guarantee. In order for GRE to be eligible for the Guarantee True-Up, it must maintain a capacity of at least 35 units per month. 
 MyoPal Product 

The Company intends to launch the MyoPal product for adolescents in late 2021. The Company and GRE shall agree to negotiate pricing for such
products in good faith. 
 GRE Price and Fee Changes 

Notwithstanding anything to the contrary contained herein, any and all prices or fees for any services, products or work to be performed
pursuant to this Agreement may be adjusted in the event that GRE’s costs and/or expenses related to such services, products, or work increases by ten percent (10%) during the Term and any such cost and/or expense increases directly
result from COVID-19. Any such changes to prices or fees herein shall be effective upon prior written notice to the Company. 

	 	4)	 PAYMENTTERMS 

The Company, upon acceptance of work, shall pay GRE invoice net 30 days from date of receipt of the invoice. Late payments will be charged
interest at a rate 1.5% per month. 
  

	 	5)	 TIME OF COMPLETION: 

Revenue Units to be performed under this Agreement shall be completed within 7 business days from GRE receipt of the Valid Order (“the
Completion Period”). 
 If a Valid Order is received past 12:00pm (after allowing for COVID-19
incoming hold described in Section 1), the Completion Period begins the following business day. A Valid Order is defined by a patient mold and order form that is within the tolerance set forth by the Company’s Valid Order process. This
includes measurements that fall within the accepted Company order intake standards as defined in the order intake quality system, such as usable hand photos as applicable, a purchase order, and completed order form. Business days are non-weekend and
non-Federal holidays. GRE shall work such reasonable hours with facility and personnel as determined by GRE to complete the Work in accordance with the Valid Order as specified within that time frame. Company
is not to send GRE orders that are not otherwise on hold. 
 Myomo is responsible for vetting and approving all orders prior to being
received at GRE. Incomplete or invalid orders shall be subject to the administrative fee as discussed in Section 1. When Company authorizes a fabrication order, in writing, in spite of an intake non-conformance, such as bad hand photos, GRE
shall not be held accountable for fit metrics. 
 GRE will fabricate to the best of its ability a well-fitting brace based on the intake
measurements and molds 
 At the Company’s request, rapid response service, when available, may be offered to the Company. An additional
$200.00 will be charged to Company and approved by written PO. A rapid response request is chargeable when Company asks for an order
less than the normal tum-around time of seven business days. GRE, in good faith, will always try and get orders out less than 7 business days if overall volume allows. 

At the Company’s request, GRE shall accelerate the completion of RMA’s and GRE agrees that the processing time of RMA’s shall
not exceed seven (7) business days from date of receipt. Should a request to accelerate RMA processing result in a potential delay in production of revenue orders, GRE and Company will mutually agree as to what revenue orders will be delayed
without penalty to GRE. GRE is not able to control delays caused by inventory or other kit or part shortages or non-working Company components. The Company shall be charged for any RMA associated with fit
remakes when the patient volume or size has changed. The Company shall not be charged for RMAs with regard to braces not made to the patient measurements or mold. 

	 	6)	 QUALITY CONTROL: 

GRE shall maintain compliance for specific parts, identified in the bill of materials and device master record that is consistent with the
Myomo Quality Management System as applicable for the work performed for Myomo. For additional compliance requests required at GRE, GRE and Company shall negotiate in good faith on new charges to Company for extra time, labor, documentation, or
other requirements set for by Company. Should the Company require additional or new quality control measures beyond the current Myomo Quality Management System, GRE can negotiate in good faith extra charges for new quality requirements. 

This includes but is not limited to: 
  

	 	•	 	 Being trained to Myomo SOPs, Forms, Templates, etc. 

 

	 	•	 	 Document / Revision Control 

 

	 	•	 	 Utilization and compliance with these documents 

 

	 	•	 	 Maintaining Employee Training Records 

 

	 	•	 	 Use and completion of Change Acknowledgement Forms 

 

	 	•	 	 Acceptance of receiving QS Audits from Myomo 

 

	 	•	 	 Timely close out of non-compliance audit findings under agreed due dates
of action items. 

 Therefore, GRE shall maintain (but not be limited to) the following: 

 

	 	•	 	 Accurate device and lot history records (DHRs/LHRs); 

 

	 	•	 	 Updating and maintaining
Bill-of-Materials (BOMs) 

  

	 	•	 	 Device Service and Repair Records 

 

	 	•	 	 Change Orders 

  

	 	•	 	 Batch and inventory tracking 

 

	 	•	 	 Approved Supplier List (ASL) 

 

	 	•	 	 Maintained fabrication location accredited by the American Board for Certification’s (ABC) facility
accreditation program 

  

	 	•	 	 Trained personnel; and 

 

	 	•	 	 Production and Process control 

The Company and GRE shall negotiate in good faith the regarding costs to be incurred by GRE and any reimbursement by the Company to address
quality system audit non-conformities. 
 GRE shall maintain records and metrics of an agreed upon
quality control plan and report them to Company on a quarterly basis or as otherwise agreed. For support metrics, Company to inform GRE of any brace related support or RMA calls for GRE to also investigate and track. For quarterly reporting, metrics
requirements are listed in Exhibit B and shall be presented to Company quality officer within 30 days of each quarter end. 
 GRE agrees to
complete an outgoing inspection form supplied by Company. This inspection protocol is set forth by Company and includes an incoming inspection of the kit. 

 Measurements to be validated by GRE (the “Order Specifications”) as part of
outgoing inspection include, but are not limited to (See Exhibit B): 
  

	 	•	 	 Tolerance of 5mm for the lateral epicondyle to apex of the styloid; 

 

	 	•	 	 Forearm circumference; 

 

	 	•	 	 Humeral circumference; 

 

	 	•	 	 ML@MCP; 

  

	 	•	 	 AP@palmar; 

  

	 	•	 	 Finger saddle lengths; 

 

	 	•	 	 Finger saddle widths, and 

 

	 	•	 	 Thumb saddle diameter. 

QUALIFICATION: 
 To assure
the aforementioned training was effective, and processes understood, GRE agrees to participate and complete the new Myomo Cfab Qualification Process. This process is meant to assure both parties have effectively executed the needed training,
documentation, testing, inspection, and other elements as applicable. is expected to include: 
  

	 	•	 	 First Article Inspection (FAI) / of Fabrication Units 

 

	 	•	 	 Inspection of associated documentation 

 

	 	•	 	 Review of records 

  

	 	•	 	 Design Review and Associated Design V&V (as applicable for new Orthosis designs) 

The Company and GRE agree to discuss any ongoing cost increases or decreases in good faith associated with any changes to the fabrication
process as a result of completing the aforementioned qualification procedures 
  

	 	7)	 DELIVERY TERMS (Title, Freight, and Risk of Loss): 

GRE will provide a tracking mechanism. GRE shall bear risk of loss of all incoming materials upon receipt by GRE. and of the custom fabricated
orthosis until it has been shipped from GRE to the Company for product validation, or to the customer. Title to the goods or materials and risk of loss shall pass at the time the shipment leaves GRE. Freight and shipping charges shall be paid by
Company for the finished device when the finished device is shipped. 
  

	 	8)	 SERVICE/RETURNS: 

 

	 	a)	 GRE shall ship completed orders for validation to Company. Orders not passing the validation process at Company
will be shipped back to GRE, who shall pay the shipping costs for return to GRE and back again to Company. See Section 5 for processing time requirements for orders returned to GRE. 

 

	 	b)	 Any device that meets the Order Specifications for the particular individual but does not fit correctly shall
be returned directly to Company. Any device that does not meet the Order Specifications for the particular individual but has fit issues, within 2 weeks of shipping, shall be returned directly to GRE at GRE’s expense for shipping only if and
when the order did not match the measurements and mold specified by the Company’s customer. GRE may require new measurements of the patient showing the accuracy of 

	 	the measurement that was non-conformed. Such documentation shall be equivalent to what is provided to GRE for an original cast. GRE shall not be held responsible for any ill-fitting devices without evidence of the ill-fit. See Section 5 for processing time requirements on such orders returned to GRE. Any device that meets the Order
Specifications but is deemed ill-fitting by the Company’s customer will be returned to GRE at the Company’s expense. GRE shall quote the Company a cost for such changes to the device that were not on
the measurement form or mold. GRE shall not be held accountable when any Company intake non-conformances existed in the order process such as, but not limited to, missing measurements, invalid hand
measurements, or other invalid order intake. 

  

	 	c)	 GRE shall keep and maintain for its use and for Company such full and detailed accounts and records as shall be
reasonably necessary in accordance with U.S. generally accepted accounting principles, for the proper determination and settlement of the liabilities of Company and those of GRE under this Agreement. The Company shall be afforded the ability to
review GRE’s books and records, solely relating to Company fabrication and no other GRE business, and its correspondence, receipts and other business memoranda solely relating to this Agreement at all reasonable times during business hours, for
auditing, inspection and copying. GRE shall preserve all such records per the Myomo-Quality Records SOP and required retention times, after the work has been completed and all costs and fees have been paid. 

 

	 	9)	 ACCEPTANCE/PERFORMANCE TESTING: 

 

	 	a)	 Pre-shipment Inspection: Prior to shipment of the fabricated
device to Myomo, GRE shall conduct a pre-shipment trial pursuant to the procedure agreed upon by the Parties set forth in the outgoing inspection. The purpose of this inspection shall be primarily to identify
any mechanical interference between machine members, improper adjustments made during assembly, and generally to determine that the device is in good working order and matching the validated BOM. The Company shall have the option to observe this
outgoing inspection and have access to associated records. It is understood that all defects in materials and workmanship which may be identified as a result of the inspection shall be corrected by GRE prior to shipment of the Work unless
specifically directed in writing by the Company to the contrary. 

 The Company shall provide GRE with outgoing inspection
forms and education in order for GRE to complete the inspection process. Both parties must sign off on acceptable outgoing inspection criteria. Should the outgoing inspection change, both parties will negotiate in good faith if extra charges will be
assessed by GRE. 
  

	 	b)	 Acceptance Test: Upon completion of the Work, GRE shall notify the Company (through shared documents or other
means) that the Work is ready as specified and transmit the completed outgoing inspection forms to the Company. GRE shall notify the Company upon completion of fabrication and testing before shipping the product to the end customer.

	 	10)	 ASSIGNMENT/SUBCONTRACTING: 

Neither Party shall assign this Agreement, or any right or obligation hereunder, without the express written approval of the other Party. GRE
may use subcontractors, suppliers, or consultants, but The Company retains the right to reasonably reject any subcontractor, supplier, or consultant selected by GRE. GRE shall ensure that such subcontractor and consultant are bound to an agreement
to protect Company’s confidential information consistent with the obligation imposed on GRE in this Agreement. All Work Product developed by GRE or its subcontractor shall belong to the Company unless otherwise carved out in a separate
agreement. Either Party may assign this Agreement without consent to a subsidiary controlled by such Party, where control is defined as greater than 50% direct or indirect ownership of the subsidiary. ((Work product developed should specify at sub-contracting agreement/ $75/hr. rate)) 

 

	 	11)	 QUALITYMETRICS 

GRE, as a requirement of this Agreement, shall maintain the following key delivery and quality metrics: 

 

	 	1)	 GRE shall use its reasonable best efforts to ensure that Custom fabricated orders be completed within 7
business days of a complete order at a rate no worse than 95% in each quarter. However, notwithstanding anything to the contrary contained herein, GRE’s failure to maintain this metric shall not result in the Company’s ability to terminate
this Agreement. Should major projects be assigned by the Company to GRE that impact time of fabrication, the Company and GRE shall discuss such impact prior to entering into such a project. Orders delayed by Company, such as but not limited to
Company designed parts not working correctly or inventory related delays from Company kits, are not factored into timely fabrication metrics. 

  

	 	2)	 GRE shall maintain an outgoing inspection yield of at least 95%;

  

	 	3)	 GRE shall maintain accurate device history files for each patient order in accordance with the Company’s
compliance program; 

  

	 	4)	 GRE custom patient orders shall not produce returns for fit issues at a rate of more than 10% of total quarterly fabrication volume when fabricated to intake spec. Orders not fitting that are outside the scope of the product order, include but are not limited to patient volume changes, are not
included in this 10% category. 

  

	 	5)	 GRE shall work with the Company to resolve any correction and preventive action (“CAPA”) or supplier
corrective action request (“SCAR”) to ensure resolution and closure by agreed-upon due dates. Due dates shall be based on urgency, risk, and agreed upon corrective actions or plans. 

 

	 	6)	 Should RMA’s in a given month, for which the root cause is attributable to GRE, exceed fifteen (15) RMA’s per month (“RMA Threshold”), the Company shall be entitled to a credit of 10%
of the Base Fee for each RMA in excess of the RMA Threshold. For clarity, direct and indirect material defects that occur despite GRE’s compliance with Myomo’s Quality System shall not be considered a root cause arrtibutable to GRE.

	 	12)	 COMPLIANCE WITH APPLICABLE LAWS AND STANDARDS: 

GRE shall furnish only goods, services and materials which comply with the Myomo Quality System as such has been supplied to GRE in writing as
of the Effective Date, including all FDA requirements for FDA registration, European Union medical device regulation EU-MDR and other filings, as appropriate. During the Term of this Agreement, GRE shall comply with all local, state, and federal
laws, codes, and regulations relating to privacy (including HIPAA and related amendments), safety, health, and environmental compliance. In the event that GRE work does not comply with any such laws, codes, and regulations, GRE shall correct any
such noncompliance at its sole expense and indemnify and hold the Company harmless from any claims, costs, fines, penalties, expenses, liabilities, or losses on account of any such noncompliance. 

GRE shall timely notify the Company of complaints or adverse events per the Myomo Quality Management System. 

 

	 	13)	 CONFIDENTIAL INFORMATION: 

All information related to either Party, including but not limited to, intellectual property, the Agreement terms, Party databases of
individuals and employees, employee rates, schedules and compensation, and other information and data (the “Confidential Information”) provided to one Party (the “Receiving Party”) by the other Party (the “Disclosing
Party”) is proprietary to the Disclosing Party and shall be protected in accordance with the confidentiality and non-use limitation imposed herein. Specific adherence to the Massachusetts Data Security
Act, any other applicable state privacy laws and the implicated provisions of HIPAA shall apply hereto. 
 Any and all Confidential
Information shall be treated as confidential in that: (1) it is to be used solely in connection with work to be performed and the obligations contained in this Agreement, 

(2) it is not to be published or disclosed to any third party, and (3) if the information is in tangible form, it shall be returned to the
Disclosing Party at the Disclosing Party’s expense upon written request. The Receiving Party shall indemnify the Disclosing Party for all damages (including but not limited to attorneys’ fees) incurred by the Disclosing Party resulting
from the Receiving Party’s failure to adhere to these terms. The terms of this Section may be specifically enforced by the Disclosing Party and the Disclosing Party may be entitled to pursue any equitable remedies (including injunctive relief)
at its discretion. 
 Any inquires of GRE by investors of the Company or government agencies should be directed to the Company’s Chief
Financial Officer. 
 These foregoing requirements shall not apply, however, to any information which is, or subsequently may become through
no fault of GRE, within the knowledge of the general public, or which may be known to GRE at the time of receipt from the Company or may subsequently be rightfully obtained from a third party. 

	 	14)	 CONFLICT OF TERMS: 

The terms and conditions stated in this Agreement shall govern in the event of any conflict with any additional terms proposed by the Parties.
Except as otherwise stated herein, these terms and conditions are not subject to change by reason of any written or oral statements by either Party or by any terms stated in any release, order, order acknowledgment, invoice, or other documentation
unless signed by an authorized representative of both Parties and reflecting an intention to amend or modify a particular provision of this Agreement (with reference being made to such provision). 

 

	 	15)	 DELIVERY CONTINGENCIES: 

a) Option to Delay Delivery: The Company shall have the right, at no additional charge, to postpone the delivery of the Work, or any of
its components, for a maximum period of forty-five
(45) calendar days at its discretion. If the Work gets cancelled, the Company will be responsible for all charges of the
Work that had been completed up to the stoppage date. Should the Company delay delivery under this Section 16, the penalty provisions for late delivery under Section 5 shall not apply. 

If Company goes on a stop ship, for reasons chosen by the Company, then GRE has the right to reduce costs and capacity at its discretion after 30 days. GRE will work to its best ability to bring on new staff or otherwise increase capacity as soon as possible. 

b) Delivery Delays - Reparable: Company shall have the option to expedite the shipment of the Work by employing a premium transportation
mode such as, but not limited to, exclusive-use van or air freight. The Company shall bear such premium costs should it elect to use such premium transportation mode in an effort to recover the time lost due
to GRE’s late shipment. Furthermore, GRE shall use its best efforts to assist the Company in the routing or rerouting of the shipment. 
  

	 	c)	 Delivery Delays - Irreparable: If shipment of the Work is delayed in excess of forty-five (45) calendar days after the Delivery Date for any reason (excluding a Force Majeure), Company may, without prejudice to any other remedy, declare GRE
in default and terminate this Agreement in whole or in part. Should Company elect to excuse the delay, it shall do so by an instrument that shall include the adjourned date of delivery. 

 

	 	d)	 Delivery Notice: On the day of actual shipment, GRE shall confirm shipment by posting on the shared
shipping log, facsimile, or email notification that shall be in an agreed upon format. 

  

	 	e)	 Packaging and Shipping: GRE shall package and ship the Work in a manner consistent with packaging
instructions provided by the Company. Should it be necessary to ship the Work in a disassembled state, GRE shall ship the Work in the largest possible units consistent with expedient shipment. 

 

	 	16)	 EQUAL EMPLOYMENT/AFFIRMATIVE ACTION: 

GRE shall comply with all applicable federal, state, or local laws, rules, or regulations, including but not limited to the following, which
are incorporated by reference: Equal Opportunity Laws; Affirmative Action Laws of Disabled Veterans and Veterans of the Vietnam Era; Affirmative Action Laws for Handicapped Workers; and the Certification ofNon-segregated Facilities Laws. GRE also
certifies, if applicable, that it has developed a written affirmative action compliance program. In addition, GRE shall comply with all applicable federal laws and regulations regarding the utilization of small business concerns and/or small
disadvantaged business concerns, including, if applicable, any subcontracting plans thereunder. 

	 	17)	 EXPORT COMPLIANCE: 

GRE will not export or re-export any information furnished by Company in connection with this Agreement
unless it complies fully with all regulations of the United States relating to such export or re-export. All information received from Company shall be handled in strict accordance with the U.S. export
administration regulations, and GRE agrees to comply, and do all things necessary to cause its subcontractors to comply, with all applicable federal, state, and local laws including (but not limited to) the Regulations of the U.S. Department of
Commerce relating to the Export of Technical Data, insofar as they relate to activities to be performed under this Agreement. GRE further represents and warrants that it will not permit any Foreign Nationals, as employees of GRE or any
subcontractor, to perform work at any of its facility in connection with this Agreement without first notifying Company in writing of such Foreign Nationals and receiving Company’s written consent. For purposes of this Agreement, Foreign
Nationals shall include any individuals who are neither citizens of the United States nor permanent residents (green card holders) of the United States. In addition to the above, any diversion contrary to U.S. law is prohibited. 

 

	 	18)	 FAIR LABOR STANDARDS: 

GRE certifies that the production of the goods, materials, and/or the performance of the services covered by this Agreement have complied with
all applicable requirements of Sections 6, 7, and 12 of the Fair Labor Standards Act, as amended, and regulations and orders of the United States Department of Labor issued under Section 14 thereof. 

 

	 	19)	 FORCE MAJEURE: 

Neither party shall be held responsible for the failure or delay in performance hereunder where such failure or delay is due to any act of God,
the public enemy or war, compliance with laws, governmental acts or regulations, fire, flood, epidemic or pandemic (specifically including, but not limited to, COVID-19), accident, unusually severe weather, or
other causes substantially similar to the foregoing beyond their reasonable control. Any party whose performance is affected by such force majeure shall promptly give notice to the other party of the occurrence or circumstance upon which it intends
to rely to excuse its performance. Other than for any force majeure event and delay related to COVID-19, if the circumstances of force majeure affecting either party’s performance hereunder delays
performance for more than thirty (30) calendar days, then the other party may terminate this Agreement upon five (5) calendar days advance written notice. Failure of subcontractors, labor disputes, or inability to obtain material shall not
be considered as a force majeure delay. In no event shall a failure or delay in performance attributable to the computer system and/or software related malfunction be excusable under this paragraph or any other paragraph of this Agreement. 

	 	20)	 INDEMNIFICATION: 

GRE shall indemnify, defend and hold harmless the Company and each of Company’s subsidiaries and affiliates, and their respective
customers, employees, officers, directors, successors and assigns, from and against any claims, including Company’s claims and claims of third parties, for costs, losses, damages, penalties, fines, judgments, liabilities, or expenses (including
attorney’s fees) that arise from or are attributable to (a) injuries or death to persons or damage to property, caused or alleged to have been caused by the negligent act or omission of GRE, or by any employee or subcontractor of GRE, or
(b) assertions under Worker’s Compensation or similar acts made by persons furnished by GRE, or (c) a material breach by GRE or any of its employees or subcontractors of any provision of this Agreement. 

The Company shall indemnify, defend and hold harmless GRE and each of GRE’s subsidiaries and affiliates, and their respective customers,
employees, officers, directors, successors and assigns, from and against any claims, including GRE’s claims and claims of third parties, for costs, losses, damages, penalties, fines, judgments, liabilities, or expenses (including
attorney’s fees) that arise from or are attributable to (a) injuries or death to persons or damage to property, caused or alleged to have been caused by the negligent act or omission of Company, or by any employee or subcontractor of
Company, or (b) a material breach by Company or any of its employees or subcontractors of any provision of this Agreement. 
  

	 	21)	 INVENTORY CONTROL: 

The Company shall adequately insure materials at full replacement value it owns that are physically located at GRE. GRE shall be responsible
for lost or physical damage to the Kit while in its custody until the completed device is shipped, but any such responsibility or cost allocated to GRE shall be offset by any recovery the Company may receive from any applicable insurance policies.
GRE shall not be responsible for non-working electromechanical malfunctions that have not resulted from physical damage. For example, should a motor not power, and no physical damage has occurred, then GRE
shall not be responsible. GRE should not be responsible for inherent defective parts of the Company’s Kits. GRE shall have seventy-two (72) hours from receipt to notify Company in writing of visual damage
to the Kit. GRE shall have 72 hours to notify Company when a non-working kit is discovered during assembly. GRE shall set up an inventory control process acceptable to Company. During the course of the Work,
Company is also entitled to inspect the Work at GRE’s or its supplier’s facility at any reasonable time with adequate notice. 
 At
Company’s option, any delivered non-conforming Work that does not match the mold or measurement form to an end patient shall be: 
  

	 	a)	 Returned to GRE, freight collect, invoices shall be rejected, and previously paid money shall be refunded.

  

	 	b)	 Repaired or made useable. If Company elects to take this action, Company shall be entitled to the direct and
incidental costs incurred in remedying the non-conformance. GRE’s action to effect cure of any non-conformance shall be without prejudice but shall not relieve GRE
of any of its obligations under this Agreement or under the Uniform Commercial Code. 

 GRE will conduct a physical inventory, at least four times per year on a quarterly basis (as
of March 31st\ June 30th, September 30th and December 31st and maintain records of such counts. GRE shall issue the results of the inventory count to the Company, no later than 3 business days from the end of the quarter. GRE will work with the Company
finance and operations staff to resolve any inventory discrepancies as they arise and in a timely manner. 
  

	 	22)	 OWNERSHIP OF WORK PRODUCT/COPYRIGHT: 

 

	 	a)	 All work product including but not limited to computer files, concepts, designs, discoveries, drawings,
inventions, models, plans, programming, schedules, specifications, technical documentation, software, or source code, adaptations or improvements (“Work Product”) produced in connection with the performance of the GRE’s (or any of its
affiliates) obligations under this Agreement are and shall remain the property of Company whether the Work is executed or not. GRE shall not photograph or otherwise visually document the Work or Work Product except for GRE’s own professional
use and with the written permission of Company, which shall not be unreasonably withheld. GRE must seek the Company’s consent before GRE subcontracts for work the may generate intellectual property. 

 

	 	b)	 GRE shall promptly advise the Company of all reasonably available technological advances which are known or
become known to GRE over the course of performance of its obligation under this Agreement which may result in the Work having added value to Company. Such technological improvements include, but are not limited to, the following: design,
maintainability, material, performance, and useful life. The Company and GRE shall negotiate in good faith regarding a right of first refusal to obtain ownership any improvements or adaptations in the fabrication process. 

 

	 	23)	 PROMOTION LIMITATION/DISCLOSURE: 

GRE and Company shall authorize the announcement to the public of the C-Fabrication relationship on the
websites of their respective organizations. Such authorization shall not be unreasonably withheld. GRE shall add such information as agreed upon by the Parties on the Web, in marketing and other written or electronic communications and on its
invoices. The Company will add such information to its existing MyoPro partner resource folder. Any other use of Company’s name by GRE in any other promotional material, including without limitation advertisements or press releases must be made
with advance written authorization from Company. 
  

	 	24)	 NON-SOLICITATION OF EMPLOYEES. 

Each Party acknowledges that neither Party will directly or indirectly hire or employ any members of either Parties’ current staffs for
the Term of this Agreement (as defined in Section 26) unless agreed to writing. It is understood by both Parties that individuals involved may respond to general advertisements to employment openings at each Party and that this is not a breach
of the Agreement. 

	 	25)	 TERM AND TERMINATION: 

This Agreement shall be non-exclusive to both Parties and shall remain in effect for one (1) year
(the “Term”). The parties agree to negotiate in good faith should either Party desire to extend the Term. Each Party has the right to terminate this agreement upon ninety (90) calendar days written notice to the other Party. Should
the Company terminate this Agreement prior to completion of the Term, it shall be obligated to promptly pay any unpaid amounts under the Annual Guarantee described in Section 3.
At the completion or early termination of the Term, the Company shall pay GRE (the “Severance Amounts”) the product of$7,312 and the number of base technicians then
currently employed that GRE decides to terminate in its sole discretion, up to a maximum of four (4) such base technicians. In addition, the Company shall pay GRE the product of $9,246 and the number of senior technicians then currently
employed GRE decides to terminate in its sole discretion, up to a maximum of one (1) such senior technician. All such Severance Amounts shall be due within three (3) business days of any base or senior technician’s termination, as
applicable If GRE terminates this Agreement prior to the completion of the Term, it shall forfeit any unearned amounts under the Annual Guarantee and the Company shall not be obligated to pay the
Severance Amounts. 

Should GRE, prior to the completion of the Term, (i) cease conducting business in the normal course, (ii) become insolvent,
(iii) make a general assignment for the benefit of creditors, (iv) suffer or permit the appointment of a receiver of its business or assets, (v) avail itself of or becomes subject to any proceeding under any bankruptcy act (domestic
or foreign), any state relating to insolvency or the protection of the rights of creditors, (vi) withdraw or cease to support any product integral to the Work, or (vii) breach any material provision of this Agreement, after an opportunity
to cure such breach within thirty (30) business days from the date of the written notice of breach, Company may, without prejudice to any other available remedy, terminate this Agreement in whole or in part. In the event of such termination,
Company shall have the right to take possession of the Work, all documentation relating to Work Product, and all materials with the right to their continued use, and the Company may then finish the Work by any reasonable means Company deems
necessary. Further, the Company shall not be obligated to pay to GRE any unearned amounts under the Annual Guarantee or the Severance Amounts. 
 In the event of termination, GRE shall be compensated for Work performed and substantially in
process prior to termination. Expenses that are directly attributable to termination but are incurred after termination shall be paid only if agreed to before such expenses are incurred. No expense or compensation, however, shall include anticipated
profit or overhead charges. Company shall purchase all remaining material purchased by GRE, without exception, at a purchase price equal to the invoice cost for such materials plus
twenty percent (20%). Additionally, the Company shall pay for the time, cost, and materials relative to packaging and shipping of said materials purchased by the Company. The Company shall purchase and pay for all such material within
thirty (30) days of the termination or expiration of this Agreement. The Company shall pay for such unused inventory within fifteen (15) days after termination of this Agreement and shall be responsible for all shipping costs. 

	 	26)	 THIRD PARTIES: 

This Agreement is intended solely for the benefit of the Parties hereto. Nothing herein is to be construed to create any duty or standard of
care to any person not a party to this Agreement. 
  

	 	27)	 INSURANCE: 

  

	 	a)	 General. GRE shall maintain insurance as described below during the Term. Evidence of insurance shall be
provided to Company on certificate(s) of insurance before any Work is performed (each, a “Certificate of Insurance”). 

  

	 	b)	 Commercial General Liability. GRE shall have Commercial General Liability insurance which includes
products/completed operations liability, contractual liability, personal injury liability and broad form property damage coverage with limits of at least $2,000,000 per occurrence combined single limit. Certificates of Insurance shall stipulate:
“Myomo, Inc. has been made an additional insured under this policy with respect to all products, operations or services provided or performed under contract or purchase order.” 

 

	 	c)	 Statutory Workers’ Compensation and Employer’s Liability. Certificate of Insurance must
evidence coverage in the state in which the work is being performed and must evidence a limit of liability for Employers Liability (Coverage B) of not less than $1,000,000 per accident. 

 

	 	d)	 Cancellation. The Certificate of lnsurance shall state that the above policies shall not be canceled,
nor reduced in coverage, until after thirty (30) days written notice of such cancellation or reduction shall have been mailed to the Certificate Holder. 

  

	 	e)	 Subcontractors. In the event GRE employs any subcontractor, it shall require that each subcontractor
carry the same coverages in the same limits as set out in this Agreement, and other coverages as GRE or the Company deems appropriate. 

  

	 	f)	 Failure to Comply. Neither failure of GRE to comply with any or all of the insurance provisions of this
Agreement, nor the failure to secure endorsements on the policies as may be necessary to carry out the terms and provisions of this Agreement, shall be construed to limit or relieve GRE from any of its obligations under this Agreement, including any
indemnification provisions. 

  

	 	28)	 WARRANTY: 

GRE warrants that all goods and services sold hereunder or pursuant hereto will be free of any claim of any nature and by any third person and
that GRE will convey clear title thereto to the end customers order specifications. 
 GRE warrants and represents that all goods and
services sold hereunder or pursuant hereto will be free from all defects in design, workmanship and material, and that the device(s) are provided in strict accordance with the specifications, samples, drawings, designs, or other requirements
(including performance specifications) provided by the order from the end provider. 

 Any services performed by GRE or its personnel, agents, representatives, or subcontractors
in the fulfillment of the Work contemplated by this Agreement shall be performed in a diligent and workmanlike manner by properly trained personnel knowledgeable in the scope of the Work performed by them. 

The initial warranty period of fabricated device shipped under this Agreement shall be (6) months on soft-goods (Velcro, straps, neoprene
cuffs) and three (3) years on GRE-provided items (plastic shells and finger moustache) from the date of delivery to the Myomo customer or such other longer period as implied by applicable state law.
Company designed parts, such as adapters, or other brace essentials componentry are subject to repair charges by GRE under failure. Notwithstanding anything to the contrary contained herein, upon termination of expiration of this Agreement, all
warranties and obligations of GRE shall be immediately voided and of no effect without any further action by the parties. 
 The initial
warranty period of the Kit brace shipped under this Agreement shall be three (3) years from the date of delivery to the Central Fabricator and six (6) months for the straps or such other longer period as implied by applicable state law.

 Neither acceptance of nor payment for any goods sold hereunder shall release the Central Fabricator or Company from liability arising
pursuant to this warranty. 
 The Company shall have the right to approve all warranties received by GRE from suppliers and subcontractors
engaged by GRE to enable it to fulfill its obligations under the Agreement. Such warranties shall be made directly to Company or, alternatively, shall be deemed to have been assigned by GRE hereby. GRE however, shall enforce such warranties if
occasion arises. 
 Any and all warranties given by GRE or received by GRE from suppliers and subcontractors shall be inapplicable and of no
effect in the event the end products are misused by the Company or the Company’s customers and/or end users. 
 In the event that any
goods sold hereunder fail to conform to the above warranty, GRE shall without delay repair, replace, or modify such defective goods, or alternatively, credit the end customer as necessary for any money paid for the defective Work. The choice of
remedy shall be subject to the mutual agreement of the Company and GRE. 
 Notwithstanding the foregoing, GRE’s warranty obligations to
the Company shall immediately cease without further action by the parties upon the earlier of (i) early Termination of the Agreement by the Company; (ii) the completion of the Term of this Agreement; or (iii) when all orders cease
under this Agreement. 
 THE EXPRESS WARRANTIES SET FORTH HEREIN ARE THE ONLY WARRANTIES APPLICABLE TO THE GOODS AND SERVICES ACTUALLY
PROVIDED TO THE COMPANY, AND ALL OTHER WARRANTIES, WHETHER EXPRESSED OR IMPLIED, ARE HEREBY WAIVED BY GRE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE. 

	 	29)	 WARRANTY, INTELLECTUAL PROPERTY: 

The Company warrants that all goods, services, and materials sold or delivered to GRE shall not infringe any third-party copyright, patent,
trade secret, trade name, service mark or otherwise infringe any third party intellectual property right. The Company shall indemnify GRE against any costs (including reasonable attorney’s fees and costs of settlement), liabilities, or
judgments arising from any claim of copyright, patent, trade secret, trade name, service mark infringement or violation of any third party intellectual property right. 
  

	 	30)	 CHOICE OF LAW AND FORUM: 

This Agreement shall be governed by, interpreted and construed, and performance hereunder shall be determined in accordance with the law of the
State of Delaware, without regard to its conflicts of law principles. In the event of disputes, controversies, or claims arising out of or relating to this Agreement, both parties agree to first submit to mediation and then, assuming mediation is
unsuccessful in resolving the dispute, to arbitration via the American Arbitration Association where the Parties will each pay 1⁄2 of the fees and costs of the
proceeding prior to commencing any litigation. The Parties agree that the United Nations Convention on Contracts for the International Sale of Goods is specifically disclaimed and excluded and will not apply to or govern this Agreement. 

 

	 	31)	 HEADINGS: 

The clause and paragraph headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement or any of its provisions. 
  

	 	32)	 ENTIRE AGREEMENT AND CHANGE ORDERS: 

This Agreement constitutes the entire agreement between the Company and GRE with respect to the Work, and supersedes all prior and
contemporaneous negotiations, agreements, representations, understandings, and commitments. No change, modification, or extension of this Agreement shall be effective unless it is made in writing, makes specific reference to this Agreement and the
provision to be amended, and is signed by duly authorized representatives of The Company and GRE. 
  

	 	33)	 COUNTERPARTS: 

This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. Delivery of signatures to this Agreement by facsimile transmission or in PDF document format exchanged via electronic mail shall be legally binding and effective for all purposes, including evidentiary
purposes. 
  

	 	34)	 NOTICES: 

All notices delivered or demands given by Company or GRE under this Agreement shall be delivered in person, forwarded by US Mail (postage
prepaid), or transmitted via facsimile, properly addressed to the respective parties as follows: 

 If to Company: David Henry 

c/o Myomo, Inc. 
 One Broadway,
14th Floor Cambridge, MA 02142 
 Phone #    508-344-5235 

Email:      david.henry@myomo.com 

If to GRE: Vince Baroni 
 13376
Ravenna Road 
 Chardon, OH. 44024 

Phone# 440-285-5785 

Email:   vbaroni@greop.com 
  

	 	35)	 SEVERABILITY: 

If any provision of this Agreement is determined by a court to be invalid, the remainder of this Agreement shall remain in full force and
effect. 
  

	 	36)	 SURVIVAL: 

The representations, covenants, and warranties that by their terms extend beyond the completion of the Work or the termination or expiration of
this Agreement shall survive the delivery of the Work, payments, or termination or expiration of the Agreement for any reason whatsoever, for the duration contemplated by such representations, covenants, and warranties. 

 

	 	37)	 INDEPENDENT CONTRACTOR: 

For purposes of this Agreement, GRE is an independent contractor and nothing in this Agreement creates, or will be construed to create, any
agency, partnership, joint venture or other form of joint enterprise between GRE and the Company. 
  

	 	38)	 WAIVERS: 

Neither party will be deemed to have waived the exercise of any right that it holds under this Agreement or at law unless such waiver is
expressly made in writing. Failure of a party at any time, and for any length of time, to require performance by the other party of any obligation under this Agreement shall in no event affect the right to require performance of that obligation or
the right to claim remedies for breach under the Agreement or at law. A waiver by a party of any breach of any provision of this Agreement, unless otherwise expressly stated in writing, is not to be construed as a waiver of any continuing or
succeeding breach of such provision, a waiver or modification of the provision itself, or a waiver or modification of any right under this Agreement or at law. 

	 	39)	 REGULATION FD. 

GRE hereby acknowledges that it is aware, and that it will advise its Representatives who receive any Confidential Information, that the
securities laws of the United States prohibit any person who has material, non-public information concerning the Company from purchasing or selling securities in reliance upon such information or from
communicating such information to any other person or entity under circumstances in which it is reasonably foreseeable that such person or entity is likely to purchase or sell such securities in reliance upon such information. 

 GRE and the Company have executed this Agreement by their respective duly authorized
representatives as of the date first written above. 
  

			
	Myomo, Inc.	  	Geauga Rehabilitation Engineering, Inc.
		
	By:________________________________	  	By: ___________________________
		
	Printed: ___________________________	  	Printed: ___________________________
		
	Title: ____________________________	  	Title: _____________________________
		
	Date: ____________________________	  	Date: _____________________________

 EXHIBIT A (Other Fees) 

 

					
	 Changes to a device TCR or any deviation from established fabrication
	  	$	75/hr	 

  

 EXHIBITB 

Description of Measurements for DQUAL16 
  

	 	1.	 Humeral Circumference- Measurement taken from proximal edge of Upper Sensor Cuff along bunting.

  

			
	 

	 	

	 	2.	 Forearm Circumference- Measurement taken from inside of forearm shell in line with attachment screws for chafe
and closure. 

  

					
	 

	  		  	

	 	3.	 Lateral Epicondyle to Apex of Styloid- Measurement taken from forearm bar attachment at motor to hex screw
on FE Joint proximal to wrist center. 

  
 

 
  

	 	4.	 ML@MCP- Measurement taken from inside of hand shell at MCP and medial posterior edge of hand shell.

  
 

 

	 	5.	 AP@ Palmar- Measurement taken from inside of hand shell, from posterior edge of padding to anterior edge of
padding. 

  
 

 
  

	 	6.	 Finger Saddle Length/Thumb Saddle Length- Measurement taken on Finger and thumb saddle, each one.

 

 
  

	 	7.	 Finger Saddle Width/Thumb Saddle Diameter - measurement taken at widest part of saddle 

 

			
	

	  	

 EXHIBITB 

(From Quality Control Section #6) 

Quarterly Metrics and Monitoring: 

These are the current metrics, subject to change from quarter to quarter as discussed and documented with GRE. Any request for change will be
provided in writing. 
  

					
	 Metric:
	  	 Unit of Measure:
	  	 Notations:

	l.RMAs	  	 Qty of RMAs at GRE
  

Min, Max, and Avg # of days at GRE for the Qtr.
  

Breakdown of reasons for product return to GRE.
	  	Monitoring RMA lead time
			
	2.New Device Fabrication	  	 Number of units processed for the Qtr.
 Min,
Max, and Avg days at GRE
	  	Monitoring Cycle Time for new order processing
			
	3.Orders on Hold	  	 Quantity of Devices and Reasons for units on Hold
  

Min, Max, and Avg days at GRE
	  	Monitoring the volume and reasons for Orders place on Hold
			
	4.Myomo related processmg issues. e.g. —issues with Casts, Measurements, Order Forms, etc.	  	The number and type (category) of issues encountered.	  	Awareness and Monitoring
			
	5.New GRE SCARs opened during the Qtr.	  	The number and reasons for initiation of a new SCAR	  	Monitoring Supplier / Contractor Corrective Actions
			
	6.Nonconforming Materials	  	NCMRs found at Incoming Inspection or during Fabrication	  	We want to monitor nonconforming materials that were found and identified.
			
	7.Cont. Improvement Priority #1 based on recent Qtr of Cases and Complaints	  	 Number of Cases and Complaints for Orthosis related problems. The reasons for return to GRE via RMA. Myomo can pull this data

together to discuss.
	  	Identify the number 1 reason for GRE related Case/Complaints/RMAs, and lets discuss what is going on to reduce and address

  

					
	8.Capacity	  	 Device Fabrication Capacity vs Plan
  

Measured in Units/Month
	  	We want to keep Myomo and GRE m Sync as we move forward with a ramp in volume.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]